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IntroductIon

General introduction, aims and outline
Partly adapted from Physician’s Guide to the Diagnosis, Treatment, 
and Follow-Up of Inherited Metabolic Diseases. Thöny, B., Duran, M., 
Gibson, K.M., Dionisi-Vici, C. (Eds.), Chapter 22: Mitochondrial Oxidative 
Phosphorylation Disorders – P. de Laat, R. Rodenburg, J. Smeitink.
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Introduction 
A family with the m.3243A>G mutation
At the age of 21 years the proband of the family started to develop neurologic problems, 
including headaches, encephalopathy and aphasia. On retrospective evaluation he had 
experienced hearing difficulties since the age of 15 years. On cerebral imaging there was a 
suspicion of a metabolic disorder leading to the discovery of the m.3243A>G mutation, with 
a heteroplasmy level of 90% in muscle (heteroplasmy level in urine 96%, heteroplasmy level 
in blood 49%). In the same year he presented with epilepsy, which was successfully treated. 
In the following years he suffered from various stroke like episodes and was admitted for 
pseudo-ileus. He had progressive cognitive problems and a progressive myopathy. At the 
age of 28 years he was diagnosed with a severe hypertrophic cardiomyopathy, causing 
dyspnea and severe fatigue. In the following year he was diagnosed with diabetes, requiring 
insulin therapy. The cognitive function deteriorated, and psychiatric symptoms occurred, 
requiring admission in a specialized psychiatric care center. He was treated by various 
specialists to optimize his quality of life. At the end of his life he experienced features of 
the m.3243A>G mutation in almost every organ, including epileptic seizures and stroke 
like episodes, severe cardiomyopathy, diabetes, hearing difficulties, malnutrition, severe 
attention deficit, myopathy and fatigue. This led to the request for euthanasia. At the age 
of 34 years he died in presence of his close family. The proband of this family displayed 
the full Mitochondrial myopathy, Encephalopathy, Lactic Acidosis and Stroke-like episodes 
(MELAS) syndrome. 
His two years older sister had mild hearing problems during her teens. When her 
brother was diagnosed with the m.3243A>G mutation, she was also shown to be a carrier 
of the mutation (heteroplasmy level in urine 57%, heteroplasmy level in blood 49%). 
Cardiologic screening revealed a mild hypertrophic cardiomyopathy. She had no signs of 
fatigue of myopathy. At the age of 27 she was diagnosed with diabetes. In the following 
years she began to experience more signs of fatigue and myopathy, which make it hard 
to maintain her normal live, including a demanding day job. She displays the classics 
symptoms of the Maternally Inherited Diabetes Deafness (MIDD) syndrome. 
The mother of these siblings also harbors the mutation (heteroplasmy level in urine 
38%, heteroplasmy level in blood 7%), she however has no complaints at all. Although 
the care for her son was demanding she has a very positive spirit, as does her husband. 
With her asymptomatic state she should be classified as a ‘dormant carrier’. 
In this family all three members are carriers of the m.3243A>G mutation. Their 
phenotypes are very different, a common finding in carriers of the m.3243A>G mutation. 
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1Physiology of the oxidative phosphorylation
The condensation of energy in the form of adenosine triphosphate (ATP) by mitochondria 
is a stepwise process, of which the oxidative phosphorylation (OXPHOS) constitutes the 
final step. The carbohydrate metabolic pathways preceding the process of oxidative 
phosphorylation are glycolysis, pyruvate dehydrogenase and the Krebs cycle. During the 
aerobic conversion of substrates, such as glucose and fatty acids, into ATP, the formation 
of the reduction equivalents NADH and FADH2 takes place in the tricarboxylic acid cycle 
and the beta-oxidation. These reduction equivalents are oxidized by the respiratory chain 
complexes I and II, respectively. The electrons that are released during this conversion flow 
through the electron transport chain via coenzyme Q10 and cytochrome c and finally to 
molecular oxygen, which results in the formation of water. These subsequent conversions 
are catalyzed by the respiratory chain enzymes complex I, II, III, and IV. The oxidation-
reduction reactions are accompanied by the pumping of protons from the mitochondrial 
matrix to the inter membranous space by complex I, III, and IV. This results in a proton 
gradient (and membrane potential) over the inner mitochondrial membrane. This proton 
gradient is used by complex V (ATP synthase) to convert ADP and Pi into ATP. This results 
in an increase in the ATP/ADP ratio within the mitochondrial matrix, which is balanced by 
the export of ATP by the adenine nucleotide transporter (ANT), which is accompanied by 
equimolar amounts of import of ADP (1-3).
Mitochondrial function
Primary mitochondrial function is dependent of both nuclear DNA (nDNA) and mitochondrial 
DNA (mtDNA). mtDNA encodes 37 genes, 22 code for tRNA’s, two for rRNA’s and thirteen 
code for subunits of the OXPHOS complexes I, III, IV and V. Mitochondria are not self-
supporting entities, but require imported nuclear encoded proteins and other imported 
molecules in order to function properly. In addition to the OXHPOS genes, the mtDNA 
also encodes the RNA molecules required for the translation of these mtDNA-encoded 
OXPHOS genes. The mtDNA encoded ribosomal RNAs, together with nuclear encoded 
ribosomal proteins, form mitoribosomes. The mtDNA encoded tRNAs are charged with 
amino acids by their corresponding (nuclear encoded) aminoacyl tRNA synthetases. The 
mitoribosomes and charged tRNAs, with the help of nuclear encoded translation initiation 
and elongation factors, synthesize the 13 polypeptides of the OXPHOS system. Replication 
of mtDNA, under the control of nuclear encoded products, involves the unwinding of the 
double-stranded mtDNA and the polymerization of new mtDNA strands. Factors involved 
include the Polymerase Gamma´s (POLG), the Helicase Twinkle and the single stranded 
binding proteins (2, 4).
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Mitochondrial DNA
Three important features of mtDNA are: A) maternal inheritance: mtDNA is exclusively 
maternally inherited. The reproductive part of sperm contains almost no mitochondria, 
and these paternal mitochondria are actively degraded after fertilization of an oocyte. All 
mitochondria in a fertilized oocyte are therefore from maternal origin. It can be assumed 
that if a mtDNA mutation segregates in a family, all relatives in the maternal lineage are 
(dormant) carriers of the mutation. And B) heteroplasmy: most human cells contain over 
100–1000 mitochondria each, and every mitochondrion contains 1–10 copies of mtDNA. 
When all mtDNA copies are the same, there is a homoplasmic genotype. However, when 
there are two different kinds of mtDNA, there is a heteroplasmic genotype. The amount 
of mutated mtDNA is indicated in a percentage, this can range from 0% to 100%. C) 
Mitotic segregation: Heteroplasmy can vary in different tissues of one patient and it can 
change in time during a carrier’s lifetime. This variation in heteroplasmy between tissues 
and in time complicates the clear demonstration of a relationship between the severity of 
the disease and the degree of heteroplasmy. In some mutations there are clear threshold 
levels of heteroplasmy, below these levels the carriers does not express the phenotype. 
In other mutations there is much variation in the genotype-phenotype relation. Overall, 
there is a more severe phenotype in patients with a higher heteroplasmy percentage (5, 6).
Mitochondrial dysfunction
Mitochondrial dysfunction can be a result of a primary defect in the OXPHOS system, 
caused by a mutation in nDNA or mtDNA. Secondary causes of mitochondrial 
dysfunction include aging, cellular stress and inactivity. Also, other inherited metabolic 
diseases (e.g. creatine biosynthesis defects and organic acidurias) can cause secondary 
mitochondrial dysfunction. The incidence of primary mitochondrial dysfunction based 
on an OXPHOS defects is over 1:5000 of all live births. Mutations in mtDNA subunit 
coding genes theoretically cause isolated complex deficiencies of the complexes that 
contain mitochondrial encoded subunits, complex I, III, IV and V. A mutation in one of 
the mitochondrial encoded tRNA’s or rRNA’s causes most of the times a multi-complex 
deficiency of the complexes that contain mitochondrial encoded subunits. Mutations in 
nuclear genes encoding proteins involved in the OXPHOS system may cause both single 
and multi-complex deficiencies of all complexes (7, 8).
Clinical signs and symptoms
Mitochondrial dysfunction causes a wide variety of symptoms, in many different organ 
systems. The disease course is often progressive, although the rate of deterioration is highly 
variable between different patients. Onset of symptoms can be at any age. The organs 
requiring the most energy, such as the brain, retina, heart, kidney and skeletal muscle, 
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1are most commonly and severely affected. A mitochondrial disease should therefore 
be suspected in patients with progressive multisystem involvement, but mitochondrial 
disorders may present with “Any symptom of any organ at any age”. In general, symptoms 
present in mitochondrial disorders can also be seen in a variety of other diseases. Signs and 
symptoms where mitochondrial disorders should be first and foremost on the differential 
diagnosis include combinations of encephalopathy and hepatopathy, myoclonic epilepsy, 
developmental regression, stroke-like episodes, ophthalmoplegia, optic nerve atrophy, 
retinal degeneration, early onset hearing loss and ataxia. 
In many patients, diagnosis cannot be made on clinical signs and symptoms alone. 
A more structured approach is needed, including blood and/or cerebrospinal fluid (CSF) 
lactate, pyruvate and alanine concentrations, neuroimaging, cardiac evaluation and 
muscle biopsy for histological and histochemical evidence of mitochondrial disease, 
biochemistry and molecular genetic testing. Family history is of utmost importance as 
it can give indication on maternal inheritance. Maternal inheritance could be suspected 
based on a maternal history, symptoms of the above-mentioned organ systems presenting 
in maternal relatives (2, 4, 9).
Genotypic conformation of mitochondrial disorders
Several mitochondrial syndromes are known. If a patient presents with one of these 
syndromes, a mitochondrial disease is highly likely, and diagnostics and management can 
be adjusted to the known clinical course of the disease. Mostly, patients do not present 
with the whole spectrum of symptoms described. However, in the case of a mitochondrial 
DNA (mtDNA) mutation, additional clinical symptoms fitting the syndrome can be found in 
maternal relatives, such as the patient with maternally inherited diabetes and deafness who 
lost his mother in an early stroke and other neurological problems. Symptoms don’t have 
to limit exactly to the original syndrome description but may involve other organ systems.
The clinical presentation of a patient with a mitochondrial disorder is in most cases not 
as obvious as in the mitochondrial syndromes. The patient’s signs and symptoms should in 
these cases trigger a physician to perform additional testing leading to the right diagnosis. 
High throughput sequencing technologies have become available for diagnostic 
application and these techniques will change the order of the diagnostic route of rare 
genetic diseases, such as mitochondrial disorders (4).
The mitochondrial 3243A>G mutation
The acronym MELAS was first used in 1984 by Pavlakis et al. to describe a group of patients 
with Mitochondrial myopathy, Encephalopathy, Lactic Acidosis and Stroke-like episodes 
(10). In 1990 the Adenine to Guanine transition at position 3243 of mitochondrial DNA 
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(m.3243A>G) in the MT-TL1 gene encoding tRNALEU(UUR) was found as the molecular basis 
for this disease (11, 12). The m.3243A>G mutation in the MT-TL1 gene is the most common 
cause of MELAS syndrome, therefore the mutation is also known as the ‘MELAS mutation’.
Other mitochondrial syndromes have been identified to be caused by this mutation as 
well, including maternally inherited diabetes and deafness (MIDD) (13), Chronic Progressive 
External Ophthalmoplegia (CPEO) (14) and myoclonic epilepsy with ragged-red fibers 
(MERRF) (15). These syndromes can also be present as overlap syndromes (16). Besides 
these well-defined mitochondrial syndromes there are numerous clinical symptoms reported 
in association with the m.3243A>G mutation. These symptoms can present isolated or 
can occur combined with other symptoms. Previously reported symptoms in carriers of 
the m.3243A>G mutation are: hypertrophic cardiomyopathy (17), macular dystrophy 
(18), gastro-intestinal involvement (19), focal segmental glomerulosclerosis (FSGS) (20), 
psychiatric disturbances (21), obstetric complications (22), and oligosymptomatic variants 
of the previously mentioned mitochondrial syndromes (23).
The m.3243A>G mutation is the most prevalent pathogenic mutation of the mitochondrial 
DNA. Epidemiologic studies show an m.3243A>G mutation prevalence of 7.59/100,000 
in the population of North-East England (24), 16.3/100,000 in the population of Northern 
Finland (25) and up to 236/100,000 in the population of Australia (26). These studies did 
not give a complete insight in the phenotypic expression of the m.3243A>G mutation in 
the subjects examined. The high mutation prevalence in the most recent study indicates 
a high number of undiagnosed carriers of the m.3243A>G mutation. 
Since mitochondria and mtDNA are present in almost all tissues, heteroplasmy 
can theoretically be assessed in virtually every tissue. Invasively obtained muscle tissue 
heteroplasmy usually gives a higher and more consistent heteroplasmy level than 
conveniently attained blood, in de last case possibly leading to false-negative results (27). 
Recent studies showed a superiority of urine over blood as preferred non-invasive tissue 
for mutation analysis of the m.3243A>G mutation (28). The relationship between mutation 
load and clinical phenotypes has been a subject of research for many years (29, 30). 
m.3243A>G cohort studies
Several cohorts of carriers of the m.3243A>G mutation have been reported in literature. 
To give inside results and conclusions of these studies, a summary is shown below. The 
first study dates back to 1997, whereas the most recent study is published in 2018. The 
studies from this thesis (chapter 2 and 3) are not included in this summary. 
In 1997 it was Patrick F. Chinnery who first described a cohort of carriers of the 
m.3243A>G mutation (29). The cohort was an extensive review of cases from literature 
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1extended with own cases from the Department of Neurology in Newcastle Upon Tyne. A total 
of 184 carriers of the m.3243A>G were identified. Average heteroplasmy level in skeletal 
muscle was ~72.9%. Observed clinical features were predominantly of neurologic origin: 
recurrent strokes 48%, CPEO 28%, epilepsy 50% and ataxia 24%. Pigmentary retinopathy 
(15%), diabetes (15%) and deafness (44%) were also observed in a significant number of 
patients. Gastrointestinal features and cardiomyopathy were both only indentified in three 
patients. No relationship was observed between the level of heteroplasmy in blood and 
the frequency of any clinical feature. A positive relationship between heteroplasmy levels in 
skeletal muscle and the presence of strokes, epilepsy, ataxia and dementia was demonstrated. 
An opposite relationship was demonstrated for myopathy, CPEO and deafness.
A second cohort of carriers of the m.3243A>G was described by Guillausseau in 2001 
(31). This study included 71 patients from France. The paper focused on the 54 patients 
with diabetes. The other included three MELAS patients, 12 healthy carriers (dormant 
carriers), and two patients with isolated glucose intolerance. Of the 54 patients (21 men), 
53 experienced bilateral neurosensory hearing loss and could therefore be classified as 
MIDD patients. Other classic phenotypic expressions of the m.3243A>G mutation were 
also noted: Macular pattern dystrophy (86%), neuromuscular disorders (43.1%), kidney 
disease (28%), cardiomyopathy (14.8%) and psychiatric disturbance (18%). All patients had 
a normal to low BMI, so at that time the authors concluded that diabetes in the absence 
of obesity and together with the presence of deafness should alert the clinician to the 
possibility of MIDD.
In 2006 Majamaa-Voltti et al. published a clinical follow-up study of 33 carriers of 
the m.3243A>G mutation (32). The cohort consisted of 12 probands and 21 first degree 
family members, recruited from the population survey of mitochondrial disease in the 
province of Northern Ostrobothnia in Finland. At entry of the study their clinical features 
included; hearing loss (67%), cognitive decline (50%), diabetes mellitus (49%) short stature 
(42%) and left ventricular hypertrophy (42%). Epilepsy (18%) and stroke-like episodes (9%) 
were much less frequent encountered symptoms compared to the study of Chinnery. 
During a 3-year follow-up, significant deterioration of hearing occurred and left ventricular 
wall thickness increased without significant impact on left ventricular function. Seven 
patients died during the 3-year follow-up, in 5 of the deceased patients cardiomyopathy 
was present. The deceased patients had a more severe phenotypic expression of the 
m.3243A>G mutation, compared to the survivors, however the causes of death were not 
reported in the manuscript. 
In 2011, Kaufmann et al. described a cohort follow-up of 35 families, including 85 
maternal relatives (33). The study contained 31 MELAS patients (mean follow-up 3.8±2.2 
yrs), and 54 of their carrier relatives (mean follow-up 5.5±3.0 yrs). An additional 24 MELAS 
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patients were studied in a single visit. All patients were included at Colombia University 
Medical Center in the city of New York. The frequencies of symptoms were reported 
separately for patients and carrier relatives. Reported symptoms were respectively 
for patients and carrier relatives; exercise intolerance (93% and 48%), gastrointestinal 
disturbance (90% and 43%), loss of hearing (70% and 34%), diabetes (39% and 30%) and 
ptosis (41% and 16%). Genetically there was a decrease in heteroplasmy levels in blood 
over time. The patients had significant higher heteroplasmy levels in blood and urine, 
compared to their carrier relatives. During the follow-up period 24 patients died. Three of 
the carrier relatives died, all not related to the m.3243A>G mutation. Of the 21 patients 
that died, four died due to a cardiac cause, while the remaining patients died of neurologic 
complications, which were in three patients complicated by sepsis. Gastro intestinal 
pseudo obstruction was noted in one-third of the patients during the end-of-live period. 
Ma et al. reported 47 Chinese families harboring the m.3243A>G mutation. They 
studied 47 probands, their 47 mothers and 14 siblings. The probands were predominantly 
children (age 11.18±6.51 yrs). Their phenotypic expressions were consistent with MELAS 
syndrome in a majority of the cases. In the mothers there was an elevated lactate in 
40.4%. Myopathy was present in 36.2%. Hearing loss en gastro intestinal symptoms were 
present in 12.8% and diabetes in 8.5%. There was no presence of seizures or stroke like 
episodes in the mothers. In the siblings there were two cases (14.3%) of stroke like episodes 
and seizures. All other reported clinical manifestations occurred in 1 to 7 (7.1–50%) of 
the siblings. Heteroplasmy levels in the probands were threefold higher in blood and 
twofold higher in urine compared to their mothers. Eleven mothers had 2 children. Four 
mothers with a low heteroplasmy level in urine (4.6–16.5%) were reported to have only 
transmitted the mutation to the probands and not to a second sibling. Seven mothers 
with a heteroplasmy level of 5–52.3% in urine, transmitted the mutation to both children. 
Three mothers did not harbor the mutation, their offspring should be classified as a ‘de 
novo’ probands, as their siblings did not harbor the mutation either. 
A Taiwanese cohort of 22 patients was reported by Lui et al. in 2011 (34). The patients 
were retrospectively reviewed at the Chang Gung Memorial Hospital between 1988 and 
2009. The patients are grouped by prognosis scored by the Modified Rankin Scale (MRS), 
where MRS 0–3 is a good prognosis and >4 is a bad prognosis. 14 patients had a bad 
prognosis, of which 12 died during follow-up, and 2 remained severely disabled. The causes 
of death were not reported. Between groups there was no difference in sex or age at onset. 
Seizures and stroke-like episodes were more prevalent in the poor prognosis group. For 
all other symptoms, including neuropathy, myopathy, diabetes, ataxia, cardiomyopathy 
and dystonia there was no significant difference between the groups. Differences in 
heteroplasmy levels between the groups were not reported. 
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1In 2013, Victoria Nesbitt published a report on the clinical phenotypes associated 
with the m.3243A>G mutation in 129 carriers from 83 families whom were recruited to 
the Mitochondrial Disease Patient Cohort Study UK between 2009 and 2011 (16). Sixty 
eight patients (53%) were considered to have a mitochondrial phenotype that should 
prompt screening for the m.3243A>G mutation including; MELAS (10%), MIDD (30%), 
overlap syndromes (MELAS/MIDD/CPEO) occurred in 21%, MERRF in 1 patient (<1%). 
Sensorineural hearing loss was evident in 66 patients (51%), diabetes was present in 54 
patients (42%). Thirty six patients (28%) did not conform to any of the classical syndromes 
associated with the m.3243A>G mutation, these patients experienced proximal myopathy, 
ataxia, migraine and seizures. A total of 12 individuals (9%) harboring the mutation were 
clinically asymptomatic, these carriers could be categorized as dormant carriers. No 
follow-up data is provided in this report. 
A retrospective cohort study, including 126 patients carrying the m.3243A>G mutation 
from the “Nation-wide Italian Collaborative Network of Mitochondrial Diseases” was 
published in 2014 by Mancuso et al. (35). The phenotypic expressions of these patients 
included: hearing loss (57.9%); diabetes (40.5%), stroke-like episodes (40.5%), muscle 
weakness (39.7%), generalized seizures (37.3%), exercise intolerance (32.5%) and heart 
disease (31.7%). Less frequent expressions were; ptosis/ophthalmoparesis, migraine, 
cognitive impairment, muscle wasting (20–29.9%); ataxia, increased CK levels, failure to 
thrive/short stature (15–19.9%); gastrointestinal dysmotility, hypotonia, pyramidal signs, 
peripheral neuropathy, muscle pain, retinopathy (10–14.9%). Six percent of the m.3243A>G 
mutation carriers was asymptomatic. Seventeen patients died at a mean age of 37.2±22.3 
years, caused by cardiocirculatory failure (4 patients), stroke (3 patients), status epilepticus 
and intractable lactic acidosis (1 patient both). The cause of death was unknown in the 
remaining eight patients. There authors report no significant differences in age at onset 
or heteroplasmy levels between the MELAS and non-MELAS patients. They do report an 
enrichment of males in the MELAS group, which was not explained by other confounding 
factors. ‘Pure’ MIDD was only reported in 3 patients, whereas diabetes and hearing loss 
were reported in 57.9% and 40.5% of the patients, the authors therefore argue if there is 
validity for the acronym MIDD. 
In a study reporting detection rates of the m.3243A>G mutation from a molecular 
diagnostic laboratory perspective, Chin et al. reported the phenotypic spectrum of 35 
patients carrying the m.3243A>G mutation at the Victory, New South Wales and Tasmania 
regions of Australia (36). Reported clinical features included; deafness (62.8%), diabetes 
(51.4%), proximal limb weakness (31.4%), headache/migraine (28.6%), elevated lactate 
(22.9%), exercise intolerance (22.9%), short stature (22.9%), stroke (20%) and seizures 
(20%), macular degeneration/retinopathy (17.1%), nausea/vomiting (17.1%), ptosis (14.2%), 
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ophthalmoplegia (14.2%), cerebellar signs (14.2%), Neuropathy (11.4%), intellectually 
disability (11.4%), ataxia (8.6%), cardiomyopathy (5.7%), and GI pseudo obstruction 
(5.7%). No follow-up data was reported, nor were heteroplasmy levels correlated to the 
phenotypic spectrum of the patients. 
Retrospective follow-up of a cohort of 50 Czech carriers with the m.3243A>G mutation 
was published by Dvorakova et al. in 2016 (23). The cohort included 14 fully expressed 
patients (MELAS phenotype), 19 oligosymptomatic patients and 17 dormant carriers from 
22 unrelated families. Of the 33 patients the most frequently reported symptoms were; 
hearing loss (n=25), myopathy (n=19), CPEO (n=15), gastrointestinal dysmotility (n=15), 
diabetes (n=14), seizures (n=14), stroke like episodes (n=12), intellectual disability (n=12), 
short stature (n=12) and ptosis (n=12). Other less frequently reported symptoms include: 
Migraine, cerebellar symptoms, pigmentary retinal dystrophy, depression, cardiomyopathy 
and thyroid gland disease. Eleven patients died during follow-up, most frequent causes 
of death were heart failure in patients and infection with metabolic derangement that 
was irresponsive to therapy. Suicide due to depression was documented in one patient. 
Heteroplasmy levels in UEC, hair and blood showed a significant relation with disease 
severity. However, due to the great overlap in heteroplasmy levels between the three 
groups, no clinically relevant threshold level could be determined. As only 1 patient in the 
cohort manifested ‘pure’ MIDD, and the interval for the development of additional features 
reached up to 28 years the authors argue to identify patients with isolated symptoms as 
oligosymptomatic MELAS, rather than pure MIDD. 
A description of 100 Chinese pediatric patients with the m.3243A>G mutation was 
published in 2016. Xia et al. retrospectively described the clinical spectrum of 100 pediatric 
patients with the m.3243A>G mutation, from the Peking University First Hospital identified 
between 2007 and 2013. The most frequent symptoms were seizures (76%), short stature 
(73%), elevated plasma lactate (70%), abnormal magnetic resonance imaging/computed 
tomography (MRI/CT) changes (68%), vomiting (55%), decreased vision (52%), headache 
(50%), and muscle weakness (48%). Less frequent were heart disease (35%) and hearing 
loss (21%). Heteroplasmy levels in blood were correlated negatively with onset age (r=-
0.470, p<0.001). Myopathy was more frequent in patients with a higher heteroplasmy 
level. However, patients with a low or middle level of m.3243A>G mutation heteroplasmy 
were more likely to suffer hearing loss, decreased vision, and gastrointestinal disturbance 
than patients with a high level.
A paper published in 2017 by Fayssoil et. al. focuses on the prediction value of 
heteroplasmy levels in patients carrying the m.3243A>G mutation. Their cohort consists 
of 43 patients (12 male) with the m.3243A>G mutations, of whom 36 were symptomatic. 
Clinical characteristics include: hearing loss (74%), diabetes mellitus (58%), low weight 
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1(45%), left ventricular hypertrophy (45%), neuropathy (30%), muscle weakness (25%), 
depression (23%), epilepsy (19%), stroke like episodes (7%). The presence of major adverse 
events (MAE), defined as medical complications requiring hospitalization or leading to 
death, was studied. Urine heteroplasmy >45%, seizures and left ventricular hypertrophy 
were identified as patient characteristics with an independent predictability of MAE.
 A 10-year follow-up on a Danish cohort of 46 individuals carrying the m.3243A>G 
mutation was published in 2017 by Langdahl et al.(37) A decline of heteroplasmy levels 
in leucocytes was observed to be 0.7 percent point per year, consistent with previous 
studies (with shorter follow-up). There were 11 deaths reported (median age 51.7 years), 
SLE (n=4), heart failure (n=2), and cardiac arrest, pulmonary embolism and kidney failure 
(n=1), two death were of unknown origin. All of the patients who developed MELAS, 
nephropathy and/or cardiomyopathy had a urine heteroplasmy of >45%. 
The two most recent studies describing the largest cohort (n=242) of carriers of the 
m.3243A>G mutation were published by Grady et al. and Pickett et al., both from the 
Wellcome Centre for Mitochondrial Research at Newcastle upon Tyne, UK (30, 38). Both 
studies focus on predicting clinical outcome in carriers of the m.3243A>G mutation. Disease 
involvement is scored using the Newcastle Mitochondrial Disease Adult Score (NMDAS). 
Using complex statistical methods, they conclude that leukocyte heteroplasmy (corrected 
for age) is among the most useful predictors of disease severity, but there remains a large 
proportion of clinical variability that cannot be predicted by known biomarkers or genetic 
variance. It is hypothesized that nuclear factors may play a big part in this the phenotypic 
expression as there is a significant heritability of specific phenotypic traits among families. 
Thesis outline and aims
Knowledge of the natural disease course is important for patient care, counselling, and 
might also be a prerequisite for treatment development for mitochondrial disease in 
general and for carriers of the m.3243A>G mutation in specific. In studying the natural 
disease course, three domains can be distinguished; 1) general disease involvement, 2) 
genetics and 3) organ specific disease involvement. 
Part 1. General disease involvement
Before clinical trials in patients with mitochondrial disease due to the m.3243A>G mutation 
can be developed, it is important to have sufficient knowledge of the natural disease 
course. Chapter 2 describes a cohort of 34 Dutch families harboring the m.3243A>G 
mutation. Chapter 3 shows the prospective follow-up of the families of Chapter 1, along 
with an additional 25 families. 
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Part 2. Genetics
Extensive knowledge of genetics of a specific disease or specific DNA mutation is essential 
for proper counselling of patients. The m.3243A>G mutation is a mutation in the mtDNA 
which has a different mode of inheritance as compared to Mendelian (nuclear) inherited 
mutations. By studying mother-sibling and sibling-sibling relations we try to obtain insight 
in the mode of inheritance in these patients. Chapter 4 focus on the inheritance of the 
m.3243A>G mutation. In Chapter 5 three families with a ‘de novo’ appearance of the 
m.3243A>G mutation are presented. In addition to the mode of inheritance we also aim to 
identify the best tissue to examine the m.3243A>G mutation. Muscle has been considered 
the gold-standard for genetic testing of mitochondrial DNA, but a muscle biopsy is an 
invasive procedure. Genetic testing of blood and urine is much more convenient, but 
heteroplasmy levels of these tissues differ from muscle. This might have both diagnostic 
and prognostic consequences. Chapter 6 examines the value of the use of urine samples 
for heteroplasmy detection.
Part 3. Organ specific disease involvement
A mitochondrial disease can be present in all organs. To obtain more knowledge of 
the phenotypic expression of the m.3243A>G mutation we studied several different 
organs. In comparison to general disease involvement studies, the studies regarding 
specific organ involvement reach much more precision and detail in the pathology of the 
effected organ. This knowledge can be used for a better understanding of the variety of 
phenotypic expressions of the m.3243A>G mutation, as for the development of organ 
specific outcome measures to use in future treatment development. In Chapter 7 and 8 
psychological aspects like Quality of Life, fatigue and fear of progression of disease are 
studied. In Chapter 9 the ophthalmological involvement is studied. Chapter 10 shows 
the extent of gastrointestinal problems in carriers of the m.3243A>G mutation. Chapter 
11 describes the follow-up of five patients with the m.3243A>G mutation who received 
a kidney transplantation and a review of the literature concerning this topic. Chapter 12 
describes the high frequency of obstetric complications in carriers of the m.3243A>G 
mutation. 
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Abstract
The m.3243A>G mutation has become known as the MELAS mutation. However, many 
other clinical phenotypes associated with this mutation have been described, most 
frequently being Maternally Inherited Diabetes and Deafness (MIDD). The m.3243A>G 
mutation, can be detected in virtually all tissues, however heteroplasmy differs between 
samples. Recent reports indicate, a preference to perform mutation analysis  in Urinary 
Epithelial Cells (UEC).
To test this, and to study a correlation between the mutational load in different tissues 
with two mitochondrial scoring systems (NMDAS and NPMDS) we investigated 34 families 
carrying the m.3243A>G mutation. Heteroplasmy was determined in three non-invasively 
collected samples, namely leucocytes, UEC and buccal mucosa.
We included 127 patients, of which 82 carried the m.3243A>G mutation. None of 
the children (n=11) had specific complaints. In adults (n=71), a median NMDAS score of 
15 (IQR 10–24) was found. The most prevalent symptoms were hearing loss (68%), gastro-
intestinal problems (59%), exercise intolerance (54%) and glucose intolerance (52%). Ten 
patients had neurologic involvement. 
Buccal mucosa had the best correlation with the NMDAS in all adults (r=0.437, 
p<0.001), whereas UEC had the strongest correlation with the NMDAS in severely affected 
patients (r=0.593, p=0.002). Heteroplasmy declined significantly with increasing age in all 
three samples (leucocytes r=-0.705 (p<0.001), UEC r=-0.374 (p=0.001), buccal mucosa 
r=-0.460 (p<0.001).
In our cohort of 82 patients, the m.3243A>G mutation causes a wide variety of signs 
and symptoms, MIDD being far more prevalent than MELAS. Looking at the characteristics 
of the three non-invasively available tissues for testing heteroplasmy we confirm that UEC 
are the preferred sample to test.
Key sentence/synopsis
The m.3243A>G mutation causes a wide variety of signs and symptoms, UEC are the 
preferred tissues for testing heteroplasmy. Dormant carriers should be checked regularly 
by a specialized physician to see whether the disease has awaken and to be early in 
preventing and treating symptoms.
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Introduction
Mitochondria are responsible for production of adenosine triphosphate (ATP), through 
oxidative phosphorylation (OXPHOS). Mitochondrial dysfunction can result from mutations 
in either nuclear DNA (nDNA) or mitochondrial DNA (mtDNA). 
The incidence of congenital mitochondrial disorders based on an OXPHOS defect 
is at least 1:8500 of all live births (1). 
Mitochondrial DNA encodes 37 genes, 22 code for tRNA’s, two for rRNA’s and thirteen 
code for subunits of the OXPHOS complexes I, III, IV and V. 
Two important features of mitochondrial mutations are; A) maternal inheritance, it can 
be assumed that all relatives from the maternal line are (dormant) carriers of the mutation. 
This applies only if there is not a de novo mutation And B) heteroplasmy, human cells 
contain over 100–1000 mitochondria each, every mitochondrion contains 1–10 copies of 
mtDNA. When all mtDNA copies are mutated, there is a homoplasmic mutation. When 
however not all mtDNA copies are mutated, there is a variation in mutation load and the 
mutation is called heteroplasmic (2). Heteroplasmy can vary between different tissues of 
one patient and between one tissue in one patient in time (3). This variation in heteroplasmy 
between tissues complicates the demonstration of a relationship between the severity 
of the disease in a non accessible organ (e.g. the heart or the brain) and the degree of 
heteroplasmy in blood, urine or buccal mucosa. 
The acronym MELAS was first used in 1984 by Pavlakis et al. to describe a group of 
patients with Mitochondrial myopathy, Encephalopathy, Lactic Acidosis and Stroke-like 
episodes (4). In 1990 the Adenine to Guanine transition at position 3243 of mitochondrial 
DNA (m.3243A>G) in the MT-TL1 gene encoding tRNALEU(UUR) was found as molecular 
basis for this disease (5, 6). A mutation in tRNA commonly causes a combined defect of 
the mtDNA encoded OXPHOS complexes. tRNALEU(UUR) is partially (~12%) responsible for 
the incorporation of leucine into mitochondrial DNA encoded proteins, tRNALEU(CUN) is 
responsible for the other part (~88%) (7). It is proposed that because of the minimal role 
of tRNALEU(UUR) in incorporation of leucine, a mutation the tRNALEU(UUR) is less lethal and 
therefore more frequently detected (7). 
The m.3243A>G mutation in the MT-TL1 gene is the most common cause of MELAS 
syndrome, therefore the mutation is also known as the MELAS mutation. Later, more and 
more phenotypic expressions of the m.3243A>G mutation were found, including maternally 
inherited diabetes deafness (MIDD) (8), hypertrophic cardiomyopathy (9), macular 
dystrophy (10), focal segmental glomeruloslerosis (FSGS) (11), myoclonic epilepsy with 
ragged-red fibers (MERRF)(12) and oligosymptomatic variants of the acronym MELAS (13). 
Epidemiologic studies show a m.3243A>G mutation prevalence of 7.59/100,000 in 
the population of North-East England (14), 16.3/100,000 in the population of Northern 
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Finland (15) and up to 236/100,000 in the population of Australia (16). These studies did 
not give a complete insight in the phenotypic expression of the m.3243A>G mutation in 
the subjects examined. The high mutation prevalence in the most recent study indicates 
a high number of undiagnosed carriers of the m.3243A>G mutation. 
Since mitochondria and mtDNA are present in almost all tissues, heteroplasmy 
can theoretically be assessed in virtually every tissue. Two problems arise when 
testing heteroplasmy: the convenience of obtaining the sample and the differences in 
heteroplasmy levels between samples. For example, invasively obtained muscle tissue 
heteroplasmy usually gives a higher and more consistent level than conveniently attained 
blood, in de last case possibly leading to false-negative results. Recent studies showed 
a superiority of urine over blood as preferred non-invasive tissue for mutation analysis 
(3, 17, 18). The relationship between mutation load and clinical phenotypes has been a 
subject of research for many years (19). Whittaker et al. and Ma et al. recently showed a 
relationship between heteroplasmy levels in urinary epithelia and clinical symptoms in a 
small number of patients (17, 20).
Some of the many questions regarding the m.3243A>G mutation that we have 
include: Are all mutation carriers symptomatic? Should these carriers undergo screening 
for frequent and preventable symptoms such as cardiomyopathy, glucose intolerance, 
nephropathy or macular dystrophy? How should female carriers be counseled regarding 
fertility questions? 
In this study, we clinically evaluated 34 Dutch families, probands and maternal 
relatives, carrying the m.3243A>G mutation. We provide data about the whole phenotypic 
spectrum of m.3243A>G mutation as well as information regarding the correlation between 
the level of heteroplasmy in different samples and the clinical severity of the disease. 
Patients and methods
Patients
All probands are patients of the Nijmegen Center for Mitochondrial Disorders at the 
Radboud University Nijmegen Medical Centre, The Netherlands, diagnosed with the 
m.3243A>G mutation in muscle or blood. All patients and maternal relatives were 
recruited by a letter, in which they were invited to participate in this study. This study was 
approved by the ethics committee of the Nijmegen-Arnhem region, The Netherlands. 
Written informed consent according to the Helsinki agreement was obtained from all 
parents and patients ≥12 years.
Clinical features of the m.3243A>G mutation
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Newcastle Mitochondrial Disease Scales
All patients were invited for a single visit to our out-patient clinic. Adult patients (>18 
yrs) were scored using the Newcastle Mitochondrial Disease Adult Scale (NMDAS) (21), 
pediatric patients (<18 yrs) were scored using the Newcastle Pediatric Mitochondrial 
Disease Scale (NPMDS) (22). The NMDAS and NPMDS constitute a validated method to 
monitor the clinical expression of mitochondrial disease and to follow-up the course of 
disease in time. The NMDAS and NPMDS consist of the following four sections. 1) Current 
function, gives insight into the general functioning of patients in past four weeks. 2) System-
specific involvement, uses a clinical history supplemented by specific information to gain 
insight in the functioning of individual organ-systems. 3) Current clinical assessment, a 
general and neurological clinical examination, gives insight in the current functional status 
of the patient. This section includes three cognition tests. We were able to use the English 
symbol test, since it does not use language. For the reading test we used a Dutch equivalent 
test. In absence of a Dutch equivalent test for the Speed of Comprehension we could not 
use this test. We scored the cognition based on the symbol test and reading test only. 
Section 1 to 3 of the NMDAS consists respectively of ten, nine and ten questions, 
which can be scored from 0 (no involvement) to 5 (severe involvement). For section 4, 
Quality of life, we used a Dutch translation of the SF-12v2 quality of life test. A score from 
0 to 70 for mental and physical health, where 50 is the population mean, is obtained from 
this quality of life score. The NPMDS exist respectively of seven, ten and nine questions, 
which can be scored from 0 (no involvement) to 3 (severe involvement). Section 4: Quality 
of life, uses a specially designed quality of life questionnaire for children. These do not 
have a reference score, so we can only use them to show a difference in time, therefore 
they are not mentioned in this report. Intra-observer and inter-observer variability was 
shown to be low in both the NMDAS and the NPMDS (21, 22). All patients were scored 
independently by the same two investigators (PdL, SK), after which consensus was reached. 
The consensus score is used in the results of the study. 
m.3243A>G mutation analysis
At the same visit during which the NMDAS or NPMDS was scored, blood, saliva and 
urine was collected for heteroplasmy analysis. DNA was isolated from peripheral blood 
leukocytes using a salting-out method. The urine sediments and buccal swab samples 
were centrifuged for 10 min at 3000 r.p.m., the pellet was washed with phosphate-buffered 
saline. DNA was extracted using a commercially available DNA isolation kit (PuregeneTM 
DNA isolation kit; Gentra Systems, MN).
DNA samples were analyzed quantitatively using PyrosequencingTM technology 
(Pyrosequencing, Upsala, Sweden). Pyrosequencing was performed according to the protocol of 
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the manufacturer. PCR of a mtDNA fragment containing the 3243 position was performed using 
the following primers: universal primer (biotinylated), 50-GGGACACCGCTGATCGTTTA-30; 
forward primer, 50-GACGGGACACCGCTGATCGTTTACAACTTAGTA TTATACCCACAC-30; 
and reverse primer, 50-ATTAGAATGGGTACAATGAGGA-30. PCR was carried out in a 50 
ml volume containing 0.02 mM forward primer, 0.2 mM reverse primer and 0.2 mM of the 
biotinylated universal primer. PCR conditions were 92°C for 30 s, 55°C for 30 s, 72°C for 
30 s, for a total of 40 cycles. Single-stranded template DNA, which in the present assay 
is the forward strand of the fragment, was purified using streptavidin-coated Sepharose 
beads. The actual pyrosequencing was performed on the PSQ96 platform using sequence 
primer 50-TATGCGATTACCGGGC-30. In a pyrosequence reaction, the four different 
deoxynucleotide triphosphates (dNTPs) are added separately one after the other. The 
incorporation of dNTP is accompanied by release of pyrophosphate (PPi). This PPi is involved 
in a light-producing reaction of which the amount of light produced is proportional to the 
number of nucleotides incorporated. The light is detected by a charge coupled device 
camera and seen as a peak in a pyrogram. Apyrase, a nucleotide-degrading enzyme, 
continuously degrades ATP involved in the light-producing reaction, and unincorporates 
dNTPs. This switches off light production and regenerates the reaction solution. Because 
the forward strand is used as template in the sequencing reaction, the change detected 
in the present assay concerns a T to C exchange. In fact, the amount of dTTP and dCTP 
incorporated at position 3243 during the sequencing reaction was determined in this way 
and from this the percentage of heteroplasmy was calculated. The pyrosequence reaction 
of the m.3234A>G mutation has a precision of 1.5%. The mutation is detected from a 
heteroplasmy level of 5%. The detection limit for the MELAS mutation (m.3243A>G) was 
determined by serial dilution of a sample containing this mutation with wild type mtDNA.
Statistics
We used descriptive statistics to present patient characteristics and the results of the 
NMDAS and NPMDS. All data are presented as a median with interquartile ranges (IQR, 
25th and 75th percentiles). Non-parametric tests were used if the data did not reflect a 
Gaussian distribution. Spearman’s rho correlation coefficient was used to evaluate the 
relationship between the clinical scores with the heteroplasmy in the different tissues. 
Pearson’s correlation was used to correlate heteroplasmy in different levels to each other 
and to age. A t-test was used to compare the quality of life of the m.3243A>G mutation 
carriers to reference values.
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Results
Patient characteristics 
127 Individuals from 34 families were included in the study. The cohort consists of 24 
probands. 48 family members were related in the first degree to a proband, 28 in the 
second degree, 18 in the third degree and nine in the fourth degree. The age of the 
patients ranged from two months to 80 years, median 39 years (IQR: 25–54 yrs). Forty-
two patients were male and 85 female (ratio 1:2.02). In 82 individuals the m.3243A>G 
mutation was detected in at least one of the samples. In 45 family members the mutation 
was not detected. 
Children
Eleven children (4 male, 7 female) carrying the m.3243A>G mutation were scored using the 
NPMDS. Two boys were probands, the other nine patients were maternal family members. 
The median age was 6 years (IQR 5.5–8.5 yrs) Five children scored zero points on the 
NPMDAS, two children scored one point, three children scored two points and one child 
scored four points. The main complaints were a delay in development (in five children) in 
early childhood, which had been caught up by the time of investigation. One girl attended 
special school for learning difficulties. One boy had communicational problems both in 
his native language (Turkish) as in Dutch. Heteroplasmy in UEC in these children ranged 
from 8–93% and had a median level of 59% (IQR: 31.5–77%). 
Adults
Seventy-one adult carriers (25 male, 46 female) of the m.3243A>G mutation were scored 
using the NMDAS. The median age was 45 years (IQR: 34–55 yrs).  
They had a median clinical score of: 4 (IQR: 1–7) on section 1; 4 (IQR 1–8) on section 
2; and 3 (IQR 0–6) on section 3. The total median score of section 1–3 was 15 (IQR 10–24). 
Table 2.1 presents the symptoms sorted by prevalence. A complete overview of all 
results can be found in Figures 2.1a-c. 
Summary of the most important findings  
Hearing: 48 carriers (67.6%) had hearing difficulties. 24 carriers experienced mild deafness, 
whereas another 19 carriers had moderate deafness (not fully corrected with hearing aid), 
three carriers had severe deafness (poor even with hearing aid) and two carriers had end 
stage deafness requiring a cochlear implant.  
Exercise tolerance: 38 carriers (53.5%) had a compromised exercise tolerance. 
Twenty-five were only limited on inclines or stairs, whereas the other carriers were also 
limited on flat services.
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Gait stability and cerebellar ataxia: 36 carriers (50.7%) reported difficulties maintaining 
their stability. 35 carriers (49.3%) had difficulties with the heel-toe test at the clinical 
assessment. Eight carriers reported difficulties on uneven grounds and 21 carriers reported 
occasional balance problems when walking. Six carriers reported occasional falls because 
Table 2.1: Signs and symptoms of the m.3243A>G mutation scored by the NMDAS, sorted by 
prevalence (n=71)
Signs and symptoms Prevalence (%)
Hearing loss 68 
Gastro-intestinal symptoms 59 
Decreased vision 59 
Exercise intolerance 54 
Glucose intolerance 52 
Gait instability 51 
Cerebellar ataxia 49 
Myopathy 48 
Cognition  <33th percentile 45 
Ptosis 45 
Cardiovascular involvement 44 
Vision complaints 37 
Respiratory muscle weakness 37 
Problems dressing  34 
Problems hygiene 34 
Speech difficulties 31 
Psychiatric problems 28 
Migraine headaches 25 
Neuropathy 20 
Swallowing difficulties 18 
Dysphonia / dysarthria 17 
Apraxia 13 
Handwriting difficulties 13 
Seizures 13 
CPEO 7 
Encephalopatic episodes 6 
Stroke-like episodes 6 
Pyramidal involvement 6 
Extrapiramidal involvement 3 
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Figure 2.1 a-c: All clinical features scored by the NMDAS.
Results of the Newcastle Mitochondrial Disease Adult Scale (NMDAS) are shown divided in the three 
sections of the scale, for all adult carriers of the m.3243A>G mutaion (n=71). A) Section 1: Current 
function; B) Section 2: System-specific involvement. Figure continues on next page.
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Figure 2.1 a-c: Continued.
C) Section 3: Current clinical assessment.
of balance problems, one patient was unable to walk unsupported. On clinical assessment 
23 carriers had a hesitant heel-toe test, nine were unable to maintain heel-toe walking 
and three carriers were unable to walk heel-toe. 
Gastro-intestinal symptoms: 42 carriers (59.2%) reported gastro-intestinal symptoms. 
14 had mild constipation, six had occasional symptoms of irritable bowel. 17 carriers had 
severe constipation (requiring daily medication) or severe irritable bowel complaints, in 
five carriers gastro-intestinal symptoms were that severe they needed hospital admission, 
3 of them underwent surgical procedures for gastro-intestinal dysmotility.
Diabetes mellitus: 37 carriers (52.1%) had a compromised glucose tolerance, for 
which ten were treated with tablets (non insulin depending diabetes mellitus) and 20 
required insulin treatment (insulin depending diabetes mellitus). Four patient were on a 
diet and two carriers received no treatment for impaired glucose tolerance, one patient 
reported diabetes gravidarum. 
Ptosis: 32 carriers (45.1%) had a ptosis, mild ptosis (not obscuring either pupil) 
occurred in 23 carriers, moderate ptosis occurred in eight carriers, whereas one patient 
had a severe ptosis (obscuring bilateral >1/3 of pupils). 
Myopathy: 34 carriers (47.9%) had reduced muscle strength. 21 carriers had minimal 
muscle weakness in hip flexion or shoulder abduction only (MRC 4+/5). Eight carriers 
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had mild proximal muscle weakness (MRC 4/5) and four carriers had moderate muscle 
weakness (MRC 4) with difficulty to rise from 90 degree squat. One patient was unable 
to rise from 90 degree squat.
Cardiomyopathy: 25 carriers (38.5%) had cardiac involvement. 16 had asymptomatic 
changes on electrocardiogram, mainly repolarization disturbances. One had asymptomatic 
left ventricular hypertrophy (LVH). Seven had cardiomyopathy of which four had an 
ejection fraction of less than 30%. One patient had a pacemaker for a complete AV-block. 
Epilepsy: A history of seizures was present in nine carriers, of which three had had 
seizures in the past year. Stroke-like Episodes: A history of Stroke-like Episodes was 
present in four carriers, of which three had Stroke-like Episodes in the past year. 
Further neurologic examination: Twelve carriers had subtle sensory symptoms or areflexia 
(in knee and elbow reflexes). Four carriers showed symptoms of pyramidal involvement 
and two carriers showed symptoms of extrapyramidal involvement. 
Section 4 of the NMDAS scores Quality of Life (QoL). It distinguishes Quality of 
Physical Health (QoLP) and Quality of Mental Health (QoLM). QoLP had a range of 17 to 
61, with a median of 41 (IQR 32–50). QoLM had a range of 25 to 66, with a median of 48 
(IQR 42–48) (Figure 2.2).
Figure 2.2: Quality of life.
Section 4 of the NMDAS is a QoL test, divided in QoLP and QoLM. All adult carriers of the 
m.3243A>G mutation are shown (n=71). The line at 50 shows the US average of the test. QoLP is 
significantly lower than the US average.
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Using a t-test a significant (p<0.001) lower QoLP was found in patients carrying the 
m.3243A>G mutation against the test average of 50. No difference in QoLM in carriers 
against the test average could be found (p=0.055). Comparing quality of life in carriers to 
non-carriers, there was a significant lower QoLP in carriers (p<0.001) and no difference in 
QoLM (p=0.395). The QoLP was significantly negatively correlated to the NMDAS (r=-0.565, 
p>0.001). There was no correlation between QoL and the heteroplasmy in any of the samples. 
Heteroplasmy levels
Heteroplasmy levels in leucocytes were determined in 126 individuals (one child refused 
the blood draw), in UEC in 121 individuals (insufficient material was received at the 
laboratory in six individuals) and in buccal mucosa in all 127 individuals. 82 individuals 
had a heteroplasmy level of ≥5% in at least one of the samples. In the carriers, the mean 
heteroplasmy in leucocytes was 22% (range 2–65%), in UEC 48% (range 4–96%) and 35% 
(range 2–74%) in buccal mucosa. Despite these differences between the samples there 
were strong pair wise correlations between the samples (r=0.657–0.854, p<0.001 / see 
Figures 2.3a-c). A negative correlation between the level of heteroplasmy and age was 
present in all samples, for leucocytes r=-0.678 (p<0.001), for UEC r=-0.337 (p=0.003), 
and for buccal mucosa r=-0.432 (p<0.001) (see Figures 2.4a-c).
Figure 2.3 a-c.
Heteroplasmy levels in all patients carrying the m.3243A>G mutation (n=82) in three different 
samples (leucocytes, UEC and buccal mucosa) are correlated. Figure continues on next page.
A
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Figure 2.3 a-c: Continued.
B
C
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Figure 2.4 a-c: Heteroplasmy vs age.
Heteroplasmy levels in all patients carrying the m.3243A>G mutation (n=82) show a negative 
correlation to age in leucocytes, UEC and buccal saliva. Figure continues on next page.
A
B
Clinical features of the m.3243A>G mutation
41
2
Figure 2.4 a-c: Continued.
C
The heteroplasmy level in UEC was below the detection limit in one (1%) carrier that 
did have a detectable mutation load in buccal mucosa and leucocytes. Heteroplasmy 
levels in buccal mucosa were below the detection limit in seven (9%) carriers that did 
have a detectable mutation load in UEC. Heteroplasmy levels in leucocytes were below 
the detection limit in 12 (15%) carriers that did have a detectable mutation load in UEC.
A correlation between clinical condition of the patient and the level of heteroplasmy 
could not be made using the NPMDS in children, because of the limited number of 
pediatric carriers included in the study. In adults, there was a correlation between the score 
on the NMDAS and the heteroplasmy, in leucocytes r=0.254 (p=0.032), in UEC r=0.294 
(p=0.016), and in buccal mucosa r=0.427 (p<0.001) (see Figures 2.5a-c). Patients with a 
NMDAS of more than 20 (n=25), have a better correlation between the clinical scores and 
the heteroplasmy levels in leucocytes (r=0.366, p=0.072), and UEC (r=0.530, p=0.008).
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Figure 2.5 a-c: Heteroplasmy vs NMDAS score.
Heteroplasmy levels in leucocytes, UEC and buccal saliva in all adult patients carrying the m.3243A>G 
mutation (n=71) show a correlation to the score on the NMDAS. Figure continues on next page.
A
B
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Figure 2.5 a-c: Continued.
C
Discussion
Dormant carrier
Following the results of this study, we propose to introduce a new term in the mitochondrial 
genetic nomenclature: Dormant Carrier. The term “dormant carrier” is used to indicate 
that a patient that has a mitochondrial mutation, but has no obvious clinical symptoms 
of the mutation (yet). We have chosen this new term because we experienced that the 
nomenclature in mitochondrial inheritance has an overlap with nomenclature in Mendelian 
inheritance, which causes confusion in providing patient information. In the Mendelian 
nomenclature, a carrier is a patient that has a recessive mutation on one allele, and is never 
going to be a patient. On the contrary, a dormant carrier of a mitochondrial mutation may at 
some point become symptomatic (awake), depending on heteroplasmy levels and unknown 
other factors. In patient counseling and preventive medicine this makes a big difference. 
NMDAS and NPMDS
Since the Newcastle scores consists of subjective questions regarding the personal opinion 
of the patient on daily functioning (Section 1) and the interpretation of the findings at 
physical examination (Section 3), all patients were scored separately by two investigators.
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Only ten patients aged under eighteen were included in the study. All ten children 
had no or only minor complaints. However, we did include four families in which a child had 
died earlier because of symptoms of the m.3243A>G mutation, so no definite assumption 
can be made concerning the phenotype of the m.3243A>G mutation in children based 
on this study. The study does however show that children can be free of symptoms even 
with a high level of heteroplasmy (up to 93% in UEC). The adult patients with high levels 
of heteroplasmy developed complaints in late infancy to early adolescence. The younger 
children with high levels of heteroplasmy should therefore be closely monitored to indentify 
early symptoms of the clinical expression of the mutation at an early stage.
MELAS syndrome
The m.3243A>G mutation is most known for its relation with MELAS syndrome. In this study 
only one patient had Stroke-like Episodes (SLE) in the past year and three other patients 
had SLE in the past. Other neurologic symptoms as seizures (n=9) and encephalopathy 
(n=4) occurred also infrequent. Giving an indication that MELAS syndrome is not the 
primary expression of the m.3243A>G mutation in this cohort. This finding is in line with 
recent reports(16) that the m.3243A>G mutation is much more prevalent than previously 
thought. Patients presenting with symptoms of MELAS syndrome are often referred to a 
specialized centre in which exploratory research for mitochondrial mutation in performed. 
A patient with the m.3243A>G mutation with a MELAS syndrome phenotype is therefore 
unlikely to be missed. 
Maternally Inherited Diabetes Deafness (MIDD)
Forty-eight patients (67.6%) of this study had self reported hearing loss. Thirty-seven 
patients (52.1%) have diabetes mellitus. Only six of the 37 patients with diabetes mellitus 
do not have hearing loss. Making a total of 31 patients in this study that have Diabetes 
Deafness, giving an indication that MIDD is a more frequent expression of the m.3243A>G 
mutation than MELAS syndrome. The combination of diabetes mellitus and hearing loss 
is however less a trigger to refer a patient to a specialized centre. So a mutation analysis 
is less frequently performed. 
Multiorgan involvement
Besides the typical symptoms of MELAS syndrome or MIDD we observed high frequencies 
of other symptoms. Cardiac involvement, gastro-intestinal symptoms and visual 
disturbances are most frequent. Cardiac involvement has previously been described (9, 
23, 24). In our cohort we found a large group of patients with asymptomatic ECG changes 
on one hand, but some severely affected patients as well. In the four patients with an 
ejection fraction of less than 30% the cardiac problems dominate the clinical picture. 
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A large number of patients in our cohort exhibits gastro-intestinal problems. In most 
cases patients suffer from mild to moderate constipation or symptoms of irritable bowel 
syndrome. In five patients symptoms required admission or even surgical intervention. 
Cases of chronic intestinal pseudo obstruction have previously been described in patients 
with the m.3243A>G mutation (25, 26). Twenty-six percent of the patients reported visual 
disturbances and 42% of the patients did not have a vision of 1.0 on a brief visual acuity 
test. Previous reports indicate the presence of macular dystrophy in patients with the 
m.3243A>G mutation (10, 27). Because of this multi-organ involvement of the m.3243A>G 
mutation we recommend that all carriers of the mutation are checked for early stages of 
these symptoms by specialized physicians, including a consultation by a cardiologist and 
an ophthalmologist, also when there is no diabetes present.  
Quality of life
We assessed quality of life in our cohort using the SF12v2questionnaire. As visualized in 
Figure 2.2, a lower QoLP is negatively correlated to the NMDAS. Indicating, as suspected, 
that when a patient has more symptoms of the m.3243A>G mutation, a lower QoLP is 
reported. QoLM was not different from healthy controls nor from their relatives that do 
not carry the mutation. Twenty patient did report a history of depression or anxiety. This 
was however not significantly different from their relatives that did not carry the mutation.
Different samples
As indicated in Figures 2.5a-c we found a correlation between NMDAS and heteroplasmy 
in all three samples, of which buccal mucosa had the best correlation (r=0.427, p<0.001 
versus r=0.254, p=0.032 in leucocytes and r=0.294, p=0.016 in UEC). When we selected 
for the most severely affected patients (NMDAS>20) we found stronger correlation for 
leucocytes (r=0.366, p=0.072) and UEC (r=0.530, p=0.008). Whittaker et. al.(20) was the 
first to describe a correlation between heteroplasmy and symptoms. We confirm the good 
ability of UEC heteroplasmy predict clinical outcome but add that this accounts most for 
the more severely affected patients. In the general group of carriers of the m.3243A>G 
mutation heteroplasmy in buccal saliva has a better ability to predict clinical outcome. 
Different studies have described a decrease in heteroplasmy with increasing age (3, 
13, 28). As demonstrated in Figures 2.4a-c, we also find a decreasing heteroplasmy in all 
samples. The decrease in heteroplasmy with increasing age is much more prominent in 
leucocytes (r=-0.705, p<0.001) than in the other samples (UEC r=-0.374, p=0.001, buccal 
mucosa r=-0.460, p<0.001). However the decrease in heteroplasmy level with age can 
only be confirmed after a prospective follow-up study. We also found that heteroplasmy in 
UEC has a 26 percent point higher value than heteroplasmy in leucocytes and a 11 percent 
point higher value than heteroplasmy in buccal mucosa. The m.3243A>G mutation was 
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undetectable in leucocytes in 12 patients in which the mutation was detected in UEC. Of 
these 12 patients the mutation was also undetectable in buccal mucosa in seven patients. 
There was one patient in which the m.3243A>G mutation could not be detected in UEC, 
where it was detected in leucocytes and buccal mucosa. However we should take in 
account that we can never predict the values of untested tissues as muscle, heart, kidney, 
liver or brain. This makes that UEC are the best non-invasively available tissue to test if a 
patient is suspected of the m.3243A>G mutation. 
Conclusion
We conclude that the m.3243A>G mutation causes a wide variety of signs and symptoms, 
MIDD being the most prevalent phenotypic expression. Of the three non-invasively 
available tissues for testing heteroplasmy, we advice to use UEC to detect the mutation. 
Dormant carriers should be checked regularly by a specialized physician to see whether 
the disease has awaken and to be early in preventing and treating symptoms. 
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Abstract
Background: The m.3243A>G mutation is the most common pathogenic mutation of 
the mitochondrial DNA. To interpret results of clinical trials in mitochondrial disease, it is 
important to have a clear understanding of the natural course of disease. 
Methods: We prospectively followed a cohort of 151 carriers of the m.3243A>G mutation 
from 61 families for up to 6 years. The disease severity was scored using the Newcastle 
Mitochondrial Disease Adult Scale (NMDAS), including SF36 Quality of Life (QoL) scores. 
Heteroplasmy levels were measured in urinary epithelial cells (UEC), leukocytes, and saliva. 
The progression of the disease was studied using linear mixed model analysis. 
Results: Hundred-twenty-four carriers (out of 151) were symptomatic. Four clinical groups 
were identified: 1) Classical MELAS syndrome (n=7), 2) MIDD syndrome (n=60), 3) ‘Other’ 
(n=57) and 4) Dormant Carriers (n=27). A yearly increase of NMDAS score of 0.47 point 
was measured in the total group. Heteroplasmy levels in both leukocytes and UEC were 
weakly correlated with disease severity, but did not influence disease progression when 
the different clinical groups were taken into account. Physical QoL declined with age. The 
most important determinants of QoL decline were: hearing loss, speech problems, exercise 
intolerance, gait instability, psychiatric problems, and gastro-intestinal involvement. 
Conclusion: The m.3243A>G mutation causes a slowly progressive disease, with a 
yearly increase of NMDAS score of ~0.5 point overall. Clinical phenotype was the only 
determinant of disease progression.
6 year follow-up of carriers of the m.3243A>G mutation
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Introduction
The Adenine to Guanine transition at position 3243 in the mitochondrial DNA (m.3243A>G) 
in the MT-TL1 gene encoding tRNALEU(UUR) (MIM 590050) is the most common pathogenic 
mutation of the mitochondrial DNA; prevalence rates are reported in the range of 1:13.000 
to 1:423 persons (1-3).
The acronym MELAS was first used in 1984 by Pavlakis et al. to describe a group of 
patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
(MELAS, MIM 540000) (4). In 1990, the m.3243A>G mutation was identified as the molecular 
basis for MELAS syndrome (5, 6). Other mitochondrial syndromes have been identified 
to be caused by this mutation as well, including maternally inherited diabetes deafness 
(MIDD, MIM 520000) (7), Chronic Progressive External Ophthalmoplegia (CPEO) (8), and 
myoclonic epilepsy with ragged-red fibers (MERRF, MIM 545000) (9). These syndromes 
can also be present as overlap syndromes (10). Besides these well-defined mitochondrial 
syndromes, numerous other clinical symptoms are reported in association with the 
m.3243A>G mutation. These symptoms can present isolated or occur combined with other 
symptoms. Previously reported complications in carriers of the m.3243A>G mutation are: 
hypertrophic cardiomyopathy (11), macular dystrophy (12, 13), gastro-intestinal involvement 
(14), focal segmental glomerulosclerosis (FSGS) (15), obstetric complications (16), and 
oligosymptomatic variants of the previously mentioned mitochondrial syndromes (17). 
Because the m.3243A>G mutation is the most prevalent mtDNA mutation, it has been 
the subject of study for many years. Predicting the phenotypic expression of a carrier of 
the m.3243A>G mutation has proven to be very difficult. Since mitochondria and mtDNA 
are present in almost all organs, heteroplasmy can theoretically be assessed in virtually 
every tissue. Previous studies showed a superiority of urine over blood as preferred 
non-invasive tissue for mutation analysis in patients at risk of carrying the m.3243A>G 
mutation (18-21). However, the relation between mutation load and clinical phenotype is 
not straightforward and has been the subject of research for many years (10, 22-24). The 
first study concerning a large cohort of carriers of the m.3243A>G mutation was published 
in 1997 by Chinnery et al. Since then, many studies, both retrospective and prospective, 
on cohorts of m.3243A>G mutation carriers have been published (10, 17, 22-33). These 
studies report a wide variety of clinical symptoms and major differences in the prevalence 
of mitochondrial syndromes, such as MELAS syndrome. Large prospective studies, however, 
are very rare. To interpret results of clinical trials in patients with mitochondrial disease, 
it is important to have a clear understanding of the natural course of disease, for which 
large studies are imminent (34). To obtain more insight into the disease burden and the 
progression of disease in carriers of the m.3243A>G mutation, we followed a cohort of 
151 carriers from 61 families prospectively for up to 6 years. 
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Methods
Patients
All probands are patients of the Radboud Center for Mitochondrial Medicine at the 
Radboud university medical center in the Netherlands, diagnosed with the m.3243A>G 
mutation in UEC, muscle and/or blood. The study was approved by the Regional 
Committee on Research involving Human Subjects Arnhem-Nijmegen. Written informed 
consent according to the Helsinki agreement was obtained from all patients. The patients 
were seen at the outpatient clinic every 2 years, and the total follow-up time was 6 years. 
New patients were included during follow-up. Patient characteristics regarding age, gender, 
and clinical symptoms of the m.3243A>G were assessed. 
Newcastle Mitochondrial Disease Adult Scale (NMDAS)
During each visit, the clinical condition of the patient was scored using the Newcastle 
Mitochondrial Disease Adult Scale (NMDAS) (35). The NMDAS constitutes a predefined 
and validated method to monitor the clinical expression of mitochondrial disease and to 
follow-up the course of disease over time. It consists of the following four sections: 1) 
Current function, which gives insight into the general functioning of patients in the past 
four weeks. 2) System-specific involvement, which uses a clinical history supplemented 
by specific information to obtain knowledge about the functioning of individual organ 
systems. 3) Current clinical assessment, a general and neurological clinical examination, 
which gives information on the current functional status of the patient. This section includes 
three cognition tests. We were able to use the English symbol test, since it does not use 
language. For the reading test, we used a Dutch equivalent test (36). In absence of a 
Dutch equivalent test for the Speed of Comprehension, we could not use this test, so we 
scored cognition based on the symbol test and reading test only. Sections 1–3 contain a 
total of 29 items, and each item is scored on a 6-item Likert scale with scores ranging 0–5. 
For section 4, Quality of life, we used a Dutch translation of the SF-12v2 quality of life 
test at the first visits. From 2012 onward, we used the Dutch translation of the RAND (SF-
36) quality of life test, from which a similar score as from the SF-12v2 can be calculated, 
while additional information is obtained on seven domains (physical functioning; physical 
health; emotional problems; energy/fatigue; emotional well-being; social functioning; 
pain; general health). Scores for mental (QoLm) and physical (QoLp) quality of life can be 
subtracted from both the SF-12v2 and the SF-36. A score of 50 is the mean for a normal 
population (37). All NMDAS scores were obtained by the same researcher (PdL), eliminating 
inter-observer variability.
Every patient was categorized into one of the following clinical groups: 1) MELAS 
syndrome, if stroke-like episodes (SLE) or signs or significant encephalopathy were present. 
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2) MIDD syndrome, if the patient had glucose intolerance and hearing loss, but no SLE or 
significant encephalopathy. 3) All remaining symptomatic patients, classified as ‘other’. 4) 
Asymptomatic carriers of the m.3243A>G mutation, classified as dormant carriers. Data 
presented about the differences between the groups used the clinical classification at 
the last visit. If the clinical groups were used to evaluate disease progression, the clinical 
group at the first visit was used. 
Urine sample collection and mutation analysis
During each visit, blood and urine samples were collected. At the first visit, a buccal swab was 
also performed to isolate buccal saliva. DNA was isolated from peripheral blood leukocytes 
using a salting-out method. The urine sediments and buccal swab samples were centrifuged 
for 10 min at 3000 r.p.m., after which the pellet was washed with phosphate-buffered 
saline. DNA was extracted using a commercially available DNA isolation kit (PuregeneTM 
DNA isolation kit; Gentra Systems, MN). Heteroplasmy levels were determined in all 
DNA samples using PyrosequencingTM technology (Pyrosequencing, Uppsala, Sweden) 
as described earlier (15). The pyrosequence reaction of the m.3243A>G mutation had a 
precision of 1.5%, and the mutation was detected from a heteroplasmy level of 5%. The 
detection limit for the m.3243A>G mutation was determined by serial dilution of a sample 
containing this mutation with wild type mtDNA. Age-corrected heteroplasmy levels in 
leukocytes were calculated using this formula: (leukocyte heteroplasmy)/0.977(age+12). This 
correction was previously published by Grady et al. (24). The current paper refers to this 
value as age-corrected heteroplasmy level in leukocytes.  
Statistics
Descriptive statistics were used for presentation of patients’ characteristics, including 
NMDAS items. Because the data for several characteristics were not normally distributed, 
especially in the clinical subgroups, all data are presented as medians with ranges. 
Spearman’s correlation coefficients were calculated between heteroplasmy levels and 
NMDAS scores, while the Mann-Whitney U test was used to compare groups. A linear 
mixed model analysis was conducted to study overall disease progression, in which the 
effects of gender, age, clinical diagnosis, and heteroplasmy levels on disease progression 
were also determined. In addition, linear mixed model analyses were used to study the 
determinants of changes in QoL scores, initially including all relevant NMDAS items. 
Manual stepwise backward elimination was applied to retain only variables with p-values 
below 0.10 in these models. These were identified as the most important determinants. 
All statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS), version 25.0 for Windows (IBM Corp., Armonk, NY, USA).
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Results
General patient characteristics 
Hundred-fifty-one adult carriers of the m.3243A>G, originating from 61 families, were 
included in our nation-wide cohort (Table 3.1). As 11 probands of the 61 families had 
already passed away at the start of the study, these were not included in this prospective 
study. Fifty patients (33.1%) were male. Median age was 43.3 (range 16.0–68.5) years at the 
first visit and 46.7 (range 16.0–69.1) years at the last visit, which was equal to the first visit 
for 39 patients. Follow-up data were available for 112 patients. Overall median follow-up 
duration was 3.9 (range 1.2–5.9) years. Forty-one patients had four visits in the six years 
duration of the study, with a median follow-up time of 5.6 (range 4.5–5.9) years. Thirty-three 
patients had three visits with a median follow-up time of 3.8 (range 3.0–5.8) years, while 
38 patients had only two visits with a median follow-up time of 1.8 (range 1.2–5.8) years. 
Of the 151 included carriers of the m.3243A>G mutation, 124 were symptomatic. At 
the last visit, seven patients (4.6%) had a classical MELAS syndrome, 60 patients (39.7%) 
had MIDD syndrome, and 57 patients (37.7%) were classified as ‘others’. The remaining 
27 (17.9%) were asymptomatic and were classified as dormant carriers (Figure 3.1). Since 
progression of disease occurred during the years of follow-up, not all patients were 
classified in the same group at their first visit compared to the last visit. One patient was 
 
 
  
MELAS 
syndrome; 7
MIDD 
syndrome; 60
Other; 57
Dormant 
Carriers; 27
Clinical groups in carriers of the m.3243A>G mutation (n=151)
Figure 3.1: Pie-chart with the different clinical groups of carriers of the m.3243A>G mutation at 
the last visit.
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classified as ‘other’ at first, but developed stroke-like episodes at the age of 39 years and 
was classified with MELAS syndrome thereafter. One patient was classified as dormant 
carrier until he started to have hearing problems at the age of 52 years and was classified 
as ‘other’. Seven patients were classified as MIDD after first being classified as ‘other’: 
three patients with diabetes mellitus developed hearing problems and four patients who 
had hearing problems developed diabetes mellitus. 
MIDD patients were older than the carriers in all other groups (p<0.001) (Table 3.1). 
Dormant carriers were younger than patients in the group ‘other’ (p=0.039), whereas 
the seven MELAS patients were not statistically significantly different in age than ‘other’ 
patients or dormant carriers. In the MELAS group, more males were present compared 
to the MIDD group (71.4% vs 26.7%, p=0.015) and the ‘other’ group (71.4% vs 31.6% 
p=0.039). No other statistically significant differences in gender were seen between the 
groups. MELAS patients had a lower height-adjusted body weight (BMI; body mass index) 
compared to all three other groups.
Mortality
During follow-up, 12 patients died (median age 58 years; range 34–67 years). Six patients 
died because of heart failure, three due to neurologic deterioration caused by severe 
stroke-like episodes, two died of cancer, and one patient died after complications of 
gastro-intestinal pseudo obstruction syndrome. In 11 of the families studied, the proband 
had already died before start of the study. All of these probands had a classical MELAS 
phenotype, with age of death ranging from 10 to 52 years of age. 
Heteroplasmy levels
Heteroplasmy levels in saliva were obtained from 132 (87%) of the 151 patients at the first 
visit. Regarding the 19 missing samples, saliva was obtained from four (2.9%) cases, but 
we were unable to measure heteroplasmy levels in these samples. Heteroplasmy levels in 
leukocytes were measured for 369 (98%) of the 378 visits. In eight (2%) cases, no sample 
was obtained and one (0.3%) sample was not viable for heteroplasmy measurement. 
Heteroplasmy levels in UEC were measured for 349 (92%) of the 378 visits. In 12 (3.1%) 
cases, no urine sample was obtained and in 17 (3.3%) samples, we were unable to extract 
DNA for heteroplasmy analysis. 
In saliva, seven (5.3%) samples had a heteroplasmy level <5%, being under our pre-
specified limit of detection. In leukocytes, 42 (11.4%) samples with a heteroplasmy level 
<5% were identified. Analysis in UEC showed four (0.6%) samples with a heteroplasmy 
level <5%, two of which were from the same patient who had undergone a kidney 
transplantation. If this patient was excluded, only two (0.3%) of the UEC samples had a 
heteroplasmy level of <5%. 
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MELAS patients had higher heteroplasmy levels in all tissues compared to the other 
groups (p=0.043 through p<0.001) (Table 3.1). In addition, higher levels of heteroplasmy in 
buccal saliva were seen in MIDD and ‘other’ patients compared to dormant carriers (p=0.025 
and p=0.071 respectively), as well as higher levels of heteroplasmy in UEC (p= 0.237 and 
p=0.043, respectively). Differences between the age-corrected heteroplasmy levels in 
leukocytes were statistically significant between all groups (p=0.017 through p<0.001), 
except for MELAS syndrome compared to MIDD syndrome patients (11.6 vs 9.4; p=0.103). 
As expected, a strong negative correlation (r=-0.529; p<0.001) was observed 
between age and heteroplasmy levels in leukocytes (Figure 3.2a), with a weaker negative 
correlation (r=-0.238; p=0.007) between age and heteroplasmy levels in UEC (Figure 
3.2b). Strong correlations were seen between heteroplasmy levels in different tissues: 
UEC and leukocytes (r=0.645; p<0.001), UEC and saliva (r=0.670; p<0.001), and saliva 
en leukocytes (r=0.797; p<0.001). 
Heteroplasmy levels in UEC were 24.3% (95% CI 19.2%–29.4%) higher in men 
compared to woman. Heteroplasmy levels in saliva and leukocytes did not show statistically 
significant differences between genders. These findings apply to both the complete cohort 
and the individual diagnosis groups. 
NMDAS characteristics
In the 151 patients, 378 NMDAS scores were obtained. At the last visit, the median NMDAS 
score of the dormant carriers was 2 (range 0–8), whereas the median NMDAS score of the 
symptomatic patients was 18 (range 0–92). MELAS patients had the highest NMDAS scores 
with a median of 59 (range 32–92), MIDD patients had the second highest NMDAS scores 
with a median of 23.5 (range 10–52), and ‘other’ patients had the lowest NMDAS scores 
of the symptomatic carriers with the median being only 13 (range 0–53). All differences in 
NMDAS scores between the clinical groups were statistically significant (p>0.001), but no 
differences in NMDAS scores were found between men and women (p=0.186). Among 
the symptomatic patients, the most prevalent items included in the NMDAS score were 
hearing loss (n=99), gait instability (n=92), gastro-intestinal problems (n=84), exercise 
intolerance (n=79), cerebellar ataxia (n=72), glucose intolerance and diabetes mellitus 
(n=70), and decreased vision (n=64) (Figure 3.3). All NMDAS scores, sorted by clinical 
diagnose groups, are presented in Supplementary data Table S3.1.
NMDAS follow-up
Follow-up data were available for 112 patients (Figure 3.4). The overall progression 
in NMDAS score was 0.47 (95% CI 0.33–0.61) points per year, but there were large 
differences between the diagnosis groups. MELAS patients had a progression of 1.31 
(95% CI -0.78–3.40) points per year. Due to the small groups of MELAS patients (n=7), 
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however, the confidence interval was wide and included the null value. MIDD patients 
showed an increase of 0.64 (95% CI 0.43–0.85) points per year and the patients in the 
‘other’ group 0.26 (95% CI 0.13–0.40) points per year. For dormant carriers, hardly any 
disease progression was found (0.05 points per year; 95% CI -0.01–0.1). The NMDAS score 
at the start of the study did not influence these findings substantially.
Heteroplasmy levels and NMDAS scores
Heteroplasmy levels in all tissues were statistically significantly correlated with NMDAS 
scores. Heteroplasmy levels in buccal saliva had the highest correlation coefficient of 
0.302 (p<0.001), followed by leukocytes (r=0.169; p=0.04) and UEC (r=0.147; p=0.099). 
The age-corrected heteroplasmy levels in leukocytes showed an improved correlation 
coefficient of 0.472 (p<0.001) in the complete cohort. 
In the linear mixed model analysis, heteroplasmy levels in leukocytes, age-corrected 
heteroplasmy levels, and heteroplasmy levels in UEC all had a statistically significant impact 
on disease progression in the full cohort (leukocytes p=0.006, age-corrected p=0.006, 
and UEC p=0.014). When the four clinical diagnosis groups were also added to the 
models, however, no impact of heteroplasmy levels on disease progression as measured 
by NMDAS scores remained. 
Determinants of Quality of Life
At the last visit, quality of life (QoL) data were collected for 143 (94%) patients (see Table 
3.1). Mental quality of life (QoLm) had a median score of 46.2 (range 19.0–66.9), while 
physical quality of life (QoLp) had a median score of 41.5 (range 15.8–70.0). Statistically 
significant differences in QoLp were seen between the clinical groups. Dormant carriers 
had a better QoLp compared to all three other groups (p<0.001). Other patients had a 
better QoLp than MIDD patients (p=0.005). A profoundly lower QoLp in MELAS patients 
compared to MIDD and patients in the ‘other’ groups did not reach statistical significance 
(Table 3.1). MELAS patients also had a lower QoLm compared to patients in the other 
group (p=0.045) and dormant carriers (p=0.034). Differences in QoLm between the other 
groups were not statically significant. 
We also studied the individual items in the NMDAS score for their influence on 
changes in QoLm, QoLp, and overall QoL (sum of QoLm and Qolp). The most important 
determinants for QoLm were: speech difficulties, psychiatric problems, seizures, stroke-like 
episodes, gastro-intestinal involvement, and dysphonia/dysarthria. For QoLp, the most 
important determinants were hearing loss, apraxia, exercise intolerance, gait instability, 
migraine, and gastro-intestinal involvement. Overall QoL was predominantly influenced 
by items that influenced QoLp (hearing loss, exercise intolerance, gait instability, and 
gastro-intestinal involvement) as well as by speech problems and psychiatric problems. 
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QoLp clearly decreased over time, with an average of 0.23 points (95% CI -0.33–-0.12) 
per year, which was not influenced by correction for clinical diagnosis. No decrease in 
QoLm over time was found, even after correction for clinical diagnosis.
Discussion
This is one of the largest cohort studies in patients with mitochondrial disease. To obtain 
more insight in disease burden and progression of disease in carriers of the m.3243A>G 
mutation, we followed a cohort of 151 carriers from 61 families prospectively for up to 6 
years. An overall disease progression of almost 0.5 NMDAS point per year was measured. 
With a median NMDAS score of 18 points in symptomatic patients, it can be concluded 
that mitochondrial disease due to the m.3243A>G mutation is a slowly progressive disease. 
This is of high importance for evaluation of treatment for this disease, as delaying disease 
progression would already be a sign of treatment success (34).
There are distinct differences in clinical phenotypes of the m.3243A>G mutation. 
When divided in clinical diagnosis groups, a better prediction of disease severity can be 
made. Previous studies provided group classifications with small groups and/or overlap 
groups. We decided to divide the symptomatic patients in 3 clinically distinct groups 
(MELAS syndrome, MIDD syndrome, and ‘other’), while all asymptomatic patients were 
classified as dormant carriers. This group classification clearly showed differences in 
disease progression and can easily be used in clinical practice. Limitations were mainly 
found concerning the ‘other’ group, as this group consists of a broad variety of patients, 
including patients with isolated, sometimes severe, cardiomyopathy and patients with 
nephropathy leading to end stage renal failure requiring transplantation. In addition, this 
group contains patients with only hearing loss or diabetes, who do not or not yet qualify 
for the MIDD group, and patients with isolated myopathy and/or fatigue. As fatigue is not 
scored on the NMDAS, it is possible to have an NMDAS score of 0 when being classified 
in the ‘other’ group of symptomatic patients. 
 Our cohort has a relatively low number of classical MELAS patients. This is most 
likely due to the fact that 11 MELAS patients already died before start of the study, and 
to the inclusion of maternally related family members who presented with a less severe 
phenotype. The high mortality among MELAS patients certainly led to selection in our 
cohort, as 11 of the pedigrees had a deceased family member with a MELAS phenotype. It 
is also important to emphasize the absence of progression in patients classified as dormant 
carriers. Dormant carriers are a distinct group of carriers of the m.3243A>G mutation, 
that do not exhibit any symptom of mitochondrial disease. They may have complaints 
unrelated to the m.3243A>G mutation, however, leading to a NMDAS score of up to 
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8 while still being considered asymptomatic. The existence of these dormant carriers 
should be taken into account during counseling of families, as 17.9% of the carriers were 
classified as dormant carrier in our study. Disease progression was mainly determined by 
clinical phenotype, with MELAS patients having the largest disease progression, followed 
by MIDD patients and ‘other’ patients. Dormant carriers have no disease progression. 
Heteroplasmy levels in saliva were determined only once, whereas the levels in 
leukocytes and UEC were assessed every visit. Heteroplasmy levels in muscle tissue were 
not studied prospectively. Both the saliva (5.3%) and the leukocyte (11.4%) analyses 
contained a substantial level of false negative samples, in contrast to the UEC analyses 
(0.3%). Therefore, we have a strong preference for urine sampling to diagnose individuals 
with carriership of the m.3243A>G mutation. It has to be noted, however, that the 
proportion of sample errors, causing the patient to collect a new sample, was higher in 
UEC (3.3%) compared to saliva (2.9%) and much higher compared to leukocytes (0.3%). 
Several studies suggested a relation between heteroplasmy levels in urinary epithelial 
cells and clinical symptoms in a small number of patients, but the reported correlation 
coefficients were rather low (10, 18, 30, 38). In the previous cohort studies, UECs had 
predominantly been investigated as prognostic marker for severity of disease and disease 
progression. A recent study demonstrated that the measurement of heteroplasmy of the 
m.3243A>G mutation in UEC has a large intra-patient variability, which asks for caution 
when using heteroplasmy levels in UEC as a biomarker for disease progression (39). A 
newly proposed calculated value, age-corrected heteroplasmy level in leukocytes, had a 
better correlation to disease severity (24). As leukocytes provide heteroplasmy levels with 
minimal intra-patient variability and a negative correlation with age, the age-corrected 
heteroplasmy level in leukocytes may have good prognostic potential in carriers of the 
m.3243A>G mutation. The results of the current study support this hypothesis, although 
with a rather weak correlation coefficient of 0.472 (p<0.001).
MELAS syndrome has previously been reported to occur more frequently in males (28). 
In our overall cohort, only 33.1% of the patients were male, compared to five of the seven 
MELAS patients (71.4%). We hypothesize that the male-female ratio in the overall cohort 
was biased due to lack of informed consent by maternally related males with minimal or 
no disease involvement among our pedigrees. As men do not transmit the mutation, many 
found that it was not relevant for them to be tested when they had no complaints. Because 
there is no treatment for this disease to date, and carriership of a genetic abnormality 
may have social implication, including difficulties with mortgage and life insurance, the 
reduced number of male participants in our study can easily be explained. The reversed 
male-female ratio in the MELAS group was striking but based on a very small group of 
MELAS patients, so no additional data supporting a cause for this difference were derived 
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from our study. Another mitochondrial disease in which male gender is related with worse 
outcome is Leber Hereditary Optic Neuropathy (LHON, MIM 535000), for which in vitro 
studies showed a protective effect of estrogens on mitochondrial dysfunction. Others have 
hypothesized a similar effect for stoke-like episodes in MELAS patients (28).
Knowledge of determinants of Quality of Life in patients with an untreatable disease 
is of great importance to adequately provide supportive care (40). In this study, we showed 
a distinct decrease in QoLp with age, as can be expected from a progressive untreatable 
disease. An important determinant for both QoLp and QoLm were gastro-intestinal problems. 
As reported previously (41) and noted in Figure 3.3, gastro-intestinal problems are among the 
most frequent complaints in carriers of the m.3243A>G. Adequate supportive treatment of 
constipation, abdominal pain, diarrhea, and malnutrition by a trained dietician and medical 
doctor, could be greatly beneficial to these patients (42). Other important determinants 
for QoL included speech difficulties, exercise intolerance, gait instability, hearing loss, and 
apraxia. In all instances, supportive treatment by para-medics such as speech therapists, 
physiotherapist, or occupational therapist or medical assistance devices, such as hearing aids, 
can diminish the burden of disease substantially. In an era of increasing attention for patient-
family centered care and patient reported outcome measures as an indicator for quality of 
care, extensive knowledge of determinants of QoL is pertinent. In this study, we provide a 
first glimpse of these determinants, but extensive further research is needed in this field. 
Reporting on the natural course of a disease can be influenced by supportive care 
(43). All patients in our cohort are seen at the Radboud Centre for Mitochondrial Medicine 
(RCMM), a specialized clinic for mitochondrial medicine, in which supportive care by 
doctors, paramedics, and nurses is provided on a daily basis. Therefore, the natural course 
of disease, as scored by NMDAS and QoL, could be even worse than indicated in this 
report. The RCMM is the national reference centre of a relatively small country, resulting in 
a limited cohort size of 151 patients from 61 families. However, this is the second largest 
cohort of carriers of the m.3243A>G mutation known in the literature to date. Our follow-up 
period was limited to a maximum of almost 6 years, as we chose to include only prospective 
data using the only validated scoring method for mitochondrial disease in adults (NMDAS), 
all scored by the same investigator. Although the duration was thereby more limited than 
in other studies, reporting and investigator bias were minimized. Therefore, this study 
provides deeper insight in the different aspects of disease progression. 
Conclusion
The m.3243A>G mutation causes a slowly progressive disease, with a yearly increase of 
NMDAS score of ~0.5 point overall. The only important determinant of disease progression 
is the clinical phenotype.
Chapter 3
68
Acknowledgements 
Part of this work was supported by grants from ZonMw (The Netherlands Organization for 
Health Research and Development) PM-Rare Grant (113302003), the Stichting Energy4All, 
and the Tim Star Foundation awarded to JS. 
References
1. Chinnery PF, Johnson MA, Wardell TM, Singh-Kler R, Hayes C, Brown DT, et al. The 
epidemiology of pathogenic mitochondrial DNA mutations. Annals of neurology. 2000; 
48(2):188-93.
2. Majamaa K, Moilanen JS, Uimonen S, Remes AM, Salmela PI, Karppa M, et al. Epidemiology 
of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and 
strokelike episodes: prevalence of the mutation in an adult population. American journal 
of human genetics. 1998;63(2):447-54.
3. Manwaring N, Jones MM, Wang JJ, Rochtchina E, Howard C, Mitchell P, et al. Population 
prevalence of the MELAS A3243G mutation. Mitochondrion. 2007;7(3):230-3.
4. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, 
encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. 
Annals of neurology. 1984;16(4):481-8.
5. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the 
MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990;348(6302):651-3.
6. Kobayashi Y, Momoi MY, Tominaga K, Momoi T, Nihei K, Yanagisawa M, et al. A point 
mutation in the mitochondrial tRNA(Leu)(UUR) gene in MELAS (mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke-like episodes). Biochemical and biophysical 
research communications. 1990;173(3):816-22.
7. van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, 
Struyvenberg PA, et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree 
with maternally transmitted type II diabetes mellitus and deafness. Nature genetics. 1992; 
1(5):368-71.
8. Moraes CT, Ciacci F, Silvestri G, Shanske S, Sciacco M, Hirano M, et al. Atypical clinical 
presentations associated with the MELAS mutation at position 3243 of human mitochondrial 
DNA. Neuromuscul Disord. 1993;3(1):43-50.
9. Durand-Dubief F, Ryvlin P, Mauguiere F. [Polymorphism of epilepsy associated with the 
A3243G mutation of mitochondrial DNA (MELAS): reasons for delayed diagnosis]. Revue 
neurologique. 2004;160(8-9):824-9.
10. Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, et al. 
The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated 
with the m.3243A>G mutation--implications for diagnosis and management. Journal of 
neurology, neurosurgery, and psychiatry. 2013.
11. Lev D, Nissenkorn A, Leshinsky-Silver E, Sadeh M, Zeharia A, Garty BZ, et al. Clinical 
presentations of mitochondrial cardiomyopathies. Pediatric cardiology. 2004;25(5):443-50.
12. de Laat P, Smeitink JA, Janssen MC, Keunen JE, Boon CJ. Mitochondrial retinal dystrophy 
associated with the m.3243A>G mutation. Ophthalmology. 2013;120(12):2684-96.
13. Massin P, Virally-Monod M, Vialettes B, Paques M, Gin H, Porokhov B, et al. Prevalence 
of macular pattern dystrophy in maternally inherited diabetes and deafness. GEDIAM 
Group. Ophthalmology. 1999;106(9):1821-7.
6 year follow-up of carriers of the m.3243A>G mutation
69
3
14. de Laat P, Zweers HE, Knuijt S, Smeitink JA, Wanten GJ, Janssen MC. Dysphagia, 
malnutrition and gastrointestinal problems in patients with mitochondrial disease caused 
by the m3243A&gt;G mutation. Neth J Med. 2015;73(1):30-6.
15. Lowik MM, Hol FA, Steenbergen EJ, Wetzels JF, van den Heuvel LP. Mitochondrial 
tRNALeu(UUR) mutation in a patient with steroid-resistant nephrotic syndrome and focal 
segmental glomerulosclerosis. Nephrol Dial Transplant. 2005;20(2):336-41.
16. de Laat P, Fleuren LH, Bekker MN, Smeitink JA, Janssen MC. Obstetric complications in 
carriers of the m.3243A>G mutation, a retrospective cohort study on maternal and fetal 
outcome. Mitochondrion. 2015;25:98-103.
17. Dvorakova V, Kolarova H, Magner M, Tesarova M, Hansikova H, Zeman J, et al. The 
phenotypic spectrum of fifty Czech m.3243A>G carriers. Mol Genet Metab. 2016.
18. Ma Y, Fang F, Yang Y, Zou L, Zhang Y, Wang S, et al. The study of mitochondrial A3243G 
mutation in different samples. Mitochondrion. 2009;9(2):139-43.
19. Frederiksen AL, Andersen PH, Kyvik KO, Jeppesen TD, Vissing J, Schwartz M. Tissue 
specific distribution of the 3243A->G mtDNA mutation. Journal of medical genetics. 
2006;43(8):671-7.
20. Marotta R, Reardon K, McKelvie PA, Chiotis M, Chin J, Cook M, et al. Association of the 
MELAS m.3243A>G mutation with myositis and the superiority of urine over muscle, blood 
and hair for mutation detection. J Clin Neurosci. 2009;16(9):1223-5.
21. de Laat P, Koene S, van den Heuvel LP, Rodenburg RJ, Janssen MC, Smeitink JA. Clinical 
features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the 
m.3243A > G mutation. J Inherit Metab Dis. 2012.
22. Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Molecular pathology of MELAS and 
MERRF. The relationship between mutation load and clinical phenotypes. Brain. 1997;120 
(Pt 10):1713-21.
23. Liu CH, Chang CH, Kuo HC, Ro LS, Liou CW, Wei YH, et al. Prognosis of symptomatic 
patients with the A3243G mutation of mitochondrial DNA. Journal of the Formosan 
Medical Association = Taiwan yi zhi. 2012;111(9):489-94.
24. Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, et al. mtDNA heteroplasmy 
level and copy number indicate disease burden in m.3243A>G mitochondrial disease. 
EMBO molecular medicine. 2018;10(6).
25. Ma Y, Fang F, Cao Y, Yang Y, Zou L, Zhang Y, et al. Clinical features of mitochondrial DNA 
m.3243A>G mutation in 47 Chinese families. Journal of the neurological sciences. 291(1-
2):17-21.
26. Majamaa-Voltti KA, Winqvist S, Remes AM, Tolonen U, Pyhtinen J, Uimonen S, et al. A 
3-year clinical follow-up of adult patients with 3243A>G in mitochondrial DNA. Neurology. 
2006;66(10):1470-5.
27. Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Sproule DM, et al. Natural history 
of MELAS associated with mitochondrial DNA m.3243A>G genotype. Neurology. 2011; 
77(22):1965-71.
28. Mancuso M, Orsucci D, Angelini C, Bertini E, Carelli V, Comi GP, et al. The m.3243A>G 
mitochondrial DNA mutation and related phenotypes. A matter of gender? Journal of 
neurology. 2013.
29. Chin J, Marotta R, Chiotis M, Allan EH, Collins SJ. Detection rates and phenotypic spectrum 
of m.3243A>G in the MT-TL1 gene: a molecular diagnostic laboratory perspective. 
Mitochondrion. 2014;17:34-41.
30. de Laat P, Koene S, van de Heuvel LPWJ, Rodenburg RJT, Janssen MCH, Smeitink JAM. 
Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying 
the m.3243A > G mutation. J Inherit Metab Dis. 2012;35(6):1059-69.
Chapter 3
70
31. Fayssoil A, Laforet P, Bougouin W, Jardel C, Lombes A, Becane HM, et al. Prediction of 
long-term prognosis by heteroplasmy levels of the m.3243A>G mutation in patients with 
the mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome. 
Eur J Neurol. 2017;24(2):255-61.
32. Langdahl JH, Larsen M, Frost M, Andersen PH, Yderstraede KB, Vissing J, et al. Lecocytes 
mutation load declines with age in carriers of the m.3243A>G mutation: A 10-year 
Prospective Cohort. Clin Genet. 2018;93(4):925-8.
33. Zhang Z, Zhao D, Zhang X, Xiong H, Bao X, Yuan Y, et al. Survival analysis of a cohort of 
Chinese patients with mitochondrial encephalomyopathy with lactic acidosis and stroke-
like episodes (MELAS) based on clinical features. Journal of the neurological sciences. 
2018;385:151-5.
34. Pfeffer G, Horvath R, Klopstock T, Mootha VK, Suomalainen A, Koene S, et al. New 
treatments for mitochondrial disease-no time to drop our standards. Nature reviews 
Neurology. 2013;9(8):474-81.
35. Schaefer AM, Phoenix C, Elson JL, McFarland R, Chinnery PF, Turnbull DM. Mitochondrial 
disease in adults: a scale to monitor progression and treatment. Neurology. 2006;66(12): 
1932-4.
36. Schmand B, Lindeboom J, Van Harskamp F. Dutch Adaptation of the National Adult 
Reading Test (NART) by Nelson, HE (1982): Nederlandse Leestest voor Volwassenen (NLV). 
Swets & Zeitlinger, Lisse; 1992.
37. VanderZee KI, Sanderman R, Heyink JW, de Haes H. Psychometric qualities of the RAND 
36-Item Health Survey 1.0: a multidimensional measure of general health status. Int J 
Behav Med. 1996;3(2):104-22.
38. Whittaker RG, Blackwood JK, Alston CL, Blakely EL, Elson JL, McFarland R, et al. Urine 
heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation. 
Neurology. 2009;72(6):568-9.
39. de Laat P, Rodenburg R, Smeitink J, Janssen M. Intra-patient variability of heteroplasmy 
levels in urinary epithelial cells in carriers of the m.3243A>G mutation. Molecular Genetics 
& Genomic Medicine. 2018.
40. Verhaak C, de Laat P, Koene S, Tibosch M, Rodenburg R, de Groot I, et al. Quality of life, 
fatigue and mental health in patients with the m.3243A > G mutation and its correlates 
with genetic characteristics and disease manifestation. Orphanet J Rare Dis. 2016;11:25.
41. de Laat P, Zweers HE, Knuijt S, Smeitink JA, Wanten GJ, Janssen MC. Dysphagia, 
malnutrition and gastrointestinal problems in patients with mitochondrial disease caused 
by the m3243A>G mutation. Neth J Med. 2015;73(1):30-6.
42. Zweers H, Janssen MC, Leij S, Wanten G. Patients With Mitochondrial Disease Have an 
Inadequate Nutritional Intake. JPEN Journal of parenteral and enteral nutrition. 2017: 
148607117699792.
43. Keshavan N, Rahman S. Natural history of mitochondrial disorders: a systematic review. 
Essays Biochem. 2018;62(3):423-42.
6 year follow-up of carriers of the m.3243A>G mutation
71
3

Genetics
Pa
rt
 ii

Inheritance of the m.3243A>G mutation
Paul de Laat
Saskia Koene
Lambert P.W.J. van den Heuvel
Richard J.T. Rodenburg
Mirian C.H. Janssen
Jan A.M. Smeitink
JIMD Reports 2013;8:47-50
C
h
a
p
te
r
 4
Chapter 4
76
Abstract
The m.3243A>G is the most prevalent pathogenic mtDNA mutation but little is known 
about its inheritance. We studied 34 families containing 56 mother-child relations and 
82 intersibling relations to investigate its transmission. We found a significant correlation 
between mother and child heteroplasmy levels (r=0.679, p<0.001). In mothers with a 
heteroplasmy level of below 25% we found 30% offsprings without detectable mutation, 
while in mothers with a heteroplasmy level of above 25%, 100% of the offspringshowed 
the m.3243A>G mutation. Heteroplasmy levels between siblings also correlated (r=0.512, 
p<0.001), but had limited extra predictive value because of outliers. These new data on 
inheritance of the m.3243A>G mutation might be of value in counseling patients and 
preventing transmission of the mutation.
Key sentence/synopsis
In mothers carrying an m.3243A>G mutation, with a heteroplasmy level of below 25%, 
we found that 30% of the offspring were unaffected. This new data on inheritance of 
the m.3243A>G mutation will be of great help for counseling patients and preventing 
transmission of the mutation.
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Introduction
Goto et al. first described the adenine to guanine transition at position 3243 of mito-
chondrial DNA (m.3243A>G) in the MT-TL1 gene encoding tRNALEU(UUR) as the cause of 
Mitochondrial myopathy, Encephalopathy, Lactate Acidosis and Stroke-like episodes 
(MELAS) syndrome (1). Over time, more phenotypic variations of the m.3243A>G muta-
tion have been reported, the most frequent being Maternally Inherited Diabetes and 
Deafness (MIDD) (2). Other variations include cardiac, ocular and renal involvement (3-5).
The m.3243A>G mutation is the most prevalent pathogenic mitochondrial mutation 
(6) with a mutation prevalence ranging from 7.59 to 236/100,000 (7-9).
Several cohort studies have been performed, containing mainly clinical and epide-
miological data about carriers of the m.3243A>G mutation (7-15) and some containing 
data on inheritance of the m.3243A>G mutation (16, 17). In contrast to other mitochondrial 
mutations, sporadic presence of the m.3243A>G mutation is rare (18). Providing additional 
data on inheritance of mitochondrial mutations is essential to prevent transmission of 
these mutations. Poulton et al. reviewed the different possibilities to prevent transmission 
of maternally inherited mitochondrial diseases (19). We describe a cohort of 34 families 
in which 82 carry the m.3243A>G mutation, focusing on 56 mother-child relations and 
82 intersibling relations. The main purpose of this study is to indentify female carriers in 
whom transmission of the m.3243A>G mutation is present and in whom not definite. 
Methods
All probands are patients of the Nijmegen Center for Mitochondrial Disorders at the 
Radboud University Nijmegen Medical Centre, diagnosed with the m.3243A>G mutation 
in muscle or blood. All patients participated in our cohort study for the m.3243A>G 
mutation (15). This study was approved by the ethics committee of the Nijmegen-Arnhem 
region. Written informed consent according to the Helsinki agreement was obtained from 
all parents and patients ≥12 years.
Heteroplasmy levels where determined in urinary epithelial cells (UEC) in all partici-
pants using PyrosequencingTM technology (Pyrosequencing, Uppsala, Sweden) as earlier 
described by (5). The pyrosequence reaction of the m.3234A>G mutation had a precision 
of 1.5%, and the mutation was detected from a heteroplasmy level of 5%. The detection 
limit for the MELAS mutation (m.3243A>G) was determined by serial dilution of a sample 
containing this mutation with wild type mtDNA.
We analyzed the differences in heteroplasmy between mother and child and between 
familial siblings; the heteroplasmy levels of the older sibling were compared to that of 
the younger sibling. We used descriptive statistics to present the heteroplasmy levels in 
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our patients, and Pearson’s correlation coefficient was used to evaluate the relationship 
between the heteroplasmy levels between mother and child and between siblings.
Results
In our cohort of 82 patients from 34 families we identified 56 mother-child relations and 
82 intersibling relations.  
Of the 56 mother-child relations, ten mothers had one child, 14 mothers had two 
children and 6 mothers had 3 children. A total of 14 mothers that did not carry the 
m.3243A>G mutation were included, 11 mothers had a detectable mutation load but 
had a heteroplasmy level of below 25%, 5 mothers had a heteroplasmy level between 
25% and 50%. There were no mothers with a heteroplasmy level above 50%. The rate of 
transmission of the mutation is visualized in Figure 4.1a. Here we describe the transmission 
in more detail. In the mothers lacking the mutation, we found a detectable mutation in 
3 children. These 3 patients were the only ones in their pedigree that had a detectable 
mutation; we therefore concluded that these patients were most likely to have a de novo 
mutation. We excluded these 3 families, because there was (so far) no inheritance of the 
mutation in these families. When we excluded these 3 families,  a total of 9 mothers were 
excluded. The 5 remaining mothers (with an undetectable heteroplasmy level) were sisters 
of a proband. In 4 cases we found a detectable mutation in the mothers of these women. 
In one case the mother had passed away, so no heteroplasmy level could be determined. 
The 11 mothers with a detectable mutation load but a heteroplasmy level below 25% 
had 19 children. Six of these children (32%) had no detectable mutation. In the 13 children 
where the mutation was present, 4 patients were between 5% and 25%, 5 patients were 
between 25% and 50%, and 4 patients were above 50% (resp. 61%, 64%, 75% and 93%).
The 5 mothers with a heteroplasmy level between 25% and 50% had 9 children, 
all with detectable heteroplasmy levels. Three children were between 25% and 50%, 3 
children were between 50% and 75% and 3 children were above 75%.
A correlation coefficient of 0.679 (p<0.001) was found between the heteroplasmy 
levels of mothers and their children. 
In our cohort we indentified 82 intersibling relations. When we excluded the 3 
families with the sporadic mutation, 63 intersibling relations remained. We divided this 
group in 5 subgroups depending on the heteroplasmy level of the oldest sibling, (resp. 
<5%, 5–25%, 26–50%, 51–75% and >75%). The relationship between the heteroplasmy 
levels in the siblings is indicated in Figure 4.1b. Fifty percent of the oldest siblings with 
an undetectable mutation had a younger sibling with a detectable mutation. In these 10 
siblings, the mother had a detectable mutation load in 4 cases; in the other 6 cases the 
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heteroplasmy level of the mother was unknown. Of the 19 cases where the older sibling 
had a heteroplasmy level between 3% and 25%, the younger sibling had an undetectable 
mutation in 6 cases (32%). In the 24 cases where the older sibling had a heteroplasmy 
level higher than 25%, one younger sibling (4%) had an undetectable mutation. 
A correlation coefficient of 0.512 (p<0.001) was found between the heteroplasmy levels 
of the siblings.
Figure 4.1 a-b
A) Heteroplasmy levels in children divided in three groups depending on the heteroplasmy level of 
their mother, n gives the number of mother child relations in every group. B) heteroplasmy levels in 
siblings divided in five groups depending on the heteroplasmy level of the older sibling, n gives the 
number of intersibling relations in every group.
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Discussion
Because of the unique characteristics of mitochondrial inheritance (mitotic segregation, 
heteroplasmy and maternal inheritance), genetic counseling in mitochondrial diseases 
caused by a mtDNA mutation has always been very difficult (18). With this study we pro-
vide additional information regarding the inheritance of the m.3243A>G mutation. We 
used UEC to analyze heteroplasmy levels as different studies have shown a good relation 
between clinical phenotype and heteroplasmy in UEC (20). Besides, heteroplasmy in 
UEC is more stable compared to heteroplasmy in lymphocytes (15, 21). We must keep in 
mind that although there is a correlation between heteroplasmy levels in UEC and clinical 
symptoms, there are also patients with high levels of heteroplasmy that do not present with 
clinical symptoms during childhood. It is hypothesized, but as of yet unknown, whether 
these ‘dormant carriers’ develop symptoms when they reach adulthood (15).
We found a correlation of r=0.679 (p<0.001) between the heteroplasmy levels in 
mothers and their offspring, indicating that mothers with higher heteroplasmy levels 
have offspring with higher heteroplasmy levels. However, as indicated in Figure 4.1a, 
there is quite some variance in the transmission of the m.3243A>G mutation. We dem-
onstrated that mothers with a heteroplasmy level of above 25% transmit the mutation to 
all their offspring, providing clarity for patients. Thirty percent of offspring from mothers 
who have a heteroplasmy level below 25%, will have undetectable heteroplasmy levels 
of the m.3243A>G mutation (using the current techniques). These findings support 
the use of such techniques as pre-implantation genetic diagnosis (PGD) to select for 
unaffected offspring in this group. In mothers with a heteroplasmy level of higher than 
25%, all the offspring are affected, making it only possible to select for the embryo with 
the lowest level of heteroplasmy using PGD. The only options that remain for these 
women is oocyte donation or adoption to be 100% sure that there will be no transmis-
sion of the m.3243A>G mutation. A future possibility for these women could be nuclear 
transfer (19). 
Besides transmission from mother to child, we also investigated the relationship 
between heteroplasmy levels of siblings, in order to see if heteroplasmy levels in a child 
may provide extra information in predicting the heteroplasmy level of further progeny. 
Figure 4.1b indicates that the heteroplasmy level in the oldest sibling has some predic-
tive value for younger siblings, but again there are outliers. In the group where the oldest 
sibling does not have a detectable mutation there is still a 50% chance that the second 
sibling will have the mutation, and one patient even had a heteroplasmy level of above 
50%. On the other side of the spectrum, we find an almost identical case in which the 
oldest sibling has a high (above 50%) level of heteroplasmy but the mutation could not 
be detected in the younger sibling. So, even though there is a correlation between the 
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heteroplasmy levels in siblings (r=0.512, p<0.001), the presence of these outliers makes 
it difficult to offer genetic counseling to these families. 
We conclude that the female carriers of the m.3243A>G mutation do not transmit 
the mutation to all of their offspring. We suggest that mothers with a heteroplasmy level 
below 25% could consider using techniques like PGD to prevent transmission in case of 
child wish. Long-term follow-up studies should be performed to examine the stability of 
the heteroplasmy values, to investigate whether PGD for women with heteroplasmy levels 
above 25% is feasible. 
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Abstract
The m.3243A>G mutation is the most prevalent, disease-causing mitochondrial DNA 
(mtDNA) mutation. In a national cohort study of 48 families harbouring the m.3243A>G 
mutation, we identified three families in which the mutation appeared to occur sporadically 
within these families. In this report we describe these three families. Based on detailed 
mtDNA analysis of three different tissues using two different quantitative pyrosequencing 
assays with sensitivity to a level of 1% mutated mtDNA, we conclude that the m.3243A>G 
mutation has arisen de novo in each of these families. The symptomatic carriers presented 
with a variety of symptoms frequently observed in patients harbouring the m.3243A>G 
mutation. A more severe phenotype is seen in the de novo families compared to recent 
cohort studies, which might be due to reporting bias. 
The observation that de novo m.3243A>G mutations exist is of relevance for both 
diagnostic investigations and genetic counselling. Firstly, even where there is no significant 
(maternal) family history in patients with stroke-like episodes, diabetes and deafness or 
other unexplained organ dysfunction, the m.3243A>G mutation should be screened as 
a possible cause of the disease. Second, analysis of maternally-related family members 
is highly recommended to provide reliable counselling for these families, given that the 
m.3243A>G mutation may have arisen de novo.
De novo m.3243A>G mutation
87
5
Introduction
In recent years, a large body of data concerning the inheritance of mitochondrial disorders 
has been published (1-3). Knowledge relating to the mode of inheritance has great 
importance for both the diagnosis and counselling of patients. Due to the involvement 
of the nuclear and mitochondrial genomes, mitochondrial diseases can be transmitted in 
a Mendelian manner, in the case of a nuclear aetiology, be maternally transmitted in the 
case of primary mitochondrial DNA (mtDNA) defects or they may occur sporadically (4).
In the case of single, large-scale mtDNA deletions such as those observed in patients 
with the Kearns-Sayre Syndrome, Chronic Progressive External Ophthalmoplegia or Pear-
son’s Syndrome, occurrence is usually sporadic and recurrence in the offspring of female 
carriers is limited to 4% of the patients (5). Our study focuses on the m.3243A>G MTTL1 
gene mutation, first described by Goto et al. (6) as a cause of the mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome but which also 
causes maternally-inherited diabetes and deafness (MIDD) (7). Other clinical phenotypes 
include cardiac, ocular, gastrointestinal and renal involvement. The m.3243A>G mutation 
is the most prevalent, multi-system disease-causing mitochondrial DNA mutation, with a 
reported mutation prevalence of between 7.59 and 236 per 100,000 (8-10). 
A considerable number of case series and small cohorts have been published 
describ ing the phenotypic expression of the m.3243A>G mutation (11-17). In contrast 
to what is seen for other mtDNA mutations, the sporadic occurrence of the m.3243A>G 
mutation, with an expressed phenotype, is rare with only four de novo cases published 
to date (18-21) (Table 5.1).
In our own cohort of Dutch m.3243A>G mutation carriers, we identified three families 
where the m.3243A>G mutation appears to have arisen de novo. The purpose of this 
paper is to document these families, describing the probands’ presentation in detail and 
highlighting the family members in whom the m.3243A>G mutation was not detected. 
Maternal inheritance in a pedigree is a trigger for clinicians to consider the presence of 
an mtDNA mutation but even if there is no significant family history in the maternal line, 
the m.3243A>G mutation should be considered in patients with symptoms consistent 
with the MIDD or MELAS syndromes. 
Methods
All patients participated in the m.3243A>G mutation cohort study at the Radboud Center 
for Mitochondrial Medicine (22). 135 patients from 48 families were included in this study. 
The study was approved by the ethics committee of the Nijmegen-Arnhem region. Written 
informed consent according to the Helsinki agreement was obtained from all parents and 
patients ≥12 years. 
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Heteroplasmy levels were determined in urinary epithelial cells, blood and buccal cells 
of all participants using PyrosequencingTM technology (Pyrosequencing, Uppsala, Sweden) 
as described before by Lowik et al. (23). The pyrosequencing assay of the m.3243A>G 
mutation in the mtDNA (Genbank accession# NC_012920.1) has a precision of 1.5%, the 
precision relates to the correlation between independent measurements of the same 
sample. A sensitivity of 4.5% has been quoted for this technique, as determined by serial 
dilution of an m.3243A>G positive sample in a sample containing wild type mtDNA, and 
by determining the background signal + 3x SD in a panel of 43 control samples. 
The tissue samples of patient II-3 of family 3 were collected within 2 hours post 
mortem. Samples were snap frozen using liquid nitrogen and stored at -80°C. DNA was 
extracted using a Genomic DNA Purification Kit (Gentra, Mineapolis, USA), following the 
manufacturer’s procedures.
In the families in which a de novo m.3243A>G mutation was suspected, heteroplasmy 
levels in urinary epithelial cells from first degree family members were measured using a 
second pyrosequencing assay with a sensitivity calculated at 1% as previously described 
by Alston et al. (24).
The data of this study were submitted to the MITOMAP database (www.mitomap.org).
Family reports
Family 1 
The proband (III-2, Figure 5.1a) presented with aphasia and encephalopathy at the age 
of 34 years having experienced difficulty in speaking for a few months with a history 
of hearing impairment since age 5. During this episode of encephalopathy he spoke 
in short sentences and was unable to respond to complex commands. There were no 
abnormalities in the evaluation of cranial nerves, reflexes, motor skills or sensation. MRI 
imaging showed abnormal signal intensities in both cortical and sub-cortical areas of the 
left parieto-temporal lobe. MRI-Spectroscopy demonstrated elevated levels of lactic acid 
in the affected areas. A muscle biopsy was performed showing diminished ATP production 
and decreased complex I activity (see Table 5.2). Unfortunately no histopathological data 
are available. m.3243A>G mutation screening was performed, revealing a high level of 
m.3243A>G mutation load (82%) in muscle, confirming the diagnosis of m.3243A>G 
related mitochondrial disease. Assessment of m.3243A>G mutation levels in leucocytes, 
urinary epithelial cells and buccal cells were 23%, 63% and 40%, respectively. During 
follow-up, the patient developed epilepsy at the age of 35 years and diastolic dysfunction 
on echocardiography. He was myopathic and unable to perform normal work. Lactate 
levels in blood were elevated to an average level of 4.0 mmol/L (reference <2.2 mmol/L). 
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An extensive family study was performed. Family members with symptoms that could be 
consistent with the m.3243A>G mutation include a cousin (III-6) and her baby child (IV-6) 
who experienced severe congenital hearing impairment, and the proband’s mother (II-3) 
who reported non-insulin dependent diabetes and mild hearing impairment at the age 
71 years. A total of 16 family members were tested for the presence of the m.3243A>G 
mutation, but this was not detected in any other family member apart from the proband 
(Figure 5.1a). The underlying cause of the congenital hearing loss reported by (III-6) and 
(IV-6) was investigated by whole exome sequencing, and a nuclear-encoded mutation was 
identified which is likely to be pathogenic.
Family 2 
The proband (IV-1, Figure 5.1b) presented at the age of almost 2 years, with neurologi-
cal deterioration following a viral infection resulting in hypotonia, axial ataxia, ptosis and 
ophthalmoplegia. He had elevated lactate levels (5.5 mmol/L, reference <2.2 mmol/L) and 
abnormal signal intensities in the parieto-occipital region on MRI. His neurological symp-
toms improved after normalization and increase of his calorific intake. A muscle biopsy was 
performed, demonstrating diminished ATP production, decreased complex I activity but 
no histopathological abnormalities (Table 5.2). Genetic testing revealed the m.3243A>G 
mutation to be present at a level of 23% heteroplasmy in skeletal muscle. Motor skill 
development was somewhat slow, requiring physiotherapy but by the age of 8 years he 
attended mainstream school, and had normal motor skills and strength. Heteroplasmy 
levels in urinary epithelial cells and buccal cells were 38% and 27%, respectively. Six family 
members were assessed; they were all in good health. Heteroplasmy analysis showed a 
low level (6% mutation load) of m.3243A>G mutation in the urinary epithelial cells from 
the mother (III-3), whereas the mutation was undetectable in her blood and buccal cells. 
The patient’s mother (III-3) underwent muscle biopsy which showed a slightly diminished 
ATP production, normal complex activities and no histopathological abnormalities sugges-
tive of mitochondrial disease; heteroplasmy analysis showed a 5% m.3243A>G mutation 
load in muscle (see Table 5.2). Five further asymptomatic maternally-related individuals 
including grandmother underwent genetic testing in urinary epithelial cells and did not 
harbour the m.3243A>G mutation (Figure 5.1b). Patients III-1 and III-2 did not consent to 
genetic testing, their case history did not suggest any mitochondrial symptoms. 
Family 3 
The proband (II-4, Figure 5.1c) was born at term with a birth weight of 4750 grams (> 97th 
centile). He was delivered by an emergency caesarean section due to fetal distress and 
required short time respiratory support because of transient tachypneu of the neonate. 
He had hypoglycaemia that was treated with glucose infusions and elevated lactate (pH 
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7.32, reference 7.34–7.45; lactic acid 4.2 mmol/L, reference <2.2 mmol/L) Left ventricular 
hypertrophy was seen on echocardiogram with no hemodynamic consequence. Muscle 
biopsy was performed and showed a decrease of complex I and complex IV activities, 
histopathological assays were normal (Table 5.2); mtDNA analysis revealed the m.3243A>G 
mutation at a heteroplasmy level of 12% in muscle. Following a rapid recovery, the patient 
was discharged from the hospital. At age five months, a second echocardiogram showed 
a normal heart with no signs of hypertrophy or cardiomyopathy. Quantitative mutation 
analysis of urinary epithelial cells, leucocytes and buccal cells showed m.3243A>G 
heteroplasmy levels of 16%, 20% and 16%, respectively. At six years of age the patient 
had no medical problems, in particular no cardiomyopathy, fatigue or muscle weakness. 
DNA samples from his mother and siblings showed no detectable levels of the m.3243A>G 
mutation in urinary epithelial cells, leucocytes and buccal cells (Figure 5.1c). One of his 
siblings (II-3) died at four months of age from dehydration following campylobacter gastro-
enteritis complicated by metabolic acidosis and liver failure. Post-mortem muscle and liver 
biopsies showed a diffuse steatosis with no further abnormalities on either conventional 
and electron microscopy nor following further biochemical and molecular genetic testing; 
the m.3243A>G mutation was absent in these post-mortem tissues. 
Discussion
Genetic counselling in mitochondrial diseases caused by an mtDNA mutation is compli-
cated. With this report we provide additional information regarding the inheritance of 
the m.3243A>G mutation. 
There are only four previous reports of a sporadically occurring m.3243A>G muta-
tion, it is therefore of great significance that we describe these new patients who most 
likely have de novo mutations. We included 48 m.3243A>G mutation-positive families in 
our cohort study; this is a follow-up study to our previously published national inventory 
(22). 37 of these families demonstrated maternal inheritance of the m.3243A>G muta-
tion, whilst three families (8% of our cohort families) had a likely de novo occurrence of 
the m.3243A>G mutation, no data were available concerning the family members in the 
remaining seven families.
The clinical presentation of patients with a de novo m.3243A>G mutation includes 
MELAS, MELAS/MERFF overlap, MIDD and cardiomyopathy. In recent cohort studies 
there is a predominance of milder phenotypes, such as MIDD, amongst carriers of the 
m.3243A>G mutation (16, 22). Interestingly, across all cases reported to date, a MELAS 
phenotype was seen in the proband of five out of eight families with a de novo appearance 
De novo m.3243A>G mutation
95
5
of the m.3243A>G mutation (including the probands of families 1 and 2 from this study) 
(18-20). One proband had a MIDD phenotype (21), and one proband had an isolated 
cardiomyopathy (proband of family 3 of this study). There seems to be a tendency towards 
a more severe phenotype in the index patients of the families with a de novo appearance 
of the m.3243A>G mutation, this could however also be the result of a bias in recogni-
tion of the phenotype, whereas a mildly affected individual would never be subjected to 
mitochondrial DNA sequencing and these mild cases of de novo m.3243A>G mutation 
may therefore be never found. In two of the families with a de novo m.3243A>G muta-
tion, the proband’s mother had either MIDD or an isolated deafness phenotype (18, 20). 
In fact, these mothers are the individuals in whom the de novo mutational event occurred, 
and their genetic diagnosis was only made following the identification of the m.3243A>G 
mutation in their more severely affected children.
An isolated incidence of an mtDNA mutation within a family can have one of three 
causes, as stated by Maassen et al. (21); 1) other family members in the maternal lineage 
harbour the mutation, but below the detection limit, 2) there is no biological relationship 
between the proband and the other family members tested, 3) a de novo mutational event 
has occurred (23). We investigated the cause of the isolated m.3243A>G mutation in the 
three families described in this report using these three possibilities. 
To investigate the possibility that the mutation is present below the sensitivity of the 
assay, we used two different pyrosequencing techniques as described previously (23, 24). 
The pyrosequencing assay described by Lowik et al. has a sensitivity of 4.5% whereas the 
assay described by Alston et al. has a higher sensitivity (1.0%). We tested three different 
tissues for each available family member, urinary epithelial cells, leucocytes and buccal 
cells. No muscle was available of the family members (except for patient II-3 of family 3), 
but previous studies have shown a good correlation between the m.3243A>G mutation 
load in urinary epithelial cells and muscle biopsy (25, 26). With sensitivities of 4.5% and 
1.0% respectively for the two pyrosequencing assays, the probability of multiple false-
negative results are highly unlikely, it is therefore unlikely that other family members 
in the maternal lineage also carry the mutation below the detection limit. The family 
members were also clinically assessed using the NMDAS for symptoms that could be 
related to the m.3243A>G mutation. From a total of 23 adult relatives, two had hearing 
problems (including patient III-6 from family 1), two had diabetes mellitus (one insulin 
dependent), three reported constipation, two relatives reported psychiatric complaints 
and two reported visual abnormalities. No relatives reported ataxia or myopathy. The 
results from the screening of non-invasive familial samples suggest that the m.3243A>G 
mutation is unlikely to be present below the detection threshold in our proposed de novo 
m.3243A>G families.
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In order to investigate the second possibility of non-kinship as the cause of isolated 
m.3243A>G occurrence, we obtained confirmation of kinship from the mothers within 
the families. Paternity testing was not performed given that paternity is not relevant in 
establishing the inheritance of a mitochondrial DNA mutation. Having excluded kinship 
and sensitivity issues, we conclude that there is most likely a de novo appearance of the 
m.3243A>G mutation in our three families. 
The m.3243A>G mutation has previously been detected in patients with different 
haplotypes (8, 27), indicating that de novo appearance of the m.3243A>G mutation has 
occurred frequently in the past. Although the mechanism behind de novo appearance of 
the m.3243A>G mutation is unknown, it is speculated that the mutational event is likely 
to have occurred during oogenesis (in the mother’s embryonic development) or during 
early embryonic development of the proband (19). These hypotheses are supported by 
our results given that each proband harbours the mutation in tissues that originate from 
each of the three primary germ cell layers. 
This report detailing a further three cases harbouring a de novo m.3243A>G mutation 
highlights the importance of screening for the m.3243A>G mutation even if there is no 
significant (maternal) family history in a patient with MELAS or MIDD symptoms. Moreover, 
a genetic diagnosis of an m.3243A>G mutation in an isolated patient does not necessarily 
mean that others in the maternal lineage should automatically be presumed to harbour 
the mutation also. Despite the vast majority (>90%) of m.3243A>G mutation cases being 
maternally inherited, a thorough family investigation should always be performed. 
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Abstract
Background: The mitochondrial DNA m.3243A>G mutation is one the most prevalent 
mutation causing mitochondrial disease in adult patients. Several cohort studies have 
used heteroplasmy levels in urinary epithelial cells (UEC) to correlate the genotype of the 
patients to the clinical severity. However, the interpretation of these data is hampered by 
a lack of knowledge on the intra patient variability of the heteroplasmy levels. The goal 
of this study was to determine the day-to-day variation of the heteroplasmy levels in UEC. 
Methods: Fifteen carriers of the m.3243A>G mutation, collected five urine samples in a 
14 days window. Heteroplasmy levels of the m.3243A>G mutation were determined in 
these samples. Data from the national cohort study, including NMDAS scores and clinical 
diagnosis were used. 
Results: In the samples of six patients heteroplasmy levels were within a 5% margin. In 
the samples collected from five patients the margin was >20%. 
Conclusion: Heteroplasmy levels of UEC in carriers of the m.3243A>G mutation have a 
significant day-to-day variation. The interpretation of a correlation between heteroplasmy 
levels in urine and disease severity is therefore not reliable. Therefore, heteroplasmy levels 
in UEC should not be used as a prognostic biomarker in these patients.
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Introduction
In 1990 the Adenine to Guanine transition at position 3243 of mitochondrial DNA 
(m.3243A>G) in the MT-TL1 gene encoding tRNALEU(UUR) was found as the molecular 
basis for MELAS (1, 2). The acronym MELAS was first used in 1984 by Pavlakis et al. to 
describe a group of patients with mitochondrial myopathy, encephalopathy, lactic acidosis 
and stroke-like episodes (3). As the m.3243A>G mutation is the most common cause of 
MELAS syndrome (MIM 540000), it is also reported as the MELAS mutation although 
other phenotypic expressions have been described. These include maternally inherited 
diabetes and deafness (MIDD, MIM 520000) (4), hypertrophic cardiomyopathy (5), macular 
dystrophy (6), gastro-intestinal involvement (7), and oligosymptomatic variants of the 
acronym MELAS (8). The m.3243A>G mutation is one the most prevalent pathogenic 
mutation of the mitochondrial DNA, prevalence being reported in the range of 7.59-
236/100,000 persons (9-11).
Since mitochondria and mitochondrial (mt) DNA are present in all tissues except red 
blood cells, heteroplasmy percentages can theoretically be assessed in virtually every 
tissue. Two problems arise when testing heteroplasmy: most human tissues are practically 
not accessible and differences in heteroplasmy levels between samples might exist. 
For example, invasively obtained skeletal muscle tissue DNA usually gives higher and 
more consistent heteroplasmy levels than DNA extracted from a less invasively obtained 
blood sample (12). The lower levels in blood might even lead to false-negative results 
(13). Previous studies showed a superiority of urine over blood as preferred non-invasive 
tissue for mutation analysis in patients at risk of carrying the m.3243A>G mutation (14-
17). However, the relationship between mutation load and clinical phenotype has been a 
subject of research for many years (18-21). 
Surprisingly in several studies, including one of ourselves, a relationship between 
heteroplasmy levels in urinary epithelial cells (UEC) and clinical symptoms was suggested. In 
these small sample sizes the reported correlation coefficients were however rather low (13, 
14, 20, 22). There is little evidence on whether heteroplasmy levels (in any tissue) correlate 
with progression of the mitochondrial disease. A recent study showed an association 
between disease progression and age-adjusted heteroplasmy in blood (21). In the other 
mentioned cohort studies, UEC’s have predominantly been investigated as a prognostic 
marker for severity of disease and disease progression. In this study we show that the 
measurement of m.3243A>G UEC heteroplasmy levels have a large intra-patient day-to-
day variability. Cautiousness regarding the usage of m.3243A>G heteroplasmy levels in 
UEC as a prognostic biomarker as for example in drug intervention studies is warranted. 
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Methods
Patients
All subjects were genetically diagnosed with the m.3243A>G mutation in DNA extracted 
from skeletal muscle and/or blood. They all participate in our natural history cohort study 
(17). The ethics committee of the Nijmegen-Arnhem region approved this study. Written 
informed consent according to the Helsinki agreement was obtained from all patients.
Patient characteristics, regarding age, sex and clinical expression of the m.3243A>G 
were extracted from the data of the national cohort study, including Newcastle 
Mitochondrial Disease Adult Scale (NMDAS)-scores, and mtDNA heteroplasmy levels in 
other tissues. All patients were asked to report symptoms of urinary tract infections, fever, 
smoking and alcohol use.
Urine sample collection and mutation analysis
All patients received an isolation box with 5 urine containers. They were instructed to 
collect 5 urine samples in a 14 days window. The urine samples were to be collected in 
the morning of days 1, 4, 7, 10 and 13. The samples were stored at 3–6° Celsius, and send 
with regular postal service to the laboratory in the provided isolation box after collection 
of the fifth sample. DNA was isolated from the urine samples, after centrifugation of the 
urine for 10 min at 3000 r.p.m., the pellet was washed with phosphate-buffered saline. 
DNA was extracted using a commercially available DNA isolation kit (PuregeneTM DNA 
isolation kit; Gentra Systems, MN). 
Heteroplasmy levels were determined in all urine samples using PyrosequencingTM 
technology (Pyrosequencing, Uppsala, Sweden) as earlier described by (23). The 
pyrosequence reaction of the m.3234A>G mutation had a precision of 1.5%, and the 
lowest limit of detection was 5%. The detection limit for the m.3243A>G mutation was 
determined by serial dilutions of a sample containing this mutation with wild type mtDNA.
Statistics
We used descriptive statistics in analyzing the data.
Results
General patient characteristics 
Fifteen carriers were included in the study (Table 6.1). Four carriers (27%) were male. 
Median age was 39 years (range 20–69 years). Patients had different phenotypic expressions 
of the m.3243A>G mutation: MELAS syndrome (1 patient), MIDD (7 patients), isolated 
myopathy and fatigue (4 patients) and cardiomyopathy (1 patient). The remaining two 
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patients were clinically asymptomatic and should be categorized as dormant carriers. The 
median NMDAS score was 8 (range 1–56 with 1 being the least severe disease expression). 
Heteroplasmy levels
A total of 75 urine samples were collected. In two samples, it was not possible to extract 
sufficient amounts of DNA for heteroplasmy analysis. Heteroplasmy level measurement was 
successful in the remaining 73 samples (Table 6.1). In the samples of 6 patients (patients: 
1, 2, 3, 4, 14 and 15) heteroplasmy levels were within 5% margin of each other (Figure 
6.1a). In the samples of 5 patients (patients: 5, 6, 7, 9 and 13) the margin was >20% (Figure 
6.1b). In the remaining 4 patients (patients: 8, 10, 11 and 12) the variation between the 
heteroplasmy levels in the different samples was between 5% and 20%. 
Patients 9 and 12 reported some complaints of a viral upper airway infection during 
the first days. Patient 14 reported to have smoked during all days. There was no alcohol 
usage among the patients.
Discussion
UEC have been identified as the most optimal non-invasive tissue for measurement of 
heteroplasmy of mtDNA mutations (17). Heteroplasmy levels in UEC have also been 
correlated with disease severity (22). In this study we show that UEC m.3243A>G 
heteroplasmy levels within one patient might show important day-to-day variations. Based 
on these results we conclude that the level of UEC heteroplasmy should be cautiously 
interpreted in predicting disease severity and the results of intervention studies in carriers 
of the m.3243A>G mutation.
We hypothesize that the difference in heteroplasmy levels between the different urine 
samples from individual patients is caused by a variation in different types of (epithelial) 
cells in the urine samples. Previous studies extensively studied the different epithelial 
cells in random urine samples and report a broad variation in different kinds of epithelial 
cells between samples (24). Due to a genetic bottleneck there is variation between the 
heteroplasmy levels of cells from different organs or tissues in one patient (25). If there 
is a larger proportion of the cells in a urine sample with a higher or lower heteroplasmy 
level compared to another sample, this could explain the differences reported in this 
study. 
Patients with a very high or very low heteroplasmy level in UEC have a smaller range 
of heteroplasmy levels compared to patients with heteroplasmy levels in the middle 
range (Figure 6.1a and Figure 6.1b). This is consistent with our hypothesis that there is a 
variation in cell types in the different urine samples, a normal distribution of the variance 
can be expected. 
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As several cohort studies (13, 20), including one of our own, have used the hetero-
plasmy levels in UEC to correlate the genotype of the patients to the clinical severity, it 
is essential to have studied the intra patient variability of the heteroplasmy levels in UEC. 
Overall the disease progression in carriers of the m.3243A>G mutation has no significant 
Figure 6.1
Every patient is represented by one line. In Figure 6.1a heteroplasmy levels differ <5% between the 
different measurements. In Figure 6.1b heteroplasmy levels differ >20%.
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day-to-day variation. The interpretation of a correlation between heteroplasmy levels in 
urine and disease severity is therefore not reliable. 
Conclusion
In this study we demonstrated that the measurement of m.3243A>G heteroplasmy levels 
in UEC might have a substantial intra-patient day-to-day variability. The use of UEC 
m.32343A>G heteroplasmy levels as a prognostic biomarker should be interpreted in 
the light of these findings. 
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Abstract
Background: Mitochondrial disorders belong to the most prevalent inherited metabolic 
diseases with the m.3243A>G mutation reflecting being one of the most common 
mutations in mitochondrial DNA. Previous studies showed little relationship between 
mitochondrial genetics and disease manifestation. Relationship between genotype and 
disease manifestation with patient reported quality of life and other patient reported 
outcomes is still unexplored. 
Methods: Seventy-two out of the 122 invited adult patients with m.3243A>G mutation 
completed online standardized questionnaires on quality of life, functional impairment, 
fatigue and mental health as assessed by the RAND-SF36, the Sickness Impact Profile 
(SIP), the Checklist Individual Strength (CIS) and the Hospital Anxiety and Depression 
scale (HADS). Data were related to clinical manifestation reflected by the Newcastle 
Mitochondrial Disease Adult Scale (NMDAS) score and heteroplasmy levels of the mutation 
in urine epithelial cells. 
Results: Patients reported impaired quality of life. Sixty percent showed severe levels of 
fatigue, and 37% showed clinical relevant mental health problems, which was significantly 
more than healthy norms. These patient reported health outcomes showed negligible 
relationship with levels of heteroplasmy (r≤0.30) and weak (0.30<r<0.50) to moderate 
(0.50<r<0.70) relationship with clinical manifestation. 
Conclusions: Patient reported outcomes on quality of life, fatigue and mental health 
problems, are only partly reflected by clinical assessments. In order to support patients 
more effectively, integration of patient reported outcomes, alongside symptoms of their 
disease, in clinical practice is warranted.
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Introduction
Mitochondrial disorders, as a group, belong to the most prevalent inherited metabolic 
diseases. The incidence of congenital mitochondrial disorders based on oxidative phos-
phorylation (OXPHOS) defects is at least 1:8500 of all life births (1). Mitochondrial diseases 
can result from mutations in either nuclear or mitochondrial DNA and show great variability 
in expression. Although new pharmacological interventions are being explored in cells 
and animals, currently no cure or substantially alleviating therapy is available for these 
disorders and care is focused on alleviating the broad range of symptoms of the disease. 
Mitochondrial diseases have a complex and heterogeneous expression with often more 
than one system structurally and/or functionally affected (e.g. brain, muscles, the heart). 
Previous studies showed little relationship between mitochondrial genetics and clinical 
manifestation (2-4). In addition, a recent study that took patient reported outcomes on 
fatigue into account reported little relationship between these outcomes and genotype 
and clinical manifestation either (5). Information about patients’ self reported quality of 
life and impact of the disease in their daily life is important to be able to focus care on 
patients’ most important complaints, as well as to further understand the relationship of 
biological and clinical parameters with these patient reported outcomes.
In a study of 78 parents of children with a mitochondrial disorder, Koene et al. showed 
in 2013 that the most burdensome complaints of patients included fatigue, problem 
behavior, muscle weakness and a high degree of limitations in daily activities (6). Recently, 
Gorman et al. (5) supported the importance of fatigue in a group of patients with a variety 
of mitochondrial disorders.
This is in line with studies in patients with other chronic conditions such as T1DM (7), 
multiple sclerosis (8), and Ehlors-Danlos syndrome (9) showing fatigue as an important 
burden. These studies too, show little relationship of patient reported outcomes such as 
fatigue and quality of life with clinical manifestation. The aim of the present study is to 
investigate patient reported outcomes in terms of quality of life, functional impairment, 
fatigue and mental health. In addition, this study is aimed to assess the relationship 
between these patient reported outcomes and disease manifestation as well as genotype. 
We focused on a group of patients with the m.3243A>G mutation reflecting one of 
the most common genetic causes for mitochondrial disorders, often referred to as acro-
nym Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke like episodes (MELAS) 
(10) and/or MIDD (maternally Inherited Diabetes and Deafness). The disease spectrum of 
patients with the m.3243A>G mutation is multidimensional. Patients suffer from various 
mainly neurological problems (such as stroke like episodes, epilepsy, dementia, migraine, 
muscle pain or psychiatric problems), but also from a broad range of other problems 
importantly affecting their daily functioning. 
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Methods
Sample
All 122 patients, age 18 or above, with a mitochondrial disease due to the m.3243A>G 
mutation in leucocytes, urinary epithelial cells and buccal mucosa, under care of the 
Nijmegen Center for Mitochondrial Disorders at the Radboud University Medical Centre, 
were invited to participate in this longitudinal observational study. 
Procedure
After given informed consent, patients received an email with a link to a private, secure 
website that presented a set of questionnaires that could be administered at home, at 
time of first access or later. Patients were asked to complete the total set of questionnaires 
within one week. Assessments were repeated after two weeks (T2) and three months (T3). 
Newcastle Mitochondrial Disorder Assessment Scale (11) was assessed during clinical 
consultations. 
Ethical committee
This study was approved by the local ethical committee of the Radboud University Medical 
Centre, Nijmegen, the Netherlands. All participants gave informed consent.
Instruments
Genotype was assessed in terms of heteroplasmy levels in leucocytes, urine epithelial cells 
and in buccal mucosa. Genotyping procedure has been performed as described earlier (4). 
Disease Manifestation was assessed by the Newcastle Mitochondrial Disease Adult 
Scale (11). The NMDAS is a measure to monitor the clinical expression of the disease and 
consists of the following three sections: (1) Current functioning: general physical functioning 
of the patient in the past four weeks (2) System specific involvement to gain insight in the 
functioning of individual organ-systems. (3) Current clinical assessment gives insight in the 
current clinical status of the patient. Details of assessment as well as inter rater reliability 
are described previously (4).
We defined NMDAS scores of 1 to 5 as mild clinical manifestation, scores 6 to 20 as 
moderate and scores above 20 as severe clinical manifestation.
Patient reported health outcomes were assessed by online administered self-report 
on quality of life, functional impairment, fatigue and mental health. 
Quality of life was assessed with the RAND-36. The RAND-36 assesses 7 dimensions 
of quality of life (physical functioning, social functioning, emotional functioning, general 
health status, perceived change in health status, sleep problems and pain). Scores on 
different scales range from 0 (maximum limitations) to 100 (optimal functioning). As 
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reference group we used a Dutch norm group for general population of men and women 
age 18 to 75 years. (12)
Functional impairment was assessed with the Sickness Impact Profile (SIP; (13, 14)). 
The SIP, is aimed to assess changes of conduct in everyday activities due to sickness and 
assesses the following dimensions of functioning: Sleep/rest, home management, mobility, 
social interaction, ambulation, alertness and intellectual functioning, work and recreation and 
pastime. Total scores ranged from 0 to 5799 with higher scores reflecting more impairment. 
Dutch norms are not available but scores of comparison groups with same age and sex were 
used consisting of 90 health controls in a study with 94 patients with Multiple Sclerosis (15). 
Perceived fatigue severity was assessed with the fatigue severity subscale of the Check-
list Individual Strength (16). The CIS is a questionnaire with 20 items that can be scored on 
a seven-point Likert scale. The CIS is designed to assess different dimensions of fatigue: 
fatigue severity (8 items scores ranging from 8 to 56), concentration (5 items scores ranging 
from 5 to 35), motivation (4 items scores ranging from 4 to 28) and physical activity (3 items, 
scores ranging from 3 to 21). Higher scores indicate higher levels of fatigue, more concentra-
tion problems, less motivation and low levels of physical activity. Studies indicated that the 
fatigue severity subscale was best indicator of patient reported fatigue related complaints. 
It consists of items like I feel fit, I feel tired, I feel powerless, I am rested, to complete on a 
7-point Likert scale. A CIS-fatigue score of 35 or more was used to identify severe fatigue in 
correspondence with other studies (9, 15). The CIS has good reliability and is used to assess 
perceived fatigue in several groups of patients with various medical conditions. 
Mental functioning was assessed with the Hospital Anxiety and Depression scale 
(17, 18), measuring symptoms of anxiety and depression. The HADS is specially designed 
to assess symptoms of depression in people with medical conditions by controlling for 
vital aspects of depression that could easily interfere with symptoms of the disease and 
showed good reliability and validity.
Statistics
Logarithmic transformations were performed on variables with a skewness of >1. Data 
analysis was performed using SPSS version 20.0. Descriptive statistics were used to describe 
the characteristics of the sample as well as patient reported outcomes on quality of life, 
functional impairment, fatigue and mental health. Correlational analyses identified the 
main correlates of disease manifestation with different aspects of patient reported health 
status. RAND-36 score on physical functioning (RAND-36_PF), was used as indication 
for physical quality of life. Total scores were used for SIP, CIS and HADS as indication of 
functional impairment, subjective fatigue and mental health. Correlations lower than 0.30 
were considered negligible, between 0.30 and 0.50 low, between 0.50 and 0.70 moderate 
Chapter 7
118
and between 0.70 and 0.90 strong (19). Hierarchical multiple regressions were performed 
to explore the predictive value of genotype and clinical manifestation for patient reported 
outcomes. Genotype and clinical manifestation were first entered in the analyses, followed 
by patient reported outcomes. As dependent variables we focused on physical functioning, 
functional impairment, fatigue and mental health.
Results
Response  
A total of 122 patients with the m.3243A>G mutation was invited to participate. Seventy-
two patients completed the questionnaires, a response rate of 59%. Demographic 
characteristics of the patients are summarized in Table 7.1. Fifty-nine percent were women. 
Differences between response group and non response group could be assessed on 
demographic and clinical characteristics. Heteroplasmy levels did not differ between the 
two groups (t=-0.705; p=0.482). The same was true for NMDAS subscales 1 and 2. Non 
response group showed significantly more problems on the NMDAS 3 subscale (t=6.771; 
p=0.021) and nearly significant more problems on total NMDAS scale (t=3.809; p=0.053). 
Age (t=-0.641; p=0.523), BMI (t=-1.754; p=0.082) and height (t=-1.208; p=0.229) did not 
differ, however, non responders had a lower weight (t=-2.114; p=0.036). 
Response rate on repeated assessment at T2 and T3 was 50 (69%) and 48 (67%) 
respectively. Correlations on outcomes measures between T1 and T2 assessments varied 
from 0.837 (functional impairment) to 0.922 (mental health). Correlations between T1 and 
T3 assessments varied from 0.761 (functional impairment) to 0.858 (physical functioning).
Table 7.1: General characteristics of patients (n=72) as well as genotype and disease manifestation
Mean Median Range
Age (years) 45 46 19–67
BMI (kg/m2) 24 23 14–41
Length (in cm) 168 167 142–193
Weight (in kg) 68 67 35–113
Heteroplasmy level (%)
Leucocytes
UEC
Buccal mucosa
19
49
34
13
27
18
0–56
0–97
0–73
NMDAS
Current functioning
System specific involvement
Current clinical assessment
Total NMDAS
8
6
3
17
7
5
4
16
0–43
0–31
0–29
0–98
Quality of life in carriers of the m.3243A>G mutation
119
7
Genotype
Levels of heteroplasmy were assessed in Leucocytes (mean 19%; SD=13; range 0–56)), 
urinary epithelial cells (UEC; mean 49%; SD=27; range 0–97) and buccal mucosa (mean 
34%; SD=18; range 0–73).   
 Disease manifestation
Mean NMDAS score was 17 (SD=15) varying from 1 to 98, median 14.5. Twenty-one 
percent of the patients showed mild symptoms, 50% moderate and 29% severe. There 
were no asymptomatic patients in the sample. 
Quality of life 
Quality of life of patients with m.3243A>G mutation is presented in Table 7.2. Data show 
impairment in all quality of life domains. In comparison to age and sex matched norm 
groups, scores on all dimensions deviated from healthy people (t-values varied from -10.96 
(General health: p<0.001) to -2.98 (Mental health; p=0.004)). 
Scores on the RAND-36 subscale physical functioning indicated significantly more 
problems (mean 63.40) compared to norm group of comparable age and sex (mean 
81.9; t-value -5.9; p<0.001). Most limitations were experienced in putting great physical 
efforts, 61% of the patients experienced serious impairments. About one third of the 
patients experienced serious impairments with climbing stairs and walking more than 
one kilometer. One out of five indicated serious problems with putting moderate physical 
efforts, carrying groceries or stooping. Only a one out of about ten patients or less 
indicated severe impairments with walking more than 500 meters, climbing one stair or 
washing and dressing. 
Table 7.2: Quality of life (RAND-SF36) scores compared to norms (n=72)
Meana SD Norm group
Physical health 63.4 26.7 81.9
Social health 64.1 24.3 86.9
Physical role functioning 39.6 42.5 79.4
Emotional role functioning 69.4 40.2 84.1
Mental health 70.8 17.6 76.8
Vitality 49.0 18.8 67.4
Pain 68.3 25.9 79.5
General health 44.1 22.4 72.7
Experiences health change 43.1 21.1 52.4
a Higher scores reflect better quality of life.
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Functional impairment
Functional impairment was assessed with the eight dimensions of the Sickness Impact 
Profile (SIP): Mean scores on home management were 86.89 (SD=86.5; M=54; range 
0–328), on work 30.89 (SD=59.1; M=0; range 0–265), and on recreation 76.54 (SD=71.7; 
M=51; range 0–261) reflecting more functional impairments compared to healthy controls 
(t-values vary from 2.184; p=0.032 (work) to recreation t=8.016; p<0.001). 
Seventy-four percent of the patients experienced no impairment in mobility, 57% no 
impairment in ambulation. Mean mobility score was 39.5 (SD=93; M=0; range 0–2173), 
mean ambulation score was 60.0 (SD=91; M=0; range 0–494). Patients show more 
impairments than healthy comparison group (mobility t=3.018; p=0.004; ambulation 
t=5.405; p<0.001). Thirty-nine percent of the patients experienced no impairments in 
alertness. Mean alertness score was 127,10 (SD=157; M=75; range 0–664), this was more 
than healthy controls (t=16.36; p<0.001). 
Fatigue 
The majority of the patients with a m.3243A>G mutation reported abnormal levels of 
fatigue (78%), 60% reported severe levels of fatigue (n=43, 60%). The mean CIS fatigue 
score was 37.43 (SD 12.82). Mean CIS fatigue score of healthy controls was 17.3 (SD=10.1). 
Patients show a little bit less fatigue than patients with MS (t=-1.832; p=0.071) but less 
than patients with chronic fatigue syndrome (t=-9.439; p<0.001). Age and gender did not 
differ between fatigued patients and non-fatigued patients (Table 7.3). 
Table 7.3: Fatigue as assessed by CIS compared to norms
Mean SD Mean norms SD Patients vs norms
Perceived fatigue 37.4 12.8 17.3 10.1 t=13.541**
Concentration 18.7 9.2 9.5 5.9 t=8.525**
Motivation 14.8 6.3 7.9 4.1 t=9.312**
Activity 11.9 6.0 6.6 4.5 t=7.475**
Total 82.8 30.6 41.5 19.1 t=11.441**
** p<0.001.
Mental functioning
Mental functioning was assessed with the HADS. Results indicated that 26.4% and 31.6% 
of the patients indicated clinical relevant symptoms of respectively depression and anxiety. 
36.9% scored above the cutoff of clinical relevant levels of general distress. Comparing 
the patient groups with healthy Dutch controls shows higher levels of depression (t=3.092; 
p=0.003) as well as total symptom scores in the patient group (t=2.048; p=0.44). Scores 
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on anxiety were comparable to healthy control and better than a comparison group of 
general medical patients (t=-2.378; p=0.020) (17). 
Relationship of patient reported outcomes with disease manifestation (NMDAS)
To assess to what extend patient reported outcomes were related to disease manifestation 
as indicated by NMDAS, ANOVA’s were performed with three NMDAS categories as 
factor and set of patient reported outcomes as dependent variables. ANOVA’s indicated 
that scores on physical functioning, functional impairment, fatigue and mental health 
differed significantly between NMDAS severity groups, with patients with worst clinical 
manifestation indicating most physical problems, most functional impairment, most fatigue 
and most mental health problems (Table 7.4). 
Table 7.4: Patient reported outcomes by NMDAS categories mild (1–5), moderate (6–20), severe 
(>20)
F value1
Physical functioning 25.364**
Functional impairment 19.568**
Fatigue 25.364**
Mental functioning 5.701*
1 Statistic of ANOVA; ** p<0.001; * p<0.05.
To assess the strength of the relationship between disease presentation and patient 
reported outcomes, spearman correlations between NMDAS subscale scores and different 
patient reported outcomes were calculated. Correlation of physical functioning, functional 
impairment, fatigue, and mental health with three subscales and total scale on NMDAS 
varies from strong (r≥0.70) to negligible (r<0.30). Perceived physical functioning was most 
strongly related with NMDAS scores with strong correlations with the NMDAS 1 (rho=-0.727) 
and total score (rho=-0.714), and moderate correlation with NMDAS 2 (rho=-0.528) and 
3 (rho=-0.574). Functional impairment was most strongly related to NMDAS1 (rho=0.665) 
and NMDAS3 (rho=0.382). Fatigue is moderately correlated with NMDAS 1 (rho=0.564) 
and total NMDAS (rho=0.546), and weak with NMDAS 2 (rho=0.446) and 3 (rho=0.344). 
Mental health was only weakly correlated with NMDAS 1 (rho=0.376), 2 (rho=0.454) and total 
score (rho=0.425). The correlation between mental health and NMDAS 3 was negligible. 
Prediction of physical functioning, participation, fatigue and mental functioning
To explore which factors predicted patient perceived health status, four aspects of 
perceived health were taken into account as outcomes in different regression analyses: 
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physical functioning, impairments in daily functioning, fatigue and mental health. 
Hierarchical regression analyses were performed in which mitochondrial genetics and 
clinical manifestation were entered in the first steps, and subsequently physical functioning, 
functional impairment, fatigue and mental health in the next steps. The correlations are 
presented in Table 7.5. 
Table 7.5: Correlations (spearmans’s rho) between genotype, clinical presentation and patient 
reported functioning on different domains (n=72)
Physical 
functioning 
(RAND-SF36_PF)
Functional 
Impairement 
(SIP Total)
Fatigue
(CIS perceived 
fatigue)
Mental 
health
(HADS total)
Genotype 0.215 0.178 0.271* 0.225*
NMDAS total score 0.714** 0.558** 0.546** 0.425**
Physical functioning 0.695** 0.663** 0.504**
Functional impairment 0.695** 0.743** 0.669**
Fatigue 0.663** 0.743** 0.692**
Mental health 0.504** 0.415** 0.692**
** p<0.001; * p<0.05.
A first hierarchical multiple regression analysis was performed to predict physical 
functioning. Next to genotype, clinical manifestation was entered as predictor. The total 
model significantly predicted physical functioning (F (2,65)=28.174; p<0.001; R2=0.468). 
Heteroplasmy did not significantly explained variance in physical function, after controlling 
for genotype, NMDAS significantly added 45.0% explained variance. In the total model, 
NMDAS (Beta=-0.671; p<0.001) was a significant predictor of physical functioning. 
A second hierarchical multiple regression analysis was performed to predict functional 
impairment. Next to genotype and clinical manifestation, physical functioning was entered 
as predictor. The total model significantly predicted functional impairment (F (3,64)=22.617; 
p<0.001; R2=0.519). NMDAS (33.1%) and physical functioning (15.9%), significantly added 
explained variance. In the total model, only physical functioning (Beta=-0.561; p<0.001 
was a significant predictors of functional impairment.
A third hierarchical linear regression was calculated to predict perceived fatigue 
based on genotype, clinical functioning, physical functioning, and functional impairment. 
A significant regression equation of the total model was found (F(4,63)=29.461, p<0.001), 
with an R2 of 0.655. Genotype explained 7.3% variance, after controlling for genotype, 
NMDAS added another 9.0%; physical functioning another 32.7%, and, after controlling 
for previous factors, functional impairment added another 16.5% of the variance. 
Quality of life in carriers of the m.3243A>G mutation
123
7
In the total model, heteroplasmy (Beta=0.586; p=0.053), NMDAS (Beta=-0.337; 
p=0.002), physical functioning (Beta=-0.445; p<0.001), and functional impairment 
(Beta=0.586; p<0.001) significantly predicted perceived fatigue.
A last hierarchical linear regression analysis was calculated to predict mental 
health, also based on genotype, clinical manifestation, physical functioning, functional 
impairment, and fatigue. A significant regression equation of the total model was found (F 
(5,62)=13.250; p<0.001), with an R2 of 0.531. Heteroplasmy explained 6% of the variance. 
After controlling for heteroplasmy, NMDAS additionally explained 9.1% of the variance, 
physical functioning also 11.6%, functional impairment 19.6% and fatigue 5.8%. In the total 
model, functional impairment (Beta=0.396; p=0.013) and fatigue (Beta=0.412; p=0.008) 
significantly predicted mental health. 
Discussion
Patients with the m.3243A>G mutation, experience important impairments in several 
domains of their health. Sixty percent showed severe levels of fatigue, and 37% percent 
showed clinical relevant mental health problems. The variation in quality of life, functional 
impairment, fatigue and mental health could not be explained by level of heteroplasmy in 
body fluids and only partly by disease manifestation as indicated by NMDAS. This means 
that patients with a comparable clinical presentation can have a substantial variation in the 
impact of the disease in their daily life. In order to tailor treatment to complaints experienced 
by patients, integrating the perspective of the patient in clinical assessment is warranted 
(20). This is especially important in mitochondrial diseases because of the chronic and 
disabling character of the disease and because of the focus on care rather than cure (21). 
One of the explanations for the variation in patient reported health could be related 
to specific behaviour in response to the disease. For instance, being engaged in daily 
activities positively effects physical condition by being active, stimulates social functioning 
by being in contact with other people and stimulates mental health by increasing the 
possibility to experience positive events (22). From studies in patients with other chronic 
medical conditions, such as Parkinsons Disease (23), Multiple Sclerosis (24, 25), Diabetes 
(7), Ehlors Danlos (9), Rheumatoid Artritis (26), COPD (27, 28) and cancer (15), we know 
that psychological factors could play a role in the explanation of these illness behaviours 
. Concerns about impact of activities on physical functioning or specific attributions 
regarding causes of complaints have been shown to mediate relationship between disease 
characteristics and daily functioning (29). This could provide hope for patients as tailored 
care to support patients in management of daily activities could support their participation 
and so, indirectly, improve their daily functioning. However, future studies are needed to 
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understand the specific role of these factors in patients with mitochondrial diseases in 
general and with m.3243A>G mutation more specifically. 
This study included a broad range of patient reported outcomes based on standard-
ised measures also shown to be sensitive for investigating these outcomes in other patient 
groups. In addition, also genotype and disease manifestation were taken into account 
reflecting the broad range of disease manifestation from genotype, to clinical phenotype, 
to daily functioning and perceived health. Quality of life and patient reported outcomes 
are only sporadically integrated in studies concerning patients with mitochondrial diseases. 
Mitochondrial diseases are characterised by a great variability in expression. This even 
more supports the need for systematic assessment of patient reported outcomes. This 
study focused on a relatively homogeneous group of patients carrying the same mutation. 
Including also patients with different diagnoses even increase this variability. This makes 
it even more important to built agreement on the conceptualisation and subsequent 
assessment of patient reported outcomes in patients with mitochondrial disease. Especially 
in small patient groups such as patients with the m.3243A>G mutation, agreement in 
outcome assessments could importantly increase gain in knowledge on variability in patient 
reported outcomes, and, even more important, its possible predictors.
This study also revealed interesting information regarding outcomes of clinical trials 
predominantly focusing on medical outcomes. This study shows that, next to survival rates 
and clinical manifestation, also patient perceived functioning on different health domains 
is important to explain the relevance of trial outcomes for patients’ daily functioning. It 
could also explain the possible role of psychological and behavioral mediators explaining 
the relationship between disease manifestation and perceived functioning (21, 29, 30).
Longitudinal research should shed more light on this issue. It could explain the role of 
these mediators in changes in perceived health. It could be highly assumed, for instance, 
that coping and cognitions regarding somatic complaints are important mediators able 
to explain variation in the relationship between disease activity and patients’ complaints. 
Future studies should also include more objective assessment of daily functioning e.g. 
exercise tests and by using registrations of daily movements. However, previous studies 
revealed that ambulation subscale of the SIP, as used in the present study, highly correlates 
with physical fitness and objective physical activity (16).
Another limitation is that absence of assessment of nutrition. Especially because of 
the relatively low weight of patients in the sample, low BMI could explain fatigue and 
poor physical functioning. Future studies should take nutrition and its effects on different 
domains of quality of life into account (31).
Future research has to further elaborate the development and efficient use of patient 
reported outcomes in the practice of mitochondrial medicine, as specific tools need to be 
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validated for specific patient groups. Differentiation has to be made between instruments 
assessing general quality of life, disease specific complaints and specific bodily symptoms 
(21, 30, 32). Instruments assessing general quality of life are needed to compare outcomes 
of patients with mitochondrial disorders with patients with other, more or less comparable 
medical conditions. Disease specific measures could be used to compare the impact of 
the disease of a specific patient in relation to the whole patient group. These measures 
are also useful as outcomes for clinical trials because of their frequently reported higher 
sensitivity for chance. 
Developing these measures for the field of mitochondrial medicine asks for integrating 
instruments available in other patient groups with information from interviews with patients 
to be able to point to specific quality of life aspects for patients with a mitochondrial 
disease. One could think about the specific burden of the inherited aspect of the disease, 
the lack of tangible symptoms of the disease in communicating about impairments in the 
social environment, the unpredictable course, the possible lethal character and the lack of 
control patients could have on the symptoms they experience. These specific characteristics 
need to be integrated in a mitochondrial disease specific instrument to assess quality of 
life, or burden of the disease. 
Conclusions
This study showed that patients reported considerable impairments in their quality of 
life and daily functioning. In addition, it indicated the complexity of the relationship 
between patient reported outcomes, clinical manifestation as well as genotype in patients 
with m.3243A>G mutation. This point to the importance of integrating patient reported 
outcomes in clinical assessment as well as clinical trials to gain more understanding in the 
complexity of factors explaining outcomes in these patients, as well as to provide starting 
points for interventions to support patients in the management of their disease. 
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Abstract
Background: Being diagnosed with mitochondrial disease due to the m.3243A>G mutation 
is frequently preceded by a long diagnostic process. The disease itself is characterized by 
heterogeneous course and expression, so leaving patients with considerable uncertainty 
regarding their prognosis and treatment possibilities. This could easily result in fear of 
disease progression, which has, known from other patient groups, negative impact on 
quality of life. This study investigated the presence of this fear and its correlates with 
genetic characteristics and clinical disease severity in m.3243A>G carriers. 
Methods: In total 125 eligible m.3243A>G mutation carriers were invited to participate 
in this study. After informed consent, participants completed questionnaires including 
items on socio-demographics, fear of progression, depression, anxiety, and quality of life. 
Clinical disease severity was assessed by the NMDAS questionnaire. Heteroplasmy levels 
were assessed in leucocytes, urine epithelial cells and buccal mucosa. 
Results: Seventy-six carriers participated in this study. Results showed that 18% reported 
high fear of progression. Fear of progression was significantly related to all domains of 
quality of life. Furthermore, fear of progression was moderately correlated with feelings 
of depression (r=0.37), and anxiety (r=0.44). Patients with moderate or severe clinical 
symptoms on the NMDAS experienced more fear of progression than patients with 
mild clinical symptoms. Fear of progression was weakly correlated with heteroplasmy in 
leucocytes (r=0.27) and buccal mucosa (r=0.31). 
Conclusions: A substantial part of m.3243A>G mutation carriers experience high levels 
of fear of progression which coincide with significantly lower quality of life. Only a small 
relation with disease characteristics was found. The impact of receiving a diagnosis without 
therapeutic possibilities on fear is important to consider.
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Introduction
Living with a life-threatening disease causes uncertainty about and possible fear of the 
future for many patients. Patients have to deal with complications of the disease, increasing 
restrictions in daily functioning, progression of the disease, and reduced life expectancy. 
Therefore, fear of disease progression (FoP) is amongst the most important stressors for 
patients with a life-threatening disease (1). 
Mitochondrial diseases are rare multi-system diseases that result from problems due 
to disturbed mitochondrial oxidative phosphorylation, the final pathway in the production 
of ATP, caused by mutations in either the nuclear or mitochondrial DNA (2-4). Failure of the 
mitochondria to perform normally results a.o. in decreased energy production, cell injury 
or cell death, and eventual organ dysfunction or failure (5). Although new pharmacological 
interventions are being explored, currently no cure or substantially alleviating therapy 
is available for these disorders and care is focused on alleviating the broad range of 
symptoms of the disease (6).
Many different genetic defects of mtDNA exist which, in general, may cause a specific 
clinical syndrome. However, the relationship between genotype and phenotype is not 
absolute and syndromes might overlap (7). Establishing a diagnosis of mitochondrial 
disease is a complex process that may take years. The life of the individual with 
mitochondrial disease can be greatly compromised, according to the degree and nature 
of mitochondrial malfunction. The serious nature and erratic, complex presentation of 
mitochondrial disease often make it difficult to establish a diagnosis and may contribute 
to increased stress and worry among patients and their relatives. 
Fear of disease progression has been defined as a reactive, consciously perceived fear 
that develops from a serious, potential life-threatening or disabling disease or its treatment 
(1). Since a mitochondrial disease has serious consequences in most patients, they perceive 
disease progression as a realistic threat. In this respect, FoP does not belong to the group 
of anxiety disorders for which an irrational fear is usually one of the key characteristics. 
Basically, FoP is an appropriate response to the real threats of diagnosis, treatments and 
course of illness. However, the level of FoP can range between functional and dysfunctional 
ends. Elevated levels of fear of progression that become dysfunctional, affecting quality of 
life, are in need for treatment (8). Previous studies revealed that FoP was evident in other 
patients with cancer, rheumatoid arthritis, diabetes mellitus, Parkinson’s disease, Crohn’s 
disease, and multiple sclerosis (1, 9). Research on correlates and consequences of FoP 
mainly focuses on patients with cancer and remains inconclusive (10-12). Furthermore, 
information on the impact of a rare disease without therapeutic possibilities, a very 
heterogeneous course and a hereditary character on FoP is scarce. 
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The aim of the present study is to investigate the prevalence of fear of progression 
in patients with a mitochondrial disease. In addition, demographical, medical and 
psychological correlates of fear of progression are assessed. We focused on patients with 
a clinically and genetically heterogeneous phenotype known as the MELAS spectrum 
disorders, most commonly caused by the m.3243 A>G mutation in mitochondrial DNA. 
This spectrum is characterized by decreased exercise tolerance, elevated lactic acid levels, 
cardiac abnormalities, diabetes, and neurological symptoms like migraine, psychiatric 
problems, seizures, ataxia, myopathy, impaired vision or hearing, or disturbances in 
consciousness (12). 
Methods
Participants
Patients with a mitochondrial disease due to the m.3243 A>G mutation of the Radboud 
Center for mitochondrial medicine, were invited to participate in this study. Participants 
had to be able to read and write in Dutch. 
Procedure
This cross-sectional study was part of a longitudinal observational cohort study on patient 
reported outcomes approved by the local ethical committee of the Radboud university 
medical center, Nijmegen, the Netherlands. Patients were invited to participate in the study 
by their treating physician. After given informed consent, patients received an email with 
a link to a private, secure website that presented a set of questionnaires on demographic 
variables and psychological factors that could be administered at home at time of first 
access or later. Patients were asked to complete the total set of questionnaires within one 
week. The Newcastle Mitochondrial Disease Assessment Scale (14) was assessed during 
clinical investigation. Questionnaires regarding FoP were added in the last phase of the 
longitudinal study (two to five years after baseline) and analyzed for this study. 
Instruments
Genotype was assessed in terms of heteroplasmy levels of the m.3243A>G mutation in 
leucocytes, urine epithelial cells and buccal mucosa.
Disease manifestation was assessed by the Newcastle Mitochondrial Disease Scale 
(NMDAS (14)). The NMDAS is a validated method to monitor the clinical expression of 
mitochondrial disease and to follow-up the course of the disease in time. It consists of 
the following three sections: (1) Current functioning: general functioning of the patient in 
the past four weeks (2) System specific involvement, to gain insight in the functioning of 
individual organ-systems, (3) Current clinical assessment, a general and neurological clinical 
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examination, gives insight in the current clinical functional status of the patient. Section 
1 to 3 of the NMDAS consists respectively of ten, nine and ten questions, which can be 
scored from 0 (no involvement) to 5 (severe involvement). A NMDAS score of 0 indicates no 
clinical manifestation, NMDAS scores of 1 to 5 were defined as mild clinical manifestation, 
scores 6 to 20 as moderate and scores above 20 as severe clinical manifestation (13). 
Fear of progression was assessed with the Dutch translation of the FoP-Q-SF (15-
17). The FoP-Q-SF consists of 12 items pertaining to four dimensions (affective reactions, 
partnership/family issues, occupation and loss of autonomy) that are scored from 1 (never) 
to 5 (very often), where higher scores indicate more FoP. A cut-off score of ≥34 was used 
to define high FoP (18, 19).
Quality of life was assessed with the RAND-SF36. The RAND-SF36 assesses several 
dimensions of quality of life (physical functioning, social functioning, emotional functioning, 
general health status, perceived change in health status, fatigue and pain). Scores on 
different scales range from 0 (maximum limitations) to 100 (optimal functioning) (20, 21).
Mental functioning was assessed with the Hospital Anxiety and Depression Scale 
(HADS). This questionnaire includes 14 items divided into two subscales (Depression 
and Anxiety), each with seven items. Higher scores indicate more anxiety, depression, 
and psychological distress. The HADS does not contain any somatic items that could be 
confounded with symptoms associated with a physical illness. A total score of 11 or higher 
indicates high distress (22, 23). 
Data analyses
Data analysis was performed using SPSS version 22.0. Descriptive statistics were used to 
describe the characteristics of the sample as well as patient reported outcomes on FoP, 
quality of life, and mental functioning. Correlational analyses identified the main correlates 
of FoP with demographical, disease-related and psychological variables. To categorize the 
results, Cohen’s effect size categories were used: small (|r|≤0.3), moderate (0.3<|r|<0.5), 
or large (|r|≥0.5) (24).
Results
Sample characteristics 
Of 125 eligible patients with the m.3243 A>G mutation, 76 patients completed the 
questionnaires, a response rate of 61%. Demographic characteristics are displayed in 
Table 8.1. Differences between response group and non-responders were assessed on 
demographic and clinical characteristics. There were no differences between responders 
and non-responders with regard to age (t(122)=-0.77, p=0.45) or gender (Χ2(1)=3.17, 
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p=0.08). For clinical characteristics, the groups did not differ on levels of heteroplasmy, 
NMDAS subscales or total NMDAS score. 
Genotype
Levels of heteroplasmy were assessed in leucocytes (M=19.9%; SD=12.9; range 0–56), 
urinary epithelial cells (M=51.0%; SD=25.1; range 5–96) and buccal mucosa (M=34.4%; 
SD=14.8; range 2–63).  
Disease manifestation
Mean total NMDAS score was 17.7 (SD=15.5) varying from 0 to 86. Of the total sample, three 
patients were asymptomatic (‘’dormant carrier’’ of the mutation), 17% of the patients showed 
mild symptoms, 45% moderate and 33% had severe symptoms of mitochondrial disease.
Fear of progression
Cronbach’s alpha for the FoP-Q-SF in this sample was 0.84. The FoP mean score (FoP-Q-
SF) was 26.2 (SD=7.7; range 12–41). By applying the cutoff score ≥34, 14 patients (18.4%) 
were classified as having high FoP. Means and standard deviations for the individual items 
of the FoP-Q-SF are displayed in Table 8.2. Highest mean scores were related to the 
Table 8.1: Correlations (spearmans’s rho) between genotype, clinical presentation and patient
Mean Median Range
Age (years) 47.3 47.6 15–69
Heteroplasmy level
Leucocytes
Urine epithelial cells
Buccal mucosa 
19.9
51.0
34.4
17.0
50.0
34.5
0–56
5–96
2–63
NMDAS
1 Current functioning
2 System specific involvement
3 Current clinical assessment
Total NMDAS
8.1
6.5
3.3
17.7
6.0
6.0
1.0
16.0
0–43
0–30
0–33
0–86
N %
Gender: male 20 26%
Marital status
Married/partnership 62 82%
Children: yes 55 72%
Educational level
Primary
Secondary
Tertiary
6
46
24
8%
61%
31%
Employment status: paid work 36 47%
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possibility that children can inherit the disease, progression of the disease and worrying 
about family when something would happen with the patient. Lowest mean scores were 
related to medical appointments or treatments. 
Quality of life
Table 8.3 shows the mean (±SD) scores for the quality of life domains as assessed by the 
RAND-36. Scores on the subscales of the RAND-36 ranged from 44.2 to 73.2, indicating 
a moderate quality of life. Patients reported general health status, perceived change in 
health status and fatigue to be significant problems.
Table 8.2: Mean scores of individual FoP-Q-SF items
Item Mean* SD
1. Being afraid of disease progression 2.58 0.93
2. Being nervous prior to doctor’s appointments or periodic examinations 1.87 0.94
3. Being afraid of pain 2.03 0.98
4. Being afraid of becoming less productive at work 2.09 1.10
5. Having physical symptoms (e.g., rapid heartbeat, stomache ache) 2.13 1.04
6. Being afraid of the possibility that the children could contract the disease 2.63 1.51
7. Being afraid of relying on strangers for activities of daily living 2.24 1.04
8. Being afraid of no longer being able to pursue hobbies 2.39 1.03
9. Being afraid of severe medical treatments in course of illness 1.88 0.85
10. Worrying that medications could damage the body 1.84 0.94
11. Worrying what will become of family if something happens to me 2.51 1.13
12. Being afraid of not being able to work anymore 1.99 1.13
* On a 5-point Likert scale, where 1 = never and 5 = very often.
Table 8.3: Quality of life (RAND-36) scores
Mean SD
Physical functioning 69.1 24.7
Social functioning 69.9 22.7
Emotional functioning 72.9 16.6
General health status 44.2 23.8
Perceived change in health status 44.7 22.5
Pain 73.2 26.0
Fatigue 56.6 21.3
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Mental functioning
Mean scores for the HADS total score (M=10.3, SD=6.8) and subscales anxiety (M=5.2, 
SD=3.5) and depression (M=5.1, SD=4.1) were calculated. Results indicated that 25% and 
26.3% of the patients indicated clinical relevant symptoms of respectively anxiety and 
depression. By applying the cut-off score of ≥11 on the total score, 46% of the patients 
experienced clinical relevant levels of general distress.
Relationship fear of progression and demographical, medical and psychosocial variables
Fear of progression and demographics
Fear of progression was not related to age (r=-0.07, p=0.548; t(74)=0.20, p=0.84). A 
marginally significant relationship (t(74)=-1.9, p=0.06) was found between gender and FoP 
indicating that women (M=27.2, SD=7.9) tended to experience more FoP compared to 
men (M=23.4, SD=6.7). No significant relationships were found between FoP and marital 
status (p=0.20), having children (p=0.51), level of education (p=0.53) or employment 
status (p=0.36).
Fear of progression and medical related variables
No significant correlations were found between FoP and NMDAS scores. To assess 
the extend to what FoP was related to the degree of disease manifestation a one-way 
ANOVA was performed with three NMDAS categories (mild, moderate, severe) and FoP 
as dependent variable. Results indicated that scores on FoP differed significantly between 
NMDAS severity groups (F(2,71)=3.59, p=0.03). Patients in the moderate (M=27.4; SD=8.4) 
and severe (M=27.6; SD=6.6) group experienced significantly more FoP than patients in 
the mild group (M=21.3; SD=6.6). 
With regard to genotype, FoP was small significantly related to levels of heteroplasmy 
in leucocytes (r=0.28, p=0.03) and moderately significantly related to levels of heteroplasmy 
in buccal mucosa (r=0.31, p=0.02). No significant relationship was found between FoP 
and levels of heteroplasmy in urine epithelial cells (p=0.64).
Fear of progression and psychosocial variables
With regard to quality of life, moderate significant correlations were found between FoP 
and physical functioning (r=-0.47, p<0.001), social functioning (r=-0.39, p<0.001), general 
health status (r=-0.48, p<0.001), pain (r=-0.40, p<0.001) and fatigue (r=-0.44, p<0.001). 
Small relationships were found between FoP and perceived change in health status 
(r=-0.27, p=0.02) and emotional functioning (r=-0.29, p=0.01).
For mental functioning, FoP was moderately correlated with depression (r=0.37, 
p=0.001), anxiety (r=0.44, p<0.001), and general distress (r=0.45, p<0.001).
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Discussion
This is the first exploratory study to investigate fear of progression and one of the few studies 
reporting on quality of life in patients with a MELAS spectrum disorder. About one-fifth 
(18.4%) of the patients showed elevated levels of FoP and 46% reported clinical levels of 
general distress. Furthermore, patients reported a moderate quality of life with problems 
reported on general health status and fatigue. FoP was moderately related to components 
of quality of life, mental health and medical variables. It was hypothesized that FoP would 
be high patients with a MELAS spectrum disorder given its uncertain and unpredictable 
disease course, premature knowledge about its character and absence of treatment 
possibilities. Compared to other studies using the FoP-Q-SF the percentage of high FoP 
found in this study was lower (e.g. hematological cancer 23–26%) (18, 19). Furthermore 
the mean FoP score of patients with a MELAS spectrum disorder was significant lower than 
patients with systemic sclerosis (17) and patients with breast cancer (25). Inspection of the 
single items of the FoP-Q-SF revealed that carriers were most afraid of the possibility that 
their children could inherit the disease, progression of the disease and worrying about 
their family if something happens to them. These results confirm that dealing with this 
mitochondrial disease is characterized by dealing with uncertainty about future, disease 
course and hereditary concerns. This is different for other groups whereas cancer patients 
predominantly fear dying and the unpredictability of progression. Patients with chronic 
arthritis fear being physically dependent on others and the most common anxiety of patients 
with diabetes are long-term complications (1). Insight in why patients react differently to 
the news that they have a mitochondrial disease and why some are more fearful than 
others for disease progression could be provided by Leventhal’s Self Regulation Model of 
Illness (26) External and internal stimuli generate a subjective perception of a health threat 
and concomitant emotions (e.g. fear/distress), leading to coping strategies and appraisal 
of health outcomes. Internal stimuli might be interpreted as reminders of threat that the 
disease progresses. This study demonstrates that patients with moderate and severe clinical 
symptoms as assessed by the NMDAS reported higher FoP indicating that the presence of 
symptoms is associated with higher fear. External triggers such as medical appointments 
could also increase worry about disease status and disease course. However, in this study 
patients reported low fear scores on the item of the FoP-Q-SF whether they are nervous 
prior to doctor’s appointments or periodic examinations. Given the fact that the Radboud 
Center for Mitochondrial Medicine is the expert center for mitochondrial disorders in the 
Netherlands, patients might feel reassured by the expertise and well arranged care in this 
center, and therewith this could be a buffer for excessive fear of progression. 
Although the percentage of FoP was not as high as hypothesized, a considerable 
percentage of patients (46%) experienced clinical levels of general distress defined as a 
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complex, unpleasant emotional experience characterized by comprised psychological, 
social and/or spiritual wellbeing (27). Given that both general distress and FoP are 
associated with a lower quality of life and restrictions or problems in daily life, it is important 
in this patient group to assess mental functioning in clinical consultations and assist patients 
in accessing appropriate and available support. 
A limitation of this study is its cross-sectional design. Longitudinal research could 
elaborate the role of FoP as mediator between medical history and personal characteristics 
as antecedents and functioning and quality of life as consequences. Furthermore, given the 
uncertain and unpredictable character of the disease a valid and reliable measurement for 
uncertainty could have shed light on this issue in this research. For further research it would 
be interesting to measure uncertainty and its correlates. With regard to measurement issues 
another limitation is the use of the cut-off score of the FoP-Q-SF, validated in a sample 
of hematological cancers. Future research should replicate the validation of this cut-off 
score in a sample of patients with a mitochondrial disorder. Therewith both research and 
clinical practice could contribute to support these patients in dealing with their disease. 
In conclusion, a substantial part of patients with a MELAS spectrum disorder reported 
considerable levels of FoP and distress coinciding with impairments in their quality of 
life. Therefore, it is important to integrate assessments of mental functioning in clinical 
consultation in order to assist patients in accessing appropriate and available support. 
Based on the findings of this study, further research should elaborate on the concept 
of uncertainty about the future and should replicate and validate the cut-off score for 
FoP in a more heterogeneous sample of patients with diverse mitochondrial disorders. 
Furthermore, with regard to hereditary concerns, it might be interesting to investigate 
clusters of families affected by a mitochondrial disease and the influence of having family 
with the same progressive disease on fear of progression and uncertainty for the future. 
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Abstract
Objectives: To describe the spectrum of retinal abnormalities associated with the 
m.3243A>G mutation in the mitochondrial MTTL1 gene, and to analyze possible 
correlations of the severity of retinal abnormalities with disease severity in other organ 
systems, as well as with heteroplasmy levels. 
Design: Observational, cohort based, cross-sectional study. 
Participants: Twenty-nine patients carrying the m.3243A>G mutation. 
Methods: Extensive clinical examination, including visual acuity testing, indirect ophthal-
moscopy, color fundus photography, fundus autofluorescence, high-resolution optical 
coherence tomography (OCT) , and central visual field analysis. In selected patients, 
Goldmann perimetry, fluorescein angiography, full-field electroretinography (ERG) and 
electro-oculography (EOG), and color vision testing were performed. Heteroplasmy levels 
of the m.3243A>G mutation were measured in leucocytes, urinary epithelial cells (UEC) 
and buccal mucosa. The Newcastle Mitochondrial Disease Adult Scale (NMDAS) score 
was determined in all patients. 
Main outcome measures: Age at onset, visual acuity, fundus appearance, fundus auto-
fluorescence, OCT findings, systemic disease features, heteroplasmy levels in UEC, total 
scores on the NMDAS. 
Results: Twenty-five of 29 mutation carriers (86%) had retinal abnormalities, that could 
be classified into four stages. Six patients (21%) had stage 1 retinal dystrophy, with 
fine pigmentary abnormalities that were better visible on fundus autofluorescence and 
fluorescein angiography. Stage 2 disease (11 patients; 38%) was characterized by one or 
a few yellowish or mildly pigmented deposits in the early stage, and in advanced stage 
2 the pigmentary changes encompassed the entire macula and often encircled the optic 
disc. Six patients (21%) had stage 3 retinal dystrophy in which profound chorioretinal 
atrophy was present outside the fovea. Marked loss of visual acuity occurred in stage 4 (2 
patients, 7%), where the fovea was affected by atrophy. The stage of mitochondrial retinal 
dystrophy significantly correlated with age (r=-0.483, p=0.008) and with visual acuity (r=-
0.614, p<0.001), but there was no correlation with heteroplasmy levels or overall disease 
involvement. 
Conclusions: Mitochondrial retinal dystrophy associated with the m.3243A>G mutation has 
specific characteristics that can be classified into four stages based on ophthalmoscopy, 
fundus autofluorescence, and OCT features. However, the disease may be misdiagnosed, 
as the maternal inheritance pattern may be masked and the systemic disease associations 
are variable, atypical, or even absent.
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Introduction
The mitochondrion plays a critical role in the human energy supply. It is responsible for 
the production of adenosine triphosphate (ATP), through oxidative phosphorylation 
(OXPHOS). In addition, mitochondria take part in cell metabolism and the initiation of 
apoptosis. Mitochondrial disorders therefore primarily affect organs that have a high energy 
demand, such as the central nervous system – including the retina and cochlea – as well as 
skeletal and cardiac muscle. Mitochondrial dysfunction can result from mutations in either 
nuclear DNA (nDNA) or mitochondrial DNA (mtDNA). In the case of mtDNA mutation, the 
number and extent of the affected tissues in an individual depends highly on the amount 
of mutated mtDNA in a specific tissue. The percentage of affected mtDNA per cell in a 
specific tissue is referred to as “heteroplasmy”, and the level of heteroplasmy may vary 
widely between tissues in a single individual. Therefore, patients with a mitochondrial 
disease may present at any age, with virtually any symptom or sign, and with any mode of 
inheritance (1). This marked intra-individual and inter-individual variation in mitochondrial 
heteroplasmy explains why there is a wide spectrum of clinical symptoms and disease 
severity observed between family members that carry the same mitochondrial mutation 
(1). In 1990, an adenine to guanine transition at position 3243 of mitochondrial DNA 
(m.3243A>G) in the MTTL1 gene that encodes tRNALEU(UUR), was found to be the cause 
of MELAS syndrome, characterized by mitochondrial myopathy, encephalopathy, lactic 
acidosis and stroke-like episodes (2, 3). This m.3243A>G mutation is the most common 
cause (±80%) of MELAS syndrome. 
Later, more phenotypic variations have been reported in association with the 
m.3243A>G mutation, the most frequent being maternally inherited diabetes and deafness 
(MIDD) (4, 5). Cardiac, ocular and renal involvement are other disease variations, which 
may occur isolated or in combination with the MIDD or MELAS syndrome phenotype (6, 
7). Epidemiologic studies with different designs have shown an m.3243A>G mutation 
prevalence ranging from 7.6/100,000 in the population of North-East England (8), up 
to 236/100,000 in the population of Australia (9). The prevalence of the m.3243A>G 
mutation in European patients with adult-onset diabetes mellitus is around 0.8%, and 
1.5% in a Japanese population (10). This m.3243A>G carrier prevalence rises to more 
than 5% in patients with adult-onset diabetes who also have deafness and/or a family 
history of deafness (10, 11). 
The m.3243A>G mutation is associated with retinal pigmentary abnormalities, but 
may also cause ocular myopathy and myogenic ptosis (7, 12-17). Up to 86% of patients 
with MIDD caused by the m.3243A>G mutation has evidence of retinal dystrophy (17). 
These retinal abnormalities can be clearly visualized with fundus autofluorescence imaging, 
and tend to spare the fovea (18). Relatively little is known about the range of retinal 
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abnormalities associated with the m.3243A>G mutation, and the possible correlation 
of retinal abnormalities with heteroplasmy levels and systemic disease. In this study, we 
describe the spectrum of retinal abnormalities associated with the m.3243A>G mutation, 
and we propose a classification into four stages. We also analyze possible correlations of 
the severity of retinal abnormalities with disease severity in other organ systems, as well 
as with heteroplasmy levels. 
Methods
Patients
We included 29 patients from 18 different families who carried the m.3243A>G mutation. 
All probands were patients of the Nijmegen Centre for Mitochondrial Disorders at the 
Radboud University Nijmegen Medical Centre, diagnosed with the m.3243A>G mutation 
in urinary epithelial cells (UEC). All patients participated in our national cohort study (5). 
This study describes a cohort of m.3243A>G patients using the Newcastle Mitochondrial 
Disease Adult Scale (NMDAS) and was approved by the local ethics committee. Written 
informed consent was obtained from all patients. The study adhered to the tenets of the 
Declaration of Helsinki.
Ophthalmic examinations
All patients were examined at the Institute of Ophthalmology of the Radboud University 
Nijmegen Medical Centre (Nijmegen, the Netherlands). They underwent an extensive 
ophthalmic examination, including best-corrected Snellen visual acuity testing, Amsler 
grid testing, and fundus examination by indirect ophthalmoscopy. Pupillary dilatation was 
achieved with topical 1% tropicamide and 5% phenylephrine prior to ophthalmoscopy 
and multimodal retinal imaging. All patients underwent digital color fundus photography 
(Topcon Corporation, Tokyo, Japan), and high-resolution in vivo imaging with a combined 
instrument (Spectralis HRA+OCT, Heidelberg Engineering, Heidelberg, Germany) that 
allows for simultaneous recording of spectral-domain optical coherence tomography (SD-
OCT) and confocal scanning laser ophthalmoscope (cSLO) images as described previously 
(15). The cSLO images were obtained according to a standardized operation protocol to 
obtain fundus autofluorescence (FAF) images (excitation at λ=488 nm, barrier filter that 
blocks wavelengths <500 nm) in all patients. Simultaneous SD-OCT imaging was carried out 
in all patients, with an illumination wavelength of 870 nm, an acquisition speed of 40,000 
A-scans and a scan depth of 1.8 mm. Nineteen horizontal SD-OCT scans through the macula 
area with simultaneous cSLO imaging were obtained for each study eye. Central visual 
field analysis of the central 30° was performed in all patients by means of the Humphrey 
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30-2 Swedish Interactive Thresholding Algorithm (SITA)-Fast protocol. Goldmann perimetry 
was performed in three patients. Seven patients underwent fluorescein angiography. Full-
field electroretinography (ERG) and electro-oculography (EOG) were performed in three 
selected patients with advanced disease, according to the guidelines of the International 
Society for Clinical Electrophysiology of Vision (19, 20). Color vision testing was performed 
in the same three patients, using a previously described protocol (21).
Mutation analysis and detection of heteroplasmy levels
Heteroplasmy levels were determined in UEC, leucocytes from peripheral venous blood 
and buccal saliva in all participants using PyrosequencingTM technology (Pyrosequencing, 
Uppsala, Sweden) according to a previously described protocol by Lowik et al. (22). The 
pyrosequence reaction of the m.3243A>G mutation had a precision of 1.5%; the mutation 
was detected from a heteroplasmy level of 5%. The detection limit for the mutation was 
determined by serial dilution of a sample containing this mutation with wild type mtDNA 
(5). As previous reports have shown good correlations between heteroplasmy levels 
measured in UEC and disease severity, we used the UEC levels to determine a correlation 
between retinal dystrophy and heteroplasmy levels (23).
General symptoms
All patients were scored using the Newcastle Mitochondrial Disease Adult Scale (NMDAS) 
(24). The NMDAS constitutes a validated method to monitor the clinical expression of 
mitochondrial disease and to follow-up the course of disease in time (24). The NMDAS 
consists of the following four sections: 1) Current function, which gives insight into the 
general functioning of patients in the past four weeks; 2) System-specific involvement, 
which uses a clinical history supplemented by specific information to gain insight in the 
functioning of individual organ-systems; 3) Current clinical assessment, a general and 
neurological clinical examination, which gives insight in the current functional status of 
the patient; 4) Quality of life, for which we used a Dutch translation of the SF-12v2 quality 
of life questionnaire.
In NMDAS section 1–3, the severity of symptoms is scored on a 0 to 5 scale. With 
regard to visual functioning, NMDAS section 1 includes a question about visual function-
ing according to the patient’s experience. This question differentiates subjective visual 
functioning in best-corrected visual acuity circumstances, according to a 0 to 5 scale; 0 = 
Normal vision, 1 = No functional impairment but aware of worsened acuities, 2 = Mild – 
difficulty with small print or text on television, 3 = Moderate – difficulty outside the home 
(e.g. bus numbers, road signs or shopping), 4 = Severe – difficulty recognizing faces, 5 
= Unable to navigate without help (e.g. carer, dog, cane). Section 3 of NMDAS includes 
an item in which best-corrected visual acuity is scored using a Snellen chart. The NMDAS 
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is not meant to give a detailed assessment of a specific organ, but is used to give an 
estimate of general disease involvement (24).
Statistics
We used descriptive statistics to present the heteroplasmy levels in our patients. Averages 
are presented with their standard deviation. A median is presented with interquartile ranges 
(IQR), Pearson’s correlation coefficient was used to evaluate the relationship between 
heteroplasmy levels in UEC, scores on the NMDAS, age, and ophthalmologic findings.
Results
Ophthalmological findings 
General characteristics
Twenty-nine patients were included in the study, of which 20 (69%) were female and 9 
(31%) were male. The average age was 46±11 years (range 19–64). Seventeen patients 
(59%) were probands, 12 (41%) were first-degree relatives of a proband. Of the 29 mutation 
carriers, five (17%) experienced functional visual loss. In these patients, the age at onset 
varied from 35 to 60 years (mean, 44 years). All of them reported decreased visual acuity, 
two experienced (para)central scotoma, and one also reported a decrease in the quality 
of color vision. None of the patients had a family history of visual loss compatible with 
macular disease. The retinal abnormalities in the m.3243A>G mutation carriers varied from 
no abnormalities (in 4 patients, 14%) to profound chorioretinal atrophy in the posterior 
pole that involved the fovea (in 2 patients, 7%: Figures 9.1-9.5). 
In 3 patients from 3 different families, the retinal abnormalities were diagnosed 
prior to the identification of the m.3243A>G mutation or the definitive establishment of 
a syndrome associated with this mutation (Table 9.1). The identification of the specific 
retinal abnormalities prompted the analysis of the m.3243A>G mutation, which was 
subsequently confirmed. Despite the fact that the mitochondrial nature of the disease in 
these 3 patients was established through the recognition of their retinal dystrophy, these 
3 patients were already affected by a multisystem condition (Table 9.2).
Spectrum and classification of retinal abnormalities
The spectrum of retinal abnormalities was subdivided into four stages by an experienced 
retina specialist (CJFB), based on ophthalmoscopy, and supported by the findings on 
multimodal imaging. These four stages were delineated by analyzing the findings on 
ophthalmoscopy and fundus autofluorescence. Although not used for classification 
purposes, SD-OCT and fluorescein angiography aided in the analysis of the extent of 
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retinal abnormalities in the different stages. All patients showed symmetry of the stages 
when comparing both eyes.
In stage 1 (6 patients, 21%), very discrete pigmentary abnormalities were noted in 
the central fundus on detailed indirect ophthalmoscopy with a Volk® 90D lens (Figure 
9.1, Table 9.2). Without prior knowledge of the underlying m.3243A>G mutation, these 
changes might have been easily overlooked (Figure 9.1A-D). The mean visual acuity in 
this stage was 20/20 (range, 20/25–20/16).
In stage 2 m.3243A>G mitochondrial retinal dystrophy (11 patients, 38%), isolated or 
multifocal faintly white-yellowish and/or hyperpigmented subretinal deposits were seen 
in the posterior pole (Figure 9.2, Table 9.2). These deposits were seen in addition to the 
very fine pigmentary changes as observed in stage 1. In early stage 2 disease, one or a few 
deposits may be present (Figure 9.2A-C), but in advanced stage 2 disease the pigmentary 
changes encompassed the entire macula, and also tended to encircle the optic disc (Figure 
9.2D-F). The mean visual acuity in stage 2 disease was 20/20 (range, 20/63-20/12.5). 
Stage 3 (6 patients, 21%) was characterized by the appearance of one or more areas of 
well-delineated, profound chorioretinal (“geographic”) atrophy outside the fovea (Figures 
9.2G, H, 9.3A, B, and 9.3H-N). In contrast to stage 4 disease, these deeply atrophic 
zones could encircle the fovea, but did not involve the central fovea (Figure 9.3I-O). This 
foveal sparing explained the relatively preserved visual acuity in this stage, like in stages 
1 and 2, with a mean visual acuity of 20/25 (range, 20/40-20/16, excluding one eye with 
amblyopia). With advancing stage 3 disease, the atrophic area could gradually encircle 
the fovea (in 2 patients; 7%), leaving a “central island of vision” (Figure 9.3I-O). Although 
Fig	  1	  
Figure 9.1: Stage 1 retinal dystrophy associated with the m.3243A>G mutation.
A, Color fundus photograph of stage 1 m.3243A>G dystrophy in a 42-year-old man without visual 
symptoms. No abnormalities can be seen, but on detailed ophthalmoscopy discrete pigmentary 
changes could be observed in the macula. This patient, who had a visual acuity of 20/20, had 
diabetes since 2 years, experienced mild hearing loss and fatigue. B, The easy-to-miss discrete 
pigmentary abnormalities on ophthalmoscopy corresponded to mild but clearly visible mottled 
autofluorescence changes that were seen in the macula and peripapillary region, but seemed to 
spare the fovea. C, No obvious abnormalities were visible on OCT (horizontal section through level 
indicated by arrowhead in A). D, Fluorescein angiography showed mottled fluorescence changes.
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the foveal structure was clearly abnormal on FAF and especially SD-OCT in these cases 
of fovea-surrounding atrophy, this central foveal structure was still relatively preserved as 
compared to the surrounding atrophic zone (Figure 9.3J-O). 
In stage 4 mitochondrial retinal dystrophy (2 patients, 7%), the central fovea itself 
was also affected by profound chorioretinal atrophy (Figure 9.4), with a corresponding 
decrease in visual acuity (mean: 20/80; range, 20/630–20/40). The visual acuity in this 
stage may drop to finger counting. In this stage, it was not possible to determine whether 
RPE atrophy preceded photoreceptor atrophy or vice versa, based on the analysis of FAF 
and SD-OCT images. 
None of the patients had typical drusen on ophthalmoscopy, FAF or SD-OCT. In 
contrast to drusen, the subretinal deposits in m.3243A>G mitochondrial retinal dystrophy 
were not clustered toward the centre of the macula, nor did they correspond to typical 
sub-RPE accumulations as seen in genuine drusen. None of the patients had evidence of 
choroidal neovascularization.
Figure 9.2: Stage 2 retinal dystrophy associated with the m.3243A>G mutation.
A, Color fundus photograph of a 49-year-old patient with early stage 2 mitochondrial retinal 
dystrophy due to a m.3243A>G mutation, showing irregular yellow-white flecks around the optic 
disc. This patient, who mainly had problems related to myopathy, had a visual acuity of 20/20, and 
did not have visual complaints. B, These flecks showed mainly increased autofluorescence (AF), with 
an irregular border of decreased AF. C, A horizontal OCT scan (taken through the plane indicated 
by the arrowhead in B) showed that a fleck corresponded to a thickening and disorganization in the 
outer retinal layers, at the level of the photoreceptor inner/outer segment junction/photoreceptor 
outer segments/apical retinal pigment epithelium (RPE). D, Color fundus photograph of retinal 
abnormalities in a 27-year-old patient with a m.3243A>G mutation, who did not experience visual 
loss and had a visual acuity of 20/16. An oval area of mottled hypopigmentation was seen that 
involved the macula and surrounded the optic disc, together with hyperpigmented irregular spots 
in the macula. This patient had insulin-dependent diabetes mellitus since the age of 20, hearing 
loss, migraine, chronic diarrhea, migraine, left ventricular hypertrophy, arterial hypertension, 
and hypercholesterolemia. E, Fundus AF imaging showed that the hyperpigmented spots in the 
macula corresponded to mainly increased AF, whereas the hypopigmented spots and zones mainly 
corresponded to a decreased AF signal. The fovea had a comparatively normal aspect on fundus 
AF. F, Fluorescein angiography showed blockage of background fluorescence in the areas of 
hyperpigmentation, and hyperfluorescence due to an RPE window defect in the retinal areas that 
were hypopigmented and mildly atrophic on the fundus image in D. G, Four years later, a small round 
area of well-demarcated more profound chorioretinal atrophy appeared. This beginning geographic 
atrophy means an evolution to stage 3 m.3243A>G mitochondrial retinal dystrophy. H, Fundus AF 
at this point in time shows a corresponding absence of AF in this area due to RPE atrophy. Also 
note the other changes in AF characteristics, such as an increase of the AF changes superior to the 
optic disc as compared to the image in E that was obtained four years earlier. I, A horizontal OCT 
scan through the plane indicated by the white arrowhead in G showed an attenuation of the outer 
retinal layers, mainly at the outer photoreceptor and RPE level, in the zone of chorioretinal atrophy. 
Outside this area, the retinal layers appeared relatively normal, apart from some mild irregularity of 
the hyperreflective layer that is presumed to correspond to the photoreceptor inner/outer segment 
interface. J, On an OCT scan taken through the plane indicated by the black arrowhead in G, 
the hyperpigmented spot corresponded to a hyperreflective dome-shaped lesion that seemed to 
originate from the RPE.
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The stage of retinal dystrophy was significantly correlated to age (r=-0.483, p=0.008) 
and to visual acuity (r=-0.614, p<0.001). There was a significant correlation between the 
stage of retinal dystrophy and the scores regarding vision both in section 1 (r=0.525, 
p=0.003), and section 3 (r=0.483, p=0.014) of the NMDAS. Visual acuity as measured in 
the ophthalmologic assessment has a very good correlation with the scores regarding vision 
both in section 1 (r=0.717, p<0.001) as section 3 (r=0.816, p<0.001) of the NMDAS. There 
Figure 9.3: Stage 3 retinal dystrophy associated with the m.3243A>G mutation.
A, Color fundus photograph of a 42-year-old patient with stage 3 retinal dystrophy due to the 
m.3243A>G mutation. Areas of more profound atrophy have appeared, especially in the macula and 
the peripapillary area. The visual acuity was 20/20, and the patient experienced fluctuating vision 
in the last 7 years. Systemically, the patient suffered from fatigue, arterial hypertension, and focal 
glomerulosclerosis, for which she received renal dialysis 3 times a week. B, Fundus autofluorescence 
(AF) shows dark areas of virtually absent AF in the macula and around the optic disc that correspond 
to the zones of chorioretinal atrophy in A. In addition, spots of highly increased FAF are dispersed 
throughout the posterior pole. On cursory ophthalmoscopy, these spots appeared to correspond 
to mildly yellowish (sub)retinal depositions, and may thus contain lipofuscin components (A2E 
and/or its precursors and derivatives). The midperipheral and peripheral retina looked normal on 
ophthalmoscopy as well as on fundus AF imaging. C, The OCT scan (taken through horizontal 
scanning plane indicated by arrowhead in B) shows that the central foveal structure was relatively 
preserved, with parafoveal zones of attenuation of the outer retinal layers (outer photoreceptor 
structures and retinal pigment epithelium) and hyperreflectivity of the underlying structures 
(choroid and sclera) due to an increased penetrance of OCT laser rays through the attenuated 
retina. D, Fundus photograph of the same patient, taken 7 years earlier at the age of 35, showing 
that most of the atrophic areas were not present at that point in time, and had progressed in the 
following period of 7 years. Yellowish or slightly pigmented (sub)retinal depositions were visible 
in the macula. E, These deposits corresponded to hypofluorescence on fluorescein angiography, 
because of blockage of the background choroidal hyperfluorescence by these accumulations. F, At 
the age of 35, this patient also experienced central visual loss (visual acuity 20/32 OU) as a result of 
cystoid macula edema in both eyes without any identifiable causal trigger. The OCT scan showed 
corresponding cystoid fluid collections in the macula, without evidence of diabetic maculopathy on 
ophthalmoscopy. Topical non-steroidal anti-inflammatory drops were started 4 times a day. In the 
following two (G) and four (H) months, a gradual resolution of the edema was noted, resulting in an 
increase of the visual acuity to 20/25. I, Color fundus photograph of left eye of a 54-year-old patient 
who did not experience visual loss initially. The visual acuity in this eye was 20/32. The symmetric 
macular atrophic abnormalities in both eyes were found at a screening for diabetic retinopathy, 
and the patient was subsequently referred to our tertiary university eye clinic. The combination of 
the atrophic macular degeneration and insulin-dependent diabetes mellitus since the age of 38 
prompted an analysis of the m.3243A>G mutation, which was identified. On the fundus image, 
the fovea appears to be relatively spared, which was confirmed functionally by the visual field test 
highlighted in the lower right corner of the image. Full-field electroretinography and the electro-
oculogram were normal in both eyes. J, On fundus AF imaging, this remarkable foveal sparing was 
evident as a relatively normal AF appearence of the fovea, surrounded by a large black area where 
the retinal pigment epithelium was atrophic. This atrophic area and the optic disc were surrounded 
by granular abnormalities of decreased and increased AF. Note that the parapapillary area was also 
atrophic, as indicated by the markedly decreased AF signal. K, On a horizontal OCT scan through 
the fovea, the outer retina (photoreceptor-retinal pigment epithelium complex) was markedly 
attenuated, except in the central fovea where these structures were relatively preserved, although 
irregular. K-O, Seven year follow-up of fundus AF imaging from 2005 (L), 2006 (M), 2010 (N), and 
2011 (O). An enlargement of the black atrophic area was seen, as well as progressive narrowing 
of the area of foveal sparing. In 2011, the patient first reported visual loss, with loss of color vision 
quality as well as paracentral scotoma. At that time, the visual acuity was 20/40.
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Figure 9.4: Stage 4 retinal dystrophy associated with the m.3243A>G mutation.
A, Color fundus photograph of a 57-year-old patient with MELAS syndrome, insulin-dependent 
diabetes mellitus and deafness due to the m.3243A>G mutation. She reported marked central visual 
loss since at least 10 years. The fundus image composition showed marked chorioretinal atrophy 
in the macula. The visual acuity was 20/630. B, Fundus autofluorescence imaging showed a black 
area of RPE atrophy in the macula and around the optic disc, bordered by irregular autofluorescence 
changes. C, The atrophic area corresponded to marked atrophy of the outer retinal layers as seen 
on this horizontal OCT scan through the fovea.
were no significant correlations between the stage of retinal dystrophy and heteroplasmy 
levels in leucocytes, UEC or buccal mucosa. No correlations between retinal dystrophy 
and the total scores on the NMDAS or the quality of life scores were found. There were 
no differences in the stage of macular dystrophy between the male and female patients. 
Foveal sparing and peripapillary changes
Relative sparing of the fovea was seen in 21 patients of the 25 patients who had retinal 
abnormalities (84%), and this foveal sparing seemed to be one of the typical features in 
m.3243A>G-related retinal dystrophy. in two patients the foveal centre was affected by 
chorioretinal atrophy (stage 4 disease; Figures 9.4, 9.5A-O). One of these patients had a 
central vitelliform lesion in the fovea prior to developing foveal atrophy (Figure 9.5A-O), 
which occurred within six years. The third patient without clear foveal sparing had advanced 
stage 3 disease with chorioretinal atrophy encroaching on the central fovea. The fourth 
patient was the previously described individual with bilateral foveal lesions that appeared 
vitelliform with a tendency to atrophy, who carried a c.505_507del (p.Asn169del) mutation 
in the PRPH2 gene besides the m.3243A>G mutation. 
Retinal changes comparable to those in the macular area were also seen around the 
optic disc in 22 of the 25 patients (88%) who had retinal abnormalities. These changes 
could include very mild pigmentary abnormalities (Figure 9.1), yellowish flecks and 
pigmentary changes (Figure 9.2), but also advanced peripapillary chorioretinal atrophy. 
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Mild peripapillary changes similar to the abnormalities in the macula were seen in 3 out 
of 6 patients (50%) with stage 1 disease, whereas the other patients with stage 1 disease 
had a normal aspect of the peripapillary retina. All patients with stage 2, stage 3, and 
stage 4 disease also had a variable degree of peripapillary abnormalities (Figures 9.2-9.4). 
Advanced peripapillary chorioretinal atrophy was seen in 5 out of 25 affected patients 
(20%), all of whom had advanced stages of m.3243A>G mitochondrial retinal dystrophy: 
4 patients had stage 3 disease, and 1 patient had stage 4 disease.
Follow-up
Follow-up data were available in 7 patients, with a mean follow-up time of 6 years (range, 
1-16 years). In two patients, progression from stage 2 (subretinal pigmentary deposits 
without areas of profound chorioretinal atrophy) to stage 3 (one or more areas of well-
demarcated geographic atrophy outside and not encircling the fovea) was seen after a 
follow-up of 5 years (Figure 9.2D-H) and 7 years (Figure 9.3A-E), respectively. In one patient 
with a somewhat atypical vitelliform lesion in the left eye, this vitelliform lesion became 
progressively atrophic within 2–3 years (Figure 9.5A-O). The EOG was normal in this patient. 
Another patient developed small, central, mildly atrophic vitelliform lesions at 42 years 
of age, which resembled adult-onset foveomacular vitelliform dystrophy (Figure 9.5P-R). 
Besides the m.3243A>G mutation this patient also carried a c.505_507del (p.Asn169del) 
mutation in the PRPH2 gene. This mutation in the PRPH2 may be an important modifying 
factor of the phenotype in this patient, as PRPH2 mutations have been previously described 
in a broad range of macular dystrophies, including adult-onset foveomacular vitelliform 
dystrophy (25). One patient had remarkable foveal sparing, with a circular area of profound 
chorioretinal atrophy surrounding a central “island” of fovea (stage 4 disease) that became 
progressively smaller in the following 6 years (Figure 9.3L-O).
Visual field testing and electrophysiology
In our cohort of 29 patients, Humphrey central visual field analysis showed abnormalities 
in 17 eyes of 10 patients (34%). Of these 10 patients, 9 (90%) had at least stage 2 disease. 
Four of these patients (40%; all had stage 3 or 4 disease) had a clear bilateral (para-)
central scotoma (Figure 9.3I), three other patients (30%) had mild central sensitivity loss, 
two patients (20%) had a unilateral mildly enlarged blind spot, and one patient had a left 
homonymous hemianopia (which was confirmed on Goldmann perimetry) after previous 
cerebrovascular complications. Goldmann perimetry in one patient with advanced stage 
3 retinal dystrophy showed a mild concentric visual field constriction. In this patient, full-
field electroretinography and dark adaptation findings were within the normal range, 
whereas the electro-oculogram was low-normal (Arden ratio of 1.7 OD / 1.8 OS). In the 
other two patients with stage 3 retinal dystrophy, both full-field electroretinography and 
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the electro-oculogram were normal. Color vision testing in two patients with stage 3 
disease showed a blue-yellow defect in both patients, whereas one patient with stage 2 
disease had normal color vision testing results. 
Figure 9.5: Atypical retinal abnormalities associated with the m.3243A>G mutation.
A, Color fundus photograph of a 46-year-old patient who was referred to our university 
ophthalmology department with atypical macular abnormalities that were seen by the referring 
ophthalmologist. This patient experienced mild photophobia and mild complaints of “blurry 
sight”. The visual acuity was 20/32. She also had a multitude of systemic abnormalities, including 
diabetes mellitus treated with oral antidiabetic medication, hearing loss, slow transit colon requiring 
colectomy, and left ventricular hypertrophy. The fundus photograph, taken in 2006, showed a 
central yellowish vitelliform lesion surrounded by granular pigmentary abnormalities. The electro-
oculogram was normal. The combination of maculopathy, diabetes, and deafness lead to the 
analysis of the m.3243A>G mutation, which was identified. B, Fundus autofluorescence (AF) showed 
that the vitelliform lesion showed increased AF, with several smaller satellite lesions. Mild spots of 
decreased AF were seen outside these lesions in macula. C, A horizontal OCT scan through the 
lesion (scanning plane depicted by arrowhead in B) showed an accumulation of hyperreflective 
material adjacent to the neuroretina, between the neuroretina and the retinal pigment epithelium 
(RPE). This material may correspond to photoreceptor outer segment debris that accumulates due 
to decreased phagocytosis by the RPE as a result of a lack of apposition of the neuroretina to 
the RPE. D, Fluorescein angiography showed hypofluorescence due to blockage of the choroidal 
background fluorescence in the areas of subretinal accumulation of yellowish material. Outside 
these areas, hyperfluorescent spots were visible, that corresponded to the spots of decreased AF, 
which may indicate that these zones were compatible with mild RPE atrophy. E, Five years later, 
in 2011, the same patient reported marked central visual loss in this eye, and the visual acuity 
had decreased to 20/200. The fundus photograph showed that the area of the former yellowish 
“pseudo-vitelliform” lesion had evolved to marked chorioretinal atrophy. F, Fundus AF showed 
markedly decreased AF in the area of atrophy, as well as several new smaller zones of increased AF 
in the macula outside this area. G, On a horizontal OCT scan (through the scanning plane indicated 
by the arrowhead in F), marked attenuation of the outer retinal layers was seen in the atrophic 
area. H, Fluorescein angiography showed an RPE window defect in this atrophic area, surrounded 
by granular fluorescence changes. I, On color fundus photography of the right eye of the same 
patient taken in 2006 (at the age of 46), slightly hyperpigmented irregular spots and flecks were 
visible in the macula. The visual acuity was 20/20. In contrast to the other eye, there was no large 
central vitelliform lesion. J, Fundus AF imaging was clearly abnormal, and the spots of abnormal 
AF also involved the fovea. K, Fluorescein angiography showed, with zones of hypofluorescence 
corresponding to the hyperpigmented and yellowish areas. L, Five years later, in 2011, the patient 
reported visual loss, and visual acuity was decreased to 20/32. The color fundus photograph showed 
chorioretinal atrophy. M, This atrophic zone corresponded to an absent AF signal. N, A horizontal 
OCT scan, through the scanning plane indicated by the arrowhead in M, showed attenuation of 
the outer retinal layers in this atrophic zone. O, This atrophic zone appeared as a hyperfluorescent 
RPE window defect on fluorescein angiography. Outside this area, granular hyperfluorescence in 
the macula and around the optic disc was seen, as well as some hypofluorescent spots due to 
blockage of fluorescence by yellowish subretinal depositions. P, Color fundus photograph of a 
54-year-old patient who carried the m.3243A>G mutation. A yellow-white lesion was seen centrally 
in the macula. This patient had a visual acuity of 20/63, and suffered from central visual loss and 
metamorphopsia since 10 years. He also suffered from MELAS syndrome, epilepsia, and arterial 
hypertension. Q, Fundus AF imaging showed irregular AF changes corresponding to the yellowish 
lesion. R, A horizontal OCT scan through the scanning plane indicated by the arrowhead in Q 
showed a thickening and irregularity at the level of the photoreceptor outer segment layer.
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Systemic disease and NMDAS scores 
The average heteroplasmy level in UEC of the m.3243A>G mutation was 54±22%, whereas 
the heteroplasmy levels in leucocytes showed a lower number of 21±13%. One patient 
had an undetectable mutation load in leucocytes, but had a heteroplasmy level of 22% 
in UEC. The patients had a median NMDAS score of 15 (IQR 11–25.5), corresponding to 
a mild to moderate severity of systemic disease. The more severe MELAS phenotype was 
seen in four patients, a predominantly cardiac phenotype was seen in one patient, and 
the other 24 patients had a complete or oligosymptomatic MIDD. 
On the NMDAS, subjective visual disturbance was reported by 14 patients (48.3%). 
Nine patients (31%) reported to have no functional visual impairment but were aware of 
worsened acuities. Two patients (6.9%) reported mild functional problems (difficulty with 
small print or text on television), one patient (3.4%) reported moderate problems (difficulty 
outside the home, e.g. reading bus numbers, road signs or shopping), and two patients 
(6.9%) reported severe problems (such as difficulty recognizing faces). Of the patients 
that reported severe problems on the NMDAS, one had a stage 4 retinal dystrophy and 
one had a stage 2 retinal dystrophy. The patient reporting moderate problems also had 
a stage 4 retinal dystrophy.
Ten patients (34.4%) had a certain degree of ptosis, and three patients (10.3%) had 
mild external ophthalmoplegia. Hearing loss was reported by 25 patients (86.2%), of 
which 10 patients were using hearing aids. Diabetes mellitus was present in 13 patients 
(44.8%), of which 9 patients were treated with subcutaneous insulin. Twenty patients 
(70.0%) reported gastro-intestinal problems, of which 12 needed daily laxative medication, 
and 3 had undergone prior surgical procedures for severe constipation. Thirteen patients 
(44.8%) had a variable degree of muscle weakness and 15 patients (51.7%) reported 
exercise intolerance. Severe neurologic involvement (epilepsy or stroke-like episodes) 
was present in four patients (13.8%). 
Discussion
Clinical characteristics and classification
Mitochondrial retinal dystrophy due to the m.3243A>G mutation causes a fairly constant 
phenotype. The spectrum of severity ranges from barely discernable pigmentary 
abnormalities in the outer retinal layers of the macula to profound chorioretinal atrophy 
in the macula. The m.3243A>G mutation causes retinal lesions that are localized to the 
posterior pole, often including the retina around the optic disc. We propose a classification 
of m.3243A>G mitochondrial retinal dystrophy into four stages. This classification is based 
ophthalmoscopy, and correlates with findings on multimodal imaging including OCT, 
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fundus autofluorescence and fluorescein angiography (Table 9.2). In all stages except stage 
4, the structure and function of the fovea are relatively spared, resulting in a prolonged 
preservation of a fairly good visual acuity. Considerable visual impairment may be present 
even if the fovea is spared, as a result of paracentral scotomata in cases of progressive 
atrophy around the fovea in cases with stage 3 disease (Figure 9.3I). Atypical disease such 
as a vitelliform lesion is uncommon, but these cases may progress more rapidly to central 
chorioretinal atrophy and visual loss within a few years. 
Massin and colleagues have shown that 86% of patients with MIDD caused by 
the m.3243A>G mutation have macular dystrophy (17). They described a classification 
into 4 grades, grade 0–3 (17). Their grading system was different from the one that we 
propose in the current paper. In their classification, grade 0 indicated no abnormalities, 
grade 1 showed tiny localized subretinal deposits in the macula, in grade 2 the authors 
described subretinal deposits surrounding the macula and, in some cases, the optic disc. 
Grade 3 was described as the presence of areas of RPE and choriocapillaris. There are 
several reasons why we propose a classification that is different from the one described 
by Massin and co-workers. First, we differentiate between chorioretinal atrophy that does 
or does not affect the fovea. It seems clinically important to make this difference: if the 
chorioretinal atrophy does not affect the fovea, the visual acuity may be relatively preserved 
for years. If the atrophy does affect the fovea, this results in a marked decrease in visual 
acuity. Second, all patients with stage 2, 3, and 4 disease according to the classification 
proposed in the current study had lesions around the optic disc, and in 50% of the patients 
with the mildest form of retinal abnormalities (stage 1). Also, virtually all patients with 
m.3243A>G-associated retinal abnormalities had fine or obvious pigmentary abnormalities 
that surrounded the macula. In their classification, Massin et al. did not find an association 
between the severity of the macular dystrophy and patient age (17). In the current study 
we did find a significant association of the disease stages according to our proposed 
classification with both patient age and visual acuity. These observations suggest that our 
proposed classification has more clinical implications. 
None of the m.3243A>G patients with retinal abnormalities in our study had typical 
drusen on ophthalmoscopy and OCT, in contrast to the previous report by Michaelides 
and colleagues (26). However, these authors did not use OCT to confirm if the subretinal 
deposits corresponded to genuine drusen, which are sub-RPE deposits. 
A certain degree of ptosis and/or external ophthalmoplegia may accompany the 
retinal abnormalities, although there does not seem to be an association between the 
severity of the retinal abnormalities and the dysfunction of the periocular muscles (27, 28). 
Interestingly, diabetic retinopathy is less prevalent in patients with m.3243A>G MIDD as 
compared to controls with non-mitochondrial diabetes (7).
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Genetic background and differential diagnosis
As mtDNA mutations are inherited maternally virtually all offspring of an affected female 
will carry the mutation (29). The diagnosis of m.3243A>G mitochondrial retinal dystrophy 
is not always straightforward. The maternal inheritance pattern can be masked due to 
non-penetrance as a result of low heteroplasmy levels (29). Mutation analysis in blood has 
a 15% false-negative rate, and therefore additional DNA analysis on urine is recommended 
if blood analysis is negative despite the presence of a typical retinal phenotype (5). On 
rare occasions the disease can be caused by a de novo mutation (30). 
Carriers of the m.3243A>G mutation often have associated systemic diseases. 
However, due to the fact that heteroplasmy levels may vary widely between different 
tissues, the clinical constellation of symptoms and diseases may also show a broad clinical 
spectrum. In fact, it seems that only a minority of m.3243A>G carriers have a typical MIDD 
or MELAS syndrome presentation. In our study, 17% of families were diagnosed as carriers 
of the m.3243A>G mutation based on the findings of ophthalmological examination. In 
these three families the m.3243A>G mutation analysis was initiated by the ophthalmologist. 
The systemic involvement in these patients was very diverse and not previously recognized 
as associated with the m.3243A>G mutation. The establishment of the diagnosis of 
m.3243A>G mitochondrial retinal dystrophy should therefore rely also on a high index 
of suspicion in patients with typical macular lesions. Fundus autofluorescence appears to 
be the ophthalmic imaging modality of choice to identify retinal abnormalities that are 
typically associated with m.3243A>G. 
When no m.3243A>G mutation is found, one should critically review the clinical 
evidence for m.3243A>G retinal dystrophy and consider if other differential diagnostic 
entities might be possible. Several of these conditions are hereditary macular dystrophies, 
which differ in their underlying genetic abnormality and inheritance pattern. These patients 
lack a constellation of associated systemic abnormalities that are typically associated with 
the m.3243A>G mutation, which may also help in the differential diagnosis.
Late-onset Stargardt patients, caused by mutations in the ABCA4 gene, may show 
somewhat similar retinal lesions and also frequently have relative foveal sparing (31). 
However, these patients often have a dark choroid on fluorescein angiography. Multifocal 
pattern dystrophy simulating Stargardt disease/fundus flavimaculatus and central areolar 
choroidal dystrophy, caused by autosomal dominant PRPH2 gene mutations, should also 
be considered (21, 25, 32). In atypical cases with an m.3243A>G mutation, mutations in 
other or additional genes should also be considered, such as the PRPH2 gene (Figure 
9.5P-R). The most important differential diagnostic entity to consider is atrophic age-
related macular degeneration. After all, this is by far the most common form of atrophic 
maculopathy at older age, and diabetes mellitus as well as deafness are also common in 
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the elderly. However, patients with atrophic age-related macular degeneration usually have 
drusen on ophthalmoscopy and OCT, and lesions are less autofluorescent as compared 
to those in patients with m.3243A>G mitochondrial retinal dystrophy. Differentiation 
from desferrioxamine maculopathy and pseudoxanthoma elasticum maculopathy is more 
straightforward due to the associated systemic conditions.
Genotype-phenotype correlations
In this study, we measured heteroplasmy levels in UEC, leucocytes and buccal saliva. 
None of these heteroplasmy levels showed a correlation to the severity of the macular 
dystrophy. We also did not find a correlation between the total score on the NMDAS and 
the stage of retinal dystrophy. This indicates that the severity of systemic involvement of 
the mutation does not correspond with the level of ophthalmologic involvement. We did 
find a good correlation between the stage of mitochondrial retinal dystrophy and the 
scores regarding vision on the NMDAS, as well as a strong correlation between the visual 
acuity as measured in the ophthalmologic assessment and the scores regarding vision on 
the NMDAS. However, the NMDAS scoring system will generally not identify the relatively 
large proportion of patients with stage 1–3 mitochondrial retinal dystrophy, because these 
patients have foveal sparing and (near-)normal visual acuity. Therefore, we recommend 
that all patients with an m.3243A>G mutation are assessed by an ophthalmologist for 
evaluation and follow-up of retinal abnormalities. 
Functional consequences of the m.3243A>G mutation in the retina 
Whether or not a mitochondrial DNA mutation leads to a clinically significant biochemical 
defect depends on the type and location of the mutation within the mtDNA, as well as the 
level of heteroplasmy The deleterious consequences of most mtDNA mutations on oxidative 
phosphorylation generally become apparent when the proportion of mitochondria with a 
mtDNA mutation versus mitochondria with wild-type mtDNA in a tissue exceeds 60–80% 
(33). This threshold level of heteroplasmy has been well described in several mitochondrial 
disorders such as neuropathy, ataxia, and retinitis pigmentosa (NARP) and myoclonic epilepsy 
with ragged red fibers (MERRF) (34). In the case of the m.3243A>G mutation however, a 
clinical phenotype can be present in patients carrying the mutation with a heteroplasmy a 
low as 5% (5). It is unclear if there is a heteroplasmy threshold level regarding involvement 
of the photoreceptors and the RPE in the case of the m.3243A>G mutation. These retinal 
cell layers may be vulnerable at low heteroplasmy levels, as they function in a unique highly 
oxidative micro-environment, where they are under a constant attack of reactive oxygen 
species, of which the mitochondria itself are a major endogenous source (35). 
In comparison with nuclear DNA, the circular DNA of mitochondria is particularly 
vulnerable to additional damage, due to the nearby production of reactive oxygen species 
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and the lack of protective proteins such as histones, especially under the catalyzing 
influence of a constant exposure to light in the retina. In normal individuals, there is a 
significant decrease in the number and density of mitochondria with increasing age, 
and this is more pronounced in patients with age-related macular degeneration (36). 
This is probably even more so in patients with mtDNA mutations such as m.3243A>G, 
which may lead to a further increase of reactive oxygen species and mtDNA damage 
in photoreceptors and RPE. This resultant state of oxidative stress has the potential to 
cause major bioenergetic alterations leading to RPE and photoreceptor cell dysfunction. 
Primary photoreceptor dysfunction in m.3243A>G-related mitochondrial dysfunction 
is also possible, independent of a dysfunctional RPE. After all, photoreceptor structure 
and function rely on various biochemical processes that are highly energy-dependent 
(and thus mitochondria-dependent), such as the transport of proteins in the connecting 
cilium, continuous outer segment formation and visual pigment processing. The reactive 
oxidative environment and high levels of vulnerable poly-unsaturated fatty acids in the 
photoreceptor outer segments probably also contribute to an increased accumulation of 
lipofuscin components, which is reflected in the increased fundus autofluorescence that 
we have found in lesions of m.3243A>G carriers in this study. The toxic age lipid A2E, a 
major constituent of the autofluorescent lipofuscin, impairs photoreceptor outer segment 
phagocytosis by the RPE synergetically with mitochondrial dysfunction (37). This may lead 
to a vicious cycle of mitochondrial dysfunction, accumulation of toxic lipofuscin components 
in the RPE, and decreased photoreceptor outer segment phagocytosis, eventually leading 
to RPE and photoreceptor cell death.
It is unclear why some mitochondrial mutations cause Leber hereditary optic neu-
ro pathy without retinal abnormalities, while the m.3243A>G mutation causes retinal 
dystrophy without clinically significant optic neuropathy. There are several possible 
explanations for the variation in pathologic consequences of these different mutations. In 
contrast to other mtDNA mutations, such as those in Leber hereditary optic neuropathy, 
the m.3243A>G mutation appears to suppress normal functioning of wild-type (normal) 
tRNA, even in high levels of wild-type tRNA (33). Also, the m.3243A>G mutation may 
lead to a dysfunctional tRNA that affects mRNA association with ribosomes, causing a 
general reduction in mitochondrial protein synthesis rate (38). In contrast to m.3243A>G, 
the biochemical defect in Leber hereditary optic neuropathy mutations is often mild and 
sometimes even undetectable (39, 40). The approach of “simply” increasing the amount 
of wild-type mtDNA, as suggested for several other mitochondrial diseases, may thus not 
be the solution in m.3243A>G-related disease. In the case of the m.3243A>G mutation, 
therapeutic efforts to correct the mutation or knock-down its deleterious effect(s) may be 
the preferable approach (33).
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Histopathological correlations
It is unclear if the primary degeneration occurs on the level of the RPE, the photoreceptors, 
or both. There are two histopathological studies on genetically proven m.3243A>G 
mitochondrial retinal dystrophy that give clues. One histopathological study on a MELAS 
patient with an m.3243A>G mutation and atrophic pigmentary maculopathy showed 
degeneration of photoreceptor outer segments, as well as hyperpigmentation and 
atrophy of the RPE (41). In this case, many enlarged structurally abnormal mitochondria 
were present in the photoreceptor inner segments and the RPE. Two other confirmed 
m.3243A>G carriers with retinopathy were examined in another histopathologic study 
(28). One of these cases had a documented macular vitelliform lesion in one eye, which 
had progressed to chorioretinal atrophy with RPE attenuation, and atrophy of overlying 
photoreceptors and choriocapillaris at the time of histopathologic examination. This case 
appears to be comparable to the patient depicted in Figure 9.5A-H. In both cases of 
this histopathologic study, the abnormalities of the RPE seemed more marked than the 
overlying photoreceptor abnormalities. Outside the macula of these patients, the RPE had 
a normal height or showed some mild focal hyperplasia, but appeared to have a loss of 
basal infoldings and apical microvilli. The overlying photoreceptor outer segments in this 
more peripheral retinal area showed some disorganization but looked otherwise relatively 
normal (28). Numerous enlarged and abnormal mitochondria were present in the RPE, 
inner retina land outer nuclear layers, as well as the retinal ganglion cells. Both patients 
in this histopathological study had an accumulation of lipofuscin and melanolipofuscin in 
the RPE, which corresponds to our finding of areas of increased fundus autofluorescence 
in many patients.
The findings in these two histopathologic studies correlate with our clinical findings: 
the structure of the RPE and photoreceptors in the macula appear to be primarily affected, 
although abnormal mitochondria can be present in most retinal layers. Inner retinal 
dysfunction due to mitochondrial abnormalities could also play a role in m.3243A>G 
disease, but OCT imaging in our study mainly showed outer retinal abnormalities without 
obvious structural inner retinal changes. In our study, the full-field ERG and the EOG in 
three patients with advanced stage 3 disease was within the normal range, although one 
patient had EOG values at the borderline of normal. These functional findings also indicate 
that m.3243A>G mitochondrial retinal dystrophy is mainly localized to the posterior 
pole, without marked panretinal photoreceptor or RPE dysfunction. Although there are 
some clinical and histopathological indications that the RPE is affected earlier than the 
photoreceptors (14), we were not able to determine if the RPE is dysfunctional or structurally 
abnormal earlier than the photoreceptors, or vice versa. The process of degeneration 
in these closely interacting cell layers may occur in parallel, as these postmitotic tissues 
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both have a high metabolic rate on which they are highly dependent. In stage 3 and 4 
mitochondrial retinal dystrophy, areas of choriocapillaris also becomes markedly atrophic, 
which is probably secondary to profound atrophy of the overlying RPE (42, 43).
Foveal sparing 
Patients with m.3243A>G mitochondrial retinal dystrophy develop retinal abnormalities 
primarily in macular area outside the fovea, as well as in the retinal area around the optic 
disc. In most patients, the fovea remains relatively spared both structurally and functionally, 
for many years (Figure 9.3I-O). This intriguing phenomenon of foveal sparing could have 
(a combination of) several explanations, such as the observed increased vulnerability of 
parafoveal rods and S (“blue”) cones compared to the central M and L cones (44-46), as 
well as the presence of photoprotective macular pigment in the central fovea (47, 48). 
Unlike rods, cones do not exclusively depend on the RPE for the regeneration of 11-cis-
retinal, which could also contribute to their extended survival (49). In addition, cone outer 
segment turnover appears to be slower than rod outer segment turnover (50). Parafoveal 
rods have also been shown to be more vulnerable to aging effects (51).
The primary site of retinal degeneration in mitochondrial retinal dystrophy, the macular 
area outside the fovea, contains the highest ratio of photoreceptors per RPE cell, mainly 
due to a high numbers of densely packed rods (52). The specific vulnerability of this area 
may therefore reflect the highest metabolic burden on the photoreceptor-RPE cell complex. 
The tendency to spare the fovea in m.3243A>G mitochondrial retinal dystrophy creates 
a window of opportunity for timely therapeutic intervention to prevent severe visual loss, 
should a future treatment become available. 
Conclusions
The m.3243A>G mutation is associated with a relatively constant and fairly typical retinal 
phenotype, which is associated with MIDD and MELAS syndrome. This mitochondrial retinal 
dystrophy is clinically confined to the posterior pole and can be classified into 4 stages. 
Fundus autofluorescence highlights the “hereditary aspect” of the retinal abnormalities. 
The diagnosis of this specific ocular disorder is not always straightforward, because patients 
may be asymptomatic and have variable systemic associations. If an ophthalmologist is 
confronted with lesions that suggest mitochondrial retinal dystrophy, mutation analysis 
for the m.3243A>G mutation should be performed. All m.3243A>G mutation carriers and 
their possibly affected offspring should be evaluated in a centre with sufficient expertise 
on mitochondrial disorders and genetic counseling. 
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Abstract
Background: Previous research has shown that dysphagia and gastrointestinal problems 
occur frequently in carriers of the m.3243A>G mutation, however the exact frequency and 
severity have not been determined. We hypothesize that adult carriers have an increased 
risk for malnutrition. 
Methods: In this observational study we evaluated the presence of gastrointestinal 
problems and dysphagia in 92 carriers of the m.3243A>G mutation. The severity of the 
general disease involvement was classified using the Newcastle Mitochondrial Disease 
Adult Scale (NMDAS). Gastrointestinal involvement, dysphagia and the risk for malnutrition 
were scored using the Gastrointestinal Symptoms Questionnaire and The Malnutrition 
Universal Screening Tool. Gastrointestinal symptoms and anthropometrics were compared 
to healthy controls. 
Results: Our results show that height, weight and BMI of these carriers were lower 
than the national average (p<0.05). Seventy-nine carriers (86%) suffered from at least 
one gastrointestinal symptom, mainly flatulence or hard stool. Both frequency and 
severity of symptoms were significantly increased compared with reference data 
of healthy Dutch adults. Forty-five percent of the carriers reported (mostly mild) 
dysphagia. Solid foods cause more problems than liquids. A negative correlation 
between BMI and heteroplasmy levels in urinary epithelial cells (UEC) was present 
(spearman c.c.=-0.319, p=0.003). 
Conclusion: Dysphagia and gastrointestinal problems, especially constipation are common 
complaints in the total m.3243A>G carriers cohort and are not related to heteroplasmy 
levels in UEC or disease severity. The severity of gastrointestinal problems as well as overall 
disease severity is associated with an increased risk for malnutrition.
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Introduction
Mitochondria and the m.3243A>G mutation
Mitochondrial diseases are the most prevalent inherited metabolic diseases, with an 
incidence of approximately 1:5000 live births (1). Mitochondria are the cellular organelles 
responsible for oxidative phosphorylation, which produces energy in the form of adenosine 
triphosphate. This process is accomplished by the four complexes (complex I-IV) of the 
respiratory chain and F1-F0 ATP synthase. Mitochondrial dysfunction can result from 
mutations in either nuclear DNA (nDNA) or mitochondrial DNA (mtDNA). 
The acronym MELAS was first used by Pavlakis, Phillips (2) to describe a group of 
patients with Mitochondrial myopathy, Encephalopathy, Lactic Acidosis and Stroke-like 
episodes. In 1990 the m.3243A>G mutation was found as the molecular basis of this 
disease (3, 4). The mutation is located in the MT-TL1 gene and is the most common 
pathogenic mitochondrial mutation (5-7), commonly described as the MELAS mutation. 
The phenotype maternally inherited diabetes deafness (MIDD) is also caused by this 
same mutation and is much more frequent (8) Other phenotypic expressions of the 
m.3243A>G mutation include hypertrophic cardiomyopathy (9), retinal dystrophy (10), 
focal segmental glomeruloslerosis (11), myoclonic epilepsy with ragged-red fibers (12) and 
oligo-symptomatic variants of the acronym MELAS (13, 14). The percentage of affected 
mitochondria per cell in a specific tissue is referred to as heteroplasmy, and the level of 
heteroplasmy may vary widely between tissues of a single individual. This marked intra-
individual and inter-individual variation in mitochondrial heteroplasmy (partially) explains 
why there is a wide spectrum of diseases and disease severity observed between family 
members that carry the same mitochondrial mutation. Previous studies have shown that 
urinary epithelial cells (UEC) are the best non-invasively available tissue to test the level 
of heteroplasmy of the m.3243A>G mutation (15, 16). 
Gastrointestinal involvement in m.3243A>G carriers
Dysphagia and gastrointestinal problems occur frequently in mitochondrial patients, 
including patients carrying the m.3243A>G mutation (17-19). However, the exact 
frequency and severity of these symptoms have not been determined. In a population 
study of carriers of the m.3243A>G mutation, 61% of the subjects had gastrointestinal 
complaints. These were, after hearing loss, the most frequently reported symptoms of the 
m.3243A>G mutation using the Newcastle Mitochondrial Disease Adult Scale (NMDAS).
(20) The NMDAS is however not a specific instrument to study gastrointestinal problems.
Previously in a small cohort of MIDD patients, a high prevalence of constipation and/or 
diarrhea (88%) was found (21). Severe gastrointestinal problems like the pseudo obstruction 
syndrome, surgery-requiring constipation and pancreatitis have been described in patients 
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carrying the m.3243A>G mutation, although the incidence in these patients remains unclear 
(18, 21). Gastrointestinal problems are frequently reported in healthy controls as well (22), 
and so far studies comparing the frequency and severity of gastrointestinal problems in 
patients with a mitochondrial disease and healthy controls are lacking. 
Dysphagia in mitochondrial disease has been described in several studies which are 
hard to compare because of variations in definitions and study methods. In patient with 
the m.3243A>G mutation, incidences vary from 18% in a study using the NMDAS to score 
dysphagia to 38% in a study performed using a more specific approach (23, 24). Also, 
short stature and lower bodyweight are frequently described in mitochondrial disease. 
Patients with a MIDD phenotype have lower body mass index (BMI, weight(kg)2/height(m)) 
compared to other diabetic patients (25-27). 
For both dysphagia and gastrointestinal problems a relation with lower body weight 
and risk for malnutrition in patients with a mitochondrial disease has been suggested but 
never proven (18, 21). The present study therefore focused on dysphagia and gastroin-
testinal problems in a cohort of carriers of the m.3243A>G mutation and identification of 
symptoms that lead to decreased BMI and increased risk for malnutrition. 
Materials and methods
Patients
At the Nijmegen Center for Mitochondrial Disorders (www.ncmd.nl) at Radboud university 
medical centre 114 adult carriers of the m.3243A>G mutation participate in our cohort 
study (24). All participants received the questionnaire. This study was approved by the 
ethics committee of the Nijmegen-Arnhem region. Written informed consent according 
to the Helsinki agreement was obtained from all carriers.
General symptoms
All carriers were scored using the NMDAS (28). The NMDAS constitutes a validated method 
to monitor the clinical expression of mitochondrial disease and to follow-up the course of 
disease in time. The NMDAS consists of the following four sections. 1) Current function, 
which gives insight into the general functioning of patients in past four weeks including 
swallowing. 2) System-specific involvement, which uses a clinical history supplemented by 
specific information to gain insight in the functioning of individual organ-systems including 
gastro intestinal symptoms. 3) Current clinical assessment, i.e. a general and neurological 
clinical examination, which gives insight in the current functional status of the patient. 4) 
For quality of life, we used a Dutch translation of the SF-12v2 quality of life test. 
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Gastrointestinal symptoms evaluation
All participants received the Gastrointestinal Symptoms Questionnaire (29, 30). This self-
report questionnaire contains 16 items regarding gastrointestinal involvement of disease 
for the past four weeks. Severity of the symptoms is scored on a 7 point likert scale, 
where 0 resembles no symptoms and 6 resembles extreme symptoms. The final question 
of the questionnaire is a 50 point scale asking the overall burden of the gastrointestinal 
complaints. We added specific questions on dysphagia and frequency of stools. The 
validated Malnutrition Universal Screening Tool (MUST) (31) was used to collect the self 
reported anthropometric data and to screen for the risk for malnutrition. We compared 
the data to age matched anthropometric data from the Dutch Central Bureau of Statis-
tics (CBS) 2011 (n= 2034) and to a Dutch reference database form the Gastrointestinal 
Symptoms Questionnaire (n=1616). Data collection for this reference database was done 
in 2006 participants who matched the general Dutch population were selected with CBS 
statistics (22). 
Mutation analysis
Heteroplasmy levels of the m3243A>G mutation were determined in UEC in all partici-
pants using PyrosequencingTM technology (Pyrosequencing, Uppsala, Sweden) as earlier 
described (11). The pyrosequence reaction of the m.3234A>G mutation had a precision 
of 1.5%, and the mutation was detected from a heteroplasmy level of 5%. The detection 
limit for the mutation was determined by serial dilution of a sample containing this muta-
tion with wild type mtDNA.
Statistics
We used descriptive statistics to present the heteroplasmy levels in our patients. Mean 
(±SD) are presented with their standard deviation. To calculate the significance of the dif-
ferent variables in relation to BMI and gastrointestinal complaints Independent Samples 
T-test was used. We corrected for multiple testing using the Bonferroni test. Pearson 
correlation coefficient was used to evaluate the relationship between severity of gastro-
intestinal problems, and BMI. Spearmann correlation coefficient was used to evaluate 
the relationship between heteroplasmy in UEC, gastrointestinal problems, and BMI. We 
used the pearson chi-square to compare BMI category for males and females and carriers 
with healthy controls.
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Results
General patient characteristics and anthropometrics 
Data were collected from September to November 2011. From 114 questionnaires that 
were sent out, 92 were returned (81% response rate). Of these 92 patients 68% (n=63) were 
female. Mean age was 45 years (±14.3). In the Gastrointestinal Symptoms Questionnaire 
database Mean age was 52.3±17.2, 66% (n=1067) were female.
Mean NMDAS score was 15.7 (±10.9) range 0-56 and average heteroplasmy level in 
UEC was 50% (range 5%–98%). Thirty-eight patients (41%) were diagnosed with diabetes, 
of whom 22 (24%) used insulin. Hearing loss was reported by 59 patients (64%), 27 patients 
(29%) had a hearing aid. Six patients (6.5%) had severe neurological symptoms, of which five 
(5.4%) suffered from epilepsy and two (2.2%) had had stroke like episodes in the past year.
Female carriers were 2.7 cm shorter (average 164.8 cm versus 167.5 in healthy 
p=0.004) than healthy controls, in male carriers there was no significant difference between 
carriers and healthy controls (average 178.4 m versus 180.9 in healthy controls p=0.099) 
(Table 10.1). Male subjects weighed 8.2 kg less than controls (75.8 versus 84 kg p=0.002) 
and females weighed 4.8 kg less (65.2 versus 70 kg p=0.005). 
Carriers had a significantly less frequency of overweight (BMI >25 kg/m2) or obesity 
(BMI >30 kg/m2) (32%) compared to the average Dutch population (48%) (Figure 10.1). 
They were significant more frequently underweight (BMI <20 kg/m2) than the average 
Dutch population: 14% versus 2%. Of the women with a NMDAS score above 20, 31% were 
underweight. Carriers with BMI <20 kg/m2 had a significantly higher NMDAS (p=0.01). A 
negative correlation between BMI and heteroplasmy levels in UEC was present in carriers 
Table 10.1: Anthropometrics in male and female m.3243 A>G carriers and healthy 40–50 years old 
Dutch controls
  m.3243A>G Healthy P value 
Height men (cm) 178.4 (±6.9) 180.9 (±7.9) 0.01
Height women (cm) 164.8 (±8.3) 167.5 (±7.1)  0.004 * 
Weight men (kg) 75.8 (±12.8) 84 (±12.8) 0.002 * 
Weight women (kg) 65.2 (±17.7) 70 (±12.8) 0.005 * 
BMI men (kg/m2) 23.8 (±3.6) 25.6 (±5.4)  0.08 
BMI women (kg/m2) 23.9 (±6)  24.6 (±8.4)  0.5 
BMI category 0.00 *
Overweight or obesity: BMI >25; n (%) 30 (32) 5064 (48) 
Healthy weight: BMI 20–25; n (%) 50 (54) 5328 (50)
Low BMI <25; n (%) 13 (14) 180 (2)
* p<0.05.
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of the m.3243A>G mutation (spearman c.c.=-0.319, p=0.003). Nineteen percent (n=17) of 
the carriers had a MUST score of 1 or 2: average (12%) to high (7%) risk for malnutrition. 
In 14 carriers this score was based on their low BMI. Of the other 3 carriers with a risk for 
malnutrition 2 had a healthy weight and one was overweight, their MUST scores were 
based on more than 5% loss of bodyweight in the last 6 months.
The majority of carriers (81%) had a MUST score of zero: no risk of malnutrition. Five 
percent of the m.3243A>G carriers used medical feeding supplements, no patient was 
dependent on tube feeding.
Gastrointestinal complaints
In the four weeks previous to answering the questionnaire, 79 carriers (86%) suffered 
from at least one gastrointestinal symptom. Nearly all gastrointestinal complaints had a 
higher frequency and increased severity in carriers of the m.3243A>G mutation compared 
to the average Dutch population (Figure 10.2). Most frequent symptoms were bloating, 
hard stools and flatulence. Nausea and diarrhea and alternately solid or loose stools were 
also common but there was no significant difference to the controls for these symptoms. 
Hard stools or constipation were reported by respectively 48% and 38% of the 
carriers, whereas controls only reported these complaints in respectively 22% and 14% 
(p<0.001). Fourteen percent of the patients used laxatives and 44% had a stool frequency 
of less than once a day. 
Figure 10.1: BMI in male and female m.3243A>G carriers and healthy Dutch controls.
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Overall 69% of the carriers of the m.3243A>G mutation reported one or more 
constipation-related complaint (use of laxatives, stool frequency of <1 time a day, hard 
stools and/or self reported constipation).
Mean severity score of gastrointestinal problems was 10.7 (±11.9) range 0–50. Carriers 
with a BMI <20 (n=13) (p=0.028) and female carriers (p=0.009) had a significantly higher 
severity score of gastrointestinal complaints. Patients with postprandial fullness (p=0.045) 
or vomiting (p=0.048), had a significantly lower BMI compared to carriers without this 
specific symptom Severity of gastrointestinal problems was not clinically relevant related 
to BMI (correlation coefficient -0.152, p=0.013) 
Gastrointestinal symptoms that were most frequently reported as severe (5, 6 or 7 on 
the 7-point-likert scale) were; hard stools (14%), constipation (11%), flatulence (11%) and 
bloating (10%). All of these complaints were significantly more frequently scored as severe 
by carriers compared to controls. Also significantly more frequently scored as severe were 
regurgitation (8%), post-prandial fullness (9%), belching (10%), dysphagia for solids (2%), 
incomplete stools (8%) and sticky stool (7%).
One patient in this cohort had a pancreatitis in the past, two patients needed surgery 
for severe constipation.
There was no correlation between heteroplasmy levels in UEC and gastrointestinal 
complaints. Frequently reported symptoms in patients carrying the m.3243A>G mutation 
are myopathy and diabetes. The presence and severity of these symptoms had no 
significant relation to the gastrointestinal problems. 
Figure 10.2: Gastrointestinal symptoms in m.3243 A>G carriers and healthy Dutch controls.
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Dysphagia
In this study 21% of m.3243A>G carriers had trouble swallowing, as scored by the physician 
who performed the NMDAS. When we specifically asked for all sub-items of the NMDAS 
swallowing score in the questionnaire this frequency was much higher: 45%. Using the 
Gastrointestinal Symptoms Questionnaire, dysphagia seems to be a frequent problem 
(33%), but the severity was not very high (Figure 10.3). Liquids are less a problem compared 
to solids, the difference with controls was significant both in the carriers who have trouble 
with liquids (p=0.008) as with solids (p<0.001). 
No significant differences in BMI were present in carriers reporting dysphagia com-
pared to carriers without dysphagia. In six carriers with more severe complaints of trouble 
with swallowing liquids there was a significant difference in BMI: whereas carriers without 
trouble swallowing liquids had an average BMI of 24.1 (±5.5), carriers with such problems 
had an average BMI of 20.7 (±3.1) (p=0.046).
Figure 10.3: Dysphagia in solids and liquids in m.3243 A>G carriers and healthy Dutch controls.
Discussion
As there currently is no cure for mitochondrial disease (32), optimizing nutrition and treating 
major complaints such as constipation may be one of the few methods to improve quality 
of life. Because gastrointestinal symptoms are very common in these carriers as well as 
in the general population, and these often have a non-specific character, there may be a 
considerable risk for under-diagnosis of these possibly treatable problems. 
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The present study shows for the first time in a robust cohort that dysphagia and 
gastrointestinal problems, and more specifically constipation, are very common in carriers 
of the m.3243A>G mutation. These complaints are common in the total patient cohort and 
are not related to heteroplasmy levels in UEC, disease severity or the presence of diabetes. 
The severity of gastrointestinal problems as well as the overall disease severity and 
heteroplasmy levels in UEC are associated with a decreased BMI and an increased risk 
for the development of malnutrition. Strong points of this investigation include the high 
number of enrolled carriers with a homogeneous genetic background, despite the low 
incidence of this disease. Also, the high response rate renders these data highly relevant 
for the guidance and treatment of these carriers.
The high frequency of gastrointestinal problems has been previously described 
(17, 18, 21). We compared our cohort of 92 carriers of the m.3243A>G mutation with a 
cohort of 1627 healthy Dutch controls to identify those gastrointestinal problems that are 
specifically more frequent in carriers of the m.3243A>G mutation. Our study shows that 
motility problems of the bowel are probably the most frequent symptom: for instance 
constipation was found in 69% of carriers of the m.3243A>G, i.e. by far higher than in 
healthy controls. 
Patients presented with a range of underlying gastrointestinal problems. Some were 
diagnosed with irritable bowel syndrome (IBS) prior to the mitochondrial diagnose which 
seems not surprising given the diversity of symptoms. Although nausea, diarrhea and 
alternately solid or loose stools are common in this cohort, similar symptoms occur just as 
frequent in the control population, and seem not specific for the m.3243A>G mutation, 
yet remain potentially treatable.
We show in this study that severe gastrointestinal symptoms increase the risk for 
malnutrition in carriers of the m.3243A>G mutation. Fourteen percent of carriers had a BMI 
of <20 kg/m2 and in more severely affected patients (NDMAS >20) even up to 31% had a 
BMI of <20 kg/m2. There was no relevant correlation between gastrointestinal problems 
and BMI, indicating that probably several other confounders such as depression or fatigue 
may contribute to the risk for malnutrition. Screening for malnutrition or gastrointestinal 
symptoms can lead to early detection, and hence early treatment of these problems. 
Since malnutrition has been related to secondary mitochondrial dysfunction (33-35) and 
may worsen outcomes, like in other disease (36, 37), this remains a major concern in 
these patients. 
Dysphagia may well be more common than both doctors and patients realize. In a 
non specific questionnaire for swallowing problems (as included in the NMDAS), a low 
prevalence of dysphagia was reported. For instance, in our previous study we reported an 
18% incidence of dysphagia in a cohort of m.3243A>G carriers (24). In a partly overlapping 
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cohort we now found that 45% of patients suffered from dysphagia using a more specific 
questionnaire based on the NMDAS. 
A patient-reported incidence of dysphagia of 33% was found using the Gastrointestinal 
Symptoms Questionnaire. These differences in reported incidences of dysphagia show 
that the method to diagnose dysphagia is instrumental when assessing its incidence and 
suggests that the NMDAS underestimates this problem. 
Dysphagia usually develops slowly and is not severe in most patients, and patients 
may therefore adapt their eating pattern sufficiently. This notion might also explain why 
no differences in BMI between patients with mild dysphagia and without dysphagia were 
found. As with other neuromuscular disorders, solid foods seem to cause more problems 
than liquids (38). Muscle weakness is the most likely cause for dysphagia in this patient 
group, and demands a different treatment strategy than dysphagia from other causes (19, 
38). For example in dysphagia due to cerebral damage, it is very common to prescribe 
thickened drinks which will aggravate dysphagia in mitochondrial patients and will take 
more energy to consume.
In this study we used low BMI as a marker for malnutrition. Because it is an easy 
available continue variable suitable for comparison with healthy controls and for statisti-
cal analyses. BMI however is not a validated variable for malnutrition in neuromuscular 
disorders and it is known that patients with normal BMI could suffer from low fat free 
mass which is also an important marker for malnutrition. In future studies we would like 
to recommend to use body composition as an additional marker.
In conclusion, gastrointestinal problems and dysphagia are common in carriers of the 
m.3243A>G mutation. The severity of the gastrointestinal problems as well as the overall 
disease severity is associated with an increased risk for the development of malnutrition. 
The common disease scores used to identify severity of disease in mitochondrial patients, 
are insufficient to recognize these gastrointestinal complaints. Healthcare professionals 
treating patients with the m.3243A>G mutation should be aware of this high prevalence 
and should therefore actively ask for gastrointestinal problems to ensure a timely treatment 
of these problems. 
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Abstract
Background: Renal involvement in patients with the m.3243A>G mutation may result in 
end-stage renal disease (ESRD) requiring renal-replacement therapy. Although kidney 
transplantations have been performed in a small amount of patients, short- and long-term 
follow-up data are lacking. 
Methods: We describe five patients with the m.3243A<G mutation who received a kidney 
transplant including follow-up data up to 13 years. Besides, we summarize all cases (n=13) 
of kidney transplantation in m.3243A>G carriers described in literature. 
Results: Proteinuria with or without renal failure was the first clinical presentation of 
renal involvement in thirteen out of eighteen (72%) patients. FSGS (Focal Segmental 
Glomerulosclerosis) was found in nine out of thirteen (69%) biopsies. Sixteen out of 
eighteen (84%) patients developed hearing loss. All patients were diagnosed with diabetes 
mellitus of whom eight (44%) developed the disease after transplantation. All patients with 
reported follow-up data (13/18) had a stable kidney function from 6 months to thirteen 
years of follow-up after transplantation. 
Conclusions: Renal involvement in carriers of the m.3243A>G mutation most commonly 
leads to proteinuria and FSGS and may lead to ESRD. Proper recognition of the 
mitochondrial origin of the renal disease in these patients is important for adequate 
treatment selection and suitable supportive care. This case series and review of the available 
literature, on long term follow-up after kidney transplantation, shows it is feasible for non-
MELAS phenotype carriers of the m.3243A>G mutation to be considered for a kidney 
transplantation in case of ESRD. These patients should not be excluded from transplant 
solely for their mitochondrial diagnosis.
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Introduction
Solid organ transplants are rarely performed in both adult and pediatric patients with 
primary mitochondrial disease. It is unclear whether the underlying genetic disease has a 
significant impact on post-transplant morbidity and mortality.
Mitochondria
Mitochondria play an important role in cellular energy supply via the oxidative 
phosphorylation system (OXPHOS) producing adenosine triphosphate (ATP). Mitochondrial 
dysfunction can result from mutations in either nuclear DNA (nDNA) or mitochondrial 
DNA (mtDNA). The 37 genes of the mitochondrial genome encode for, 22 tRNA’s, two 
rRNA’s and thirteen subunits of the OXPHOS complexes I, III, IV and V. Nuclear genes 
encode the remaining 75 structural proteins of the OXPHOS (1, 2). Human mitochondria 
number per cell varies 
m.3243A>G mutation
The acronym MELAS was first used in 1984 by Pavlakis et al. to describe a group of 
patients with Mitochondrial myopathy, Encephalopathy, Lactic Acidosis and Stroke-like 
episodes (3). In 1990 the Adenine to Guanine transition at position 3243 of mitochondrial 
DNA (m.3243A>G) in the MT-TL1 gene encoding tRNALEU(UUR) was found as the molecular 
basis for this disease (4, 5). The m.3243A>G mutation in the MT-TL1 gene is the most 
common cause of MELAS syndrome, therefore the mutation is also known as the MELAS 
mutation. As this particular mutation – in literature still referred to as the MELAS mutation 
– causes many different phenotypes non-mitochondrial experts might get confused and 
draw inappropriate conclusions by searching literature with the term MELAS instead of 
m.3243A>G or alternative descriptions. This is exemplified by the fact that the mutation 
is associated also with diseases and conditions like maternally inherited diabetes deafness 
(MIDD) (6), hypertrophic cardiomyopathy (7), macular dystrophy (8), focal segmental 
glomerulosclerosis (FSGS) (9), chronic progressive external ophthalmoplegia (CPEO) 
(10), gastrointestinal involvement (11), increased risk of obstetric complications (12), and 
oligosymptomatic variants of the acronym MELAS (13). 
Renal involvement in m.3243A>G carriers 
Renal involvement is often seen in patients carrying the m.3243A>G mutation. In children 
renal involvement is seen in up to 50% of the patients. Proximal tubular dysfunction, 
including Fanconi Syndrome, is the most frequent clinical and pathological finding in 
biopsies (14). In general, renal disease is part of a severe multi-organ disease in children 
with the m.3243A>G mutation, often with a poor prognosis (15). In adults, approximately 
30% of the m.3243A>G mutation carriers have renal involvement (16). The course of renal 
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involvement varies from mild proteinuria to end-stage renal disease (ESRD) requiring 
renal replacement therapy. Pathological findings correspond with focal segmental 
glomerulosclerosis (FSGS) in about 79% of the patients (17). Other findings are tubular 
dysfunction and severe hyaline changes within cytoplasm of smooth muscle cells of afferent 
arterioles and small arteries (17, 18).
Two interesting hypotheses have been described about the pathophysiology of 
the development of renal disease in patients with mitochondrial disease. First the role 
of podocytes (17, 19, 20). These are terminally differentiated cells that are not able 
to segregate mutant mtDNA between daughter cells so they are unable to undergo 
regenerative proliferation in response to cell loss. The second hypothesis suggests 
vascular changes may contribute to the development of FSGS. The damaged vessel wall 
is characterized by hyaline changes in the cytoplasm of smooth muscle cells in afferent 
arterioles and small arteries showing signs of necrosis and apoptosis. In the end vascular 
damage results in loss of renal autoregulation (18). Dysfunction of mitochondria in smooth 
muscle and vascular endothelial cells might cause early vascular damage (9). 
When renal disease occurs, co morbidity includes (sensorineural) hearing loss, 
cardiomyopathy and diabetes mellitus. In previous literature patients were misdiagnosed 
with Alport Syndrome, although they did not have hematuria (21). In patients with the 
m.3243A>G mutation steroid treatment for proteinuria or nephrotic syndrome is ineffective 
and may induce or progress the development of myopathy and diabetes (9, 17, 22). This 
may be due to the fact that symptoms are caused by mitochondrial alterations and nephron 
loss of vascular origin. After a period of time some patients require renal replacement 
therapy. So far only thirteen cases of patients carrying the m.3243A>G mutation that 
received a kidney transplant have been described (17, 18, 21, 23-25). In this article we 
describe five patients from our Nijmegen cohort of carriers of the m.3243A>G mutation 
who received a kidney transplant, with special attention for the follow-up. Secondly we 
review the patients in previously reported case-reports who received a kidney transplant. 
Finally, we discuss the effects and possible side effects of a kidney transplantation in 
these patients. 
 
Methods
Patients
In the Radboud Center for Mitochondrial Medicine, patients harboring the m.3243A>G 
mutation that underwent kidney transplantation were identified. The mitochondrial 
diagnoses were confirmed by DNA-analysis using blood and urine samples. Five unrelated 
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adult patients received a kidney transplant. We describe their cases using information 
from their medical records. 
Mutation analysis and quantification of heteroplasmy levels
Heteroplasmy levels were determined in urinary epithelial cells (UEC) in all participants 
using PyrosequencingTM technology (Pyrosequencing, Uppsala, Sweden) as earlier 
described by Lowik et al. (9). The pyrosequence reaction of the m.3243A>G mutation 
had a precision of 1.5% and the mutation was detected from a heteroplasmy level of 5% 
and beyond (26).
Literature research 
The search for available literature on kidney transplantation in patients with the m.3243A>G 
mutation was performed using online databases (Pubmed, Cochrane, Web of Science). 
Using the following keywords MELAS, MIDD, Renal Transplantation, Kidney Transplantation, 
A3243G, m.3243A>G mutation, Renal Insufficiency, Chronic Kidney Disease. We also 
included MESH-terms if possible. Additional relevant articles were found using the 
references from the retrieved articles.
Results
1. Case reports 
Case 1
The first patient is a currently 47-year old female, who first presented with renal symptoms 
during pregnancy at the age of 31yrs. A caesarean section was performed due to signs of 
preeclampsia and fetal distress at 27 weeks amenorrhea. Simultaneously she was diagnosed 
with nephrotic syndrome. Renal biopsy showed FSGS. The nephrotic syndrome was treated 
with prednisone, cyclophosphamide and plasmapheresis, without any improvement. Four 
years later, the patient was diagnosed with mitochondrial disease due to the m.3243A>G 
mutation, heteroplasmy level in leucocytes 25%. She developed diabetes, possibly 
provoked by the high doses of prednisone. Hemodialysis was started at age 35. Three 
years later the patient received a kidney transplant from a postmortem donor. Afterwards 
she showed no signs of rejection or side effects due to the immunosuppressive medication. 
Shortly after transplantation the diabetes became persistent and was hard to regulate 
properly. Besides the renal complications of the m.3243A>G mutation the patient also 
suffers from minor perceptive hearing loss, maculopathy, severe hypercholesterolemia 
with intolerance for statins, and possibly related sensorimotor axonal polyneuropathy. 
Recently she developed hypertrophic cardiomyopathy. Eight years after transplantation 
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kidney function is still stable without any signs of proteinuria. For immunosuppressive 
therapy she uses prednisone and mycophenolate mofetil.
Case 2 
The second case is a now 48-year old male who first presented with proteinuria at the age 
of 25 years. Seven years later the proteinuria deteriorated and the patients’ creatinine 
level increased leading to renal failure. Biopsy was consistent with FSGS. He developed 
diabetes, which was difficult to manage. At age 36 the patient received a kidney transplant 
from his HLA-matched brother. One year post transplantation the m.3243A>G mutation 
was detected; heteroplasmy level in leucocytes 25%. After transplantation and using 
high doses of prednisone, the patients’ diabetes became insulin-dependent and was 
even more difficult to manage. Six years after transplantation he was diagnosed with 
moderate perceptive hearing loss and started using hearing aids. In the same period the 
ophthalmologist found mild cataract and retina pigment epithelial alterations, but no signs 
of diabetic retinopathy. Ten years after transplantation the patient is still using cyclosporine 
and prednisone. He has left ventricle hypertrophy and obstructive sleep apnea. His kidney 
function is stable without any signs of proteinuria.
Case 3
The third patient is a 41-year old female. She developed pancreatitis at young age with 
recurrent episodes. Kidney dysfunction became apparent at the age of 17. Kidney biopsy 
showed signs of chronic ischemia. At age 20 the patient was diagnosed with mitochondrial 
disease based on a complex I enzyme deficiency in muscle, at that time genetic investigation 
was not performed. At age 27 the patient was diagnosed with ESRD. Later that year, at 
age 28, she received a kidney transplant from a post mortem, heart beating donor. Before 
leaving the hospital the renal function was normal and there was no sign of proteinuria. 
Two years after transplantation cyclosporine was stopped, without complications. She 
is still using prednisone and mycophenolate mofetil as immunosuppressant. Four years 
after transplantation the patient started to develop non-insulin dependent diabetes, but 
it was not until eight years post transplantation that mtDNA-investigation confirmed the 
m.3243A>G mutation at the age of 36, heteroplasmy level in leucocytes 35%. The patient’s 
mother and sister were also diagnosed with the m.3243A>G mutation.
Case 4
The fourth patient is a 57-year old female. As a child the patient was treated for epilepsy 
until she was 10 years old. At the age of 31 and 33 years the patient gave birth to two 
children. During both pregnancies she suffered from HELLP (hemolysis, elevated liver 
enzymes and low platelets)-syndrome. At age 40 years proteinuria was detected (2.2 
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gram/L). The patient also developed sensorineural hearing loss and started to use hearing 
aids. In the same year she also developed diabetes mellitus, which was treated with oral 
medication at first. At the age of 41 years renal failure, proteinuria and hypertension 
were present. Kidney biopsy three years later showed an IgA-nephropathy, and no signs 
of Alports disease. At the age of 49 years the renal failure and proteinuria were treated 
with prednisone, but did not improve necessitating peritoneal dialysis. Simultaneously 
the patients’ diabetes became insulin-dependent. At the age of 52 years the patient 
received a kidney transplant from a post mortem, heart beating donor. Follow-up after two 
years showed severe left ventricle hypertrophy and diastolic heart failure that remained 
stable four years after transplantation. Four years post transplantation the m.3243A>G 
mutation was found, heteroplasmy level in leucocytes 6%. In this same year the patient 
was diagnosed with central scotoma causing visual problems. Currently the kidney 
function is stable with mild microalbuminuria. She is using prednisone and tacrolimus as 
immunosuppressant. 
Case 5
The fifth patient is a 43-year old female who was diagnosed with diabetes at the age of 
13 years. At age 21 her first pregnancy was complicated by an intrauterine fetal death. 
At age 23 a healthy daughter was born with a planned section caesarean. She developed 
diabetic retinopathy and nephropathy at the age of 28 and 29 years, respectively. The 
patient suffered from hypertrophic cardiomyopathy, leading to heart failure at age 35. 
Two years later hemodialysis was started. In the same year the patient received a kidney 
transplant from her brother complicated by a non-STEMI acute coronary syndrome three 
days later. One month later creatinine levels were increasing showing signs of transplant 
rejection for which treatment with intravenous methylprednisolone was started. During 
the treatment a second acute coronary syndrome occurred. Later she was admitted to the 
hospital because of a sepsis caused by a Staphylococcus Aureus infection. After treatment 
with flucoxacillin, creatinine levels increased and treatment with methylprednisolone was 
started again. Kidney function was not improving, for that reason she was treated with 
anti-thymocyte globulin (ATG) four times. During this treatment the patient suffered from 
a third acute coronary syndrome. A year after the ATG treatment the immunosuppressive 
treatment was switched from triple therapy to sirolimus and azathioprine. At the age of 40 
years, 3 years after transplantation, the m.3243A>G mutation was found in this patient as 
part of a family survey, after her niece was diagnosed with the same mutation, heteroplasmy 
level in leucocytes 16%. Further genetic investigation within the family showed that the 
patients’ sister and mother of the niece also carry the m.3243A>G mutation. Almost 5 
years after transplantation the patient has a stable moderate kidney function (MDRD 17 
ml/min/1.73m2) without any signs of proteinuria.
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2. Summary of characteristics of all patients 
In the literature we found six articles describing cases of patients with the m.3243A>G 
mutation who received a kidney transplantation. The characteristics of our patients and 
the previously reported cases are summarized in Table 11.1. All patients successfully 
received a kidney transplantation. We found that proteinuria with or without renal failure 
was the first clinical presentation of renal involvement in thirteen out of eighteen (72%) 
patients. FSGS (Focal Segmental Glomerulosclerosis) was found in nine out of thirteen 
(69%) biopsies. Sixteen out of eighteen (89%) patients developed hearing loss. All patients 
were diagnosed with diabetes mellitus of whom eight (44%) developed the disease after 
transplantation. All patients from whom follow-up data was reported (11/18) had a stable 
kidney function at six months to thirteen years of follow-up.
Discussion
We describe five not yet reported cases of patients with the m.3243A>G mutation who 
received a kidney transplant. Secondly we have summarized thirteen cases of patients with 
the same mitochondrial mutation described in the literature so far, providing an overview 
of eighteen post kidney transplantation patients carrying the m.3243A>G mutation. While 
mitochondrial disease patients may have a shortened life expectancy due to progression 
of their underlying disease, successful kidney transplantation, when feasible, allows for 
additional years of likely functional survival. 
Clinical phenotype and follow-up
MELAS syndrome is one of the possible phenotypic presentations of the m.3243A>G 
mutation in the MT-TL1 gene and probably one of the most acknowledged. However, in 
previous reports about the phenotypic expressions in carriers of the m.3243A>G mutation, 
MELAS syndrome represents a small proportion of the clinical spectrum (13, 27). Although 
all 18 patients described in this article carried the m.3243A>G mutation, none of them had 
the typical phenotypic presentation of MELAS syndrome with stroke-like episodes. The 
phenotypic spectrum of the 18 patients described in this article is clinically heterogeneous. 
In 72% of them proteinuria, with or without renal failure, was the first renal symptom. All 
patients developed diabetes, and nearly all developed hearing loss (combined known as 
the mitochondrial syndrome MIDD). Other symptoms that were present include retinal 
dystrophy, cardiomyopathy and myopathy. Three out of fourteen women had obstetric 
complications, including preeclampsia and fetal death. In these cases, the obstetric 
complications were the first sign of a mitochondrial disease, especially the first presentation 
of renal involvement in the form of proteinuria and hypertension. In general, the classical 
MELAS phenotype is associated with a poor outcome (28). This could be seen as reason 
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to withhold these patients from a kidney transplant if they develop ESRD. However, in 
this study we report on eighteen cases of patients carrying the m.3243A>G mutation, 
with a non-MELAS phenotype, with an average follow-up of 5.6 (range: 0.5–13) years 
after transplantation. This indicates that in a selection of patients carrying the m.3243A>G 
mutation kidney transplantation is feasible. 
Biopsy
Nine out of thirteen (69%) patient’s kidney biopsies showed FSGS. Diabetic glomerulopathy 
was not found at all. In the article of Guery et al., FSGS was diagnosed in 79% of the 
biopsies. Hirano et al detected FSGS in nine out of sixteen (56%) patients. But the 
spectrum of possible lesions is more variable, including tubulo-interstitial nephropathy, 
bilateral enlarged cystic kidneys (17), chronic interstitial nephritis (29), IgA-nephropathy 
(30), neoplasm (22), cystic renal disease (31) and chronic ischemia in one patient from our 
own case series.
Related donors
Family members as a potential donor should be up for discussion. Two of our patients 
(cases 2 and 5) received a kidney transplantation from their brother because both patients 
were only diagnosed with the m.3243A>G mutation several years after transplantation. It is 
recommended to be aware of the diagnosis mitochondrial disease in case of multisystemic 
problems, like renal disease, cardiac failure, diabetes and deafness. The presence of the 
mutation in potential related donor candidates should be ruled out before transplantation, 
as the risk of transmission of the mutation in the maternal lineage is very high (26). 
Anesthetics during transplantation
A recently published study summarized important considerations of the systematic 
effects of MELAS syndrome for anesthetics during a kidney transplantation surgery (25). 
They recommend standard evaluation of electrolyte abnormalities and the possible 
onset of diabetes as these are common co-morbidities. Because of the increased risk 
for cardiomyopathy and conduction abnormalities they recommend a preoperative 
electrocardiogram and a low threshold for an echocardiogram. Neuromuscular blockade 
(such as propofol) should be administered carefully, because reports have described 
prolonged effects of neuromuscular blocking agents in patients with mitochondrial 
diseases (32). During surgery patients may be at increased risk for malignant hyperthermia. 
Administration of glucose-containing fluids is also recommended to prevent hypoglycemic 
and catabolic episodes in response to the stress of surgery.
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Diabetes
It is not the transplantation itself but the post-transplant therapy with high doses of 
prednisone that may provoke or progress the development of diabetes in these patients. All 
eighteen patients were diagnosed with diabetes of whom eight (44%) developed diabetes 
following transplantation. The non-insulin-dependent diabetes in four patients became 
insulin dependent after transplantation. This results in a current use of insulin in twelve out of 
eighteen (67%) patients. It should be noted that treatment with metformin is contra-indicated 
in patients with mitochondrial disease, because of the elevated risk for lactic acidosis.
Recognition of m.3243A>G mutation carriers
Studies have suggested that renal involvement might be the first sign of mitochondrial 
disease (17, 33). Recognition of the disease is difficult when only renal symptoms are 
present. Other symptoms as deafness and diabetes may lead to the proper diagnosis. 
However, in some cases, they can be misleading, for example in case of the Alport 
Syndrome. It is important to recognize the possible mitochondrial origin of renal failure 
in a patient. Possible features that may direct to a mitochondrial origin of proteinuria 
and renal failure are; unresponsiveness of nephrotic syndrome to steroid therapy, steroid 
therapy being complicated by diabetes or the presence of other symptoms frequently seen 
in carriers of the m.3243A>G mutation. Besides neuromuscular symptoms as myopathy, 
dementia, epilepsy and migraines these also include diabetes, deafness, cardiomyopathy, 
retinal dystrophy and presence of these symptoms in (maternal) family members. Either 
alone or combined, these symptoms should make every doctor aware of the possibility of 
the existence of a mitochondrial disease. In general, we would like to recommend a liberal 
policy in determining the m.3243A>G mutation in patients with renal failure, in combination 
with hearing problems, diabetes, neurological involvement and/or cardiac failure.
Conclusion
Renal involvement in carriers of the m.3243A>G mutation most commonly leads to 
proteinuria and FSGS and may lead to ESRD. Proper recognition of the mitochondrial 
origin of the renal disease in all patients is important for adequate treatment selection 
and suitable supportive care. This case series and review of the literature on long term 
follow-up after kidney transplantation, shows it is feasible for carriers of the m.3243A>G 
mutation, with a non-MELAS phenotype, to be considered for kidney transplantation. These 
patients should not be excluded from transplant solely for their mitochondrial diagnosis. 
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Abstract
Introduction: The mitochondrial DNA m.3243A>G mutation is the most prevalent 
mutation causing mitochondrial disease in adult patients. Aside some case reports, there 
are no studies on obstetric complications in a cohort of m.3243A>G carriers. We aimed 
to identify the prevalence of obstetric complications in a cohort of women carrying the 
m.3243A>G mutation. 
Methods: All female carriers of the m.3243A>G mutation known from our previous national 
inventory were sent a questionnaire regarding their obstetric history. Data were compared 
to national references. Data from the national inventory, including NMDAS (disease severity) 
scores and heteroplasmy levels in urinary epithelial cells UEC were used to stratify women. 
Results: Sixty women participated, mean age 47 years (range 20–70), mean NMDAS was 
14.6 (range 0–46), mean heteroplasmy percentage in UEC 19.9% (range 5–85%). Ninety-
eight pregnancies in 46 women were reported. Twenty-three (25.3%) had a premature 
delivery and five of them (5.5%) had a gestation of ≤32 weeks, eleven of the women (12%) 
suffered from preeclampsia. No different heteroplasmy level was found in the women 
with preeclampsia. Nine pregnancies (11%) were complicated by gestational diabetes. 
Discussion: Obstetric complications occur frequent in carriers of the m.3243A>G mutation. 
Proper guidance during pregnancies and early detection of possible obstetric complica-
tions are needed. As techniques to prevent transmission of mitochondrial mutations are 
studied it is important to know the possible complications patients may experience from 
the ensuing pregnancy.
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Introduction
Mitochondria
Mitochondria are responsible for production of adenosine triphosphate (ATP), through 
oxidative phosphorylation (OXPHOS). OXPHOS dysfunction can result from mutations in 
either nuclear DNA (nDNA) or mitochondrial DNA (mtDNA). The incidence of congenital 
mitochondrial disorders based on an OXPHOS defect is at least 1:8500 of all live births (1).
Two important features of mitochondrial mutations are; A) maternal inheritance, it can 
be assumed that all relatives from the maternal line are (dormant) carriers of the mutation 
(2). And B) heteroplasmy, human cells contain over 100–1000 mitochondria each, every 
mitochondrion contains 1–10 copies of mtDNA. When all mtDNA copies are mutated, 
there is a homoplasmic mutation. When however not all mtDNA copies are mutated, there 
is a variation in mutation load and the mutation is called heteroplasmic (3). 
m.3243A>G
The m.3243A>G mutation in the MT-TL1 gene, encoding for the mitochondrial tRNALeu(UUR), 
is the most common cause of MELAS syndrome, therefore the mutation is also known as 
the MELAS mutation. Later, more and more phenotypic expressions of the m.3243A>G 
mutation were found, including maternally inherited diabetes deafness (MIDD) (4), 
hypertrophic cardiomyopathy(5), macular dystrophy (6), focal segmental glomeruloslerosis 
(FSGS) (7), myoclonic epilepsy with ragged-red fibers (MERRF) (8), chronic progressive 
external ophthalmoplegia (9) and oligo-symptomatic variants of the acronym MELAS (10). 
Epidemiologic studies show an m.3243A>G mutation prevalence of 7.59/100,000 in the 
population of North-East England (11), 16.3/100,000 in the population of Northern Finland 
(12) and up to 236/100,000 in the population of Australia (13). 
Obstetrics in m.3243A>G carriers
It has been reported in several case reports, that women with the m.3243A>G mutation 
may experience complications in pregnancy (14-16). Annaiah et al. described a woman with 
the m.3243A>G mutation with cardiomyopathy, diabetes mellitus and myopathy presenting 
at 25+3 weeks of gestation with ruptured membranes leading to intrauterine death (14). 
Another case of a primigravid women with preeclampsia carrying the m.3243A>G mutation 
was reported by Moriarty (15).
In 1999 a case was published of a women with MELAS, who suffered from proximal 
muscle weakness, demyelinating polyneuropathy and autonomic instability. At 36 
weeks, labor was induced because of worsened symptoms and arrhythmias. Four former 
pregnancies were complicated by gestational diabetes, preterm labor and recurrent 
urinary tract infections (16).
Chapter 12
208
Preeclampsia is a pregnancy related disease occurring after 20 weeks’ gestation. The 
prevalence of preeclampsia worldwide is 5–8% (17) and it is the most common cause of 
death for women in the western world (18). The symptoms vary widely but hypertension 
and proteinuria are criteria for the diagnosis (19). Preeclampsia can progress to hemolysis 
elevated liver enzymes and low platelets (HELPP) syndrome in which hypoalbuminemia, 
thrombocytopenia and abnormal liver functions occur. Symptomatic management is the 
only treatment that can be offered. Premature delivery is a frequent result of preeclampsia. 
The pathogenesis of preeclampsia is not fully understood. However, it is known 
that reduced perfusion of the placenta leads to ischemia and reperfusion damage (20). 
This results in oxidative stress in the placenta which causes production of inflammation 
mediators. Finally this leads to generalised endothelium activation, vasoconstriction, 
inflammation and activation of coagulation (21, 22).
Aside from the previous mentioned case reports, there are no studies on obstetric 
complications in m.3243A>G carriers (14-16). Better knowledge of obstetric complications 
in these carriers is required for both patients and physicians to improve the obstetric 
outcome of these women. As techniques like pre-implantation genetic diagnosis (PGD) 
and mitochondrial donation to prevent transmission of mitochondrial mutations are a 
topic of many studies (23-25) it is eminent to know the possible complications women 
may experience from the subsequent pregnancy. In this study the prevalence of obstetric 
complications in a cohort of women carrying the m.3243A>G mutation was investigated.
 
Methods
Patients
All probands are patients of the Nijmegen Center for Mitochondrial Disorders at Radboud 
University Nijmegen Medical Centre, diagnosed with the m.3243A>G mutation in muscle 
or blood. All patients participated in our cohort study for the m.3243A>G mutation (26). 
This study was approved by the ethics committee of the Nijmegen-Arnhem region. Written 
informed consent according to the Helsinki agreement was obtained from all patients.
Mutation analysis
Heteroplasmy levels were determined in urinary epithelial cells (UEC) in all participants 
using PyrosequencingTM technology (Pyrosequencing, Uppsala, Sweden) as earlier 
described by (7). The pyrosequence reaction of the m.3234A>G mutation had a precision 
of 1.5%, and the mutation was detected from a heteroplasmy level of 5% (2). 
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Obstetric evaluation
All participants received a questionnaire about their pregnancies. In this questionnaire 
all women were questioned on general demographics and several aspects of obstetric 
health. General obstetric questions included child wish, number of pregnancies, number 
of abortions, infertility and subfertility, use of assisted reproductive technology and pre-
implantation genetic diagnosis. Additional questions were asked to women who had 
been pregnant, these questions included the obstetric domain; number of pregnancies, 
complications during pregnancy (with particular attention to hypertension, preeclampsia 
and gestational diabetes), use of medications during pregnancy, gestational age and 
mode of delivery. And the neonatal domain; Apgar score, birth weight, neonatal hospital 
admissions and congenital defects. In addition, informed consent was obtained from 
all participant to access pregnancy related information at their midwife, obstetrician or 
family doctor. 
General symptoms
All patients were scored using the Newcastle Mitochondrial Disease Adult Scale (NMDAS) 
(27). The NMDAS constitutes a validated method to monitor the clinical expression of 
mitochondrial disease and to follow-up the course of disease in time. The NMDAS consists 
of the following four sections. 1) Current function, gives insight into the general functioning 
of patients in past four weeks. 2) System-specific involvement, uses a clinical history 
supplemented by specific information to gain insight in the functioning of individual organ-
systems. 3) Current clinical assessment, a general and neurological clinical examination, 
gives insight in the current functional status of the patient. 4) Quality of life, we used a 
Dutch translation of the Short Form-12 version 2 (SF-12v2) quality of life test. 
Statistics
We used descriptive statistics to present the heteroplasmy levels in our patients. Averages 
are presented with their standard deviation. A median is presented with interquartile 
ranges (IQR) Pearson’s correlation coefficient was used to evaluate the relationship 
between the heteroplasmy levels in UEC, the scores on the NMDAS scale, age and the 
obstetric findings. Students t-test was used to compare NMDAS score and heteroplasmy 
levels between term and premature births, and between preeclamptic pregnancies and 
non preeclamptic pregnancies.
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Results
General patient characteristics 
Sixty of 85 (71%) women completed the survey (Table 12.1). At the date of questioning the 
mean age of these women was 47 years (range 20–70). The time between the pregnancy 
and completion of the survey was 25 years (range 1–63 years). The mean NMDAS of these 
women was 14.6 (range 0–46) and the mean heteroplasmy percentage in UEC was 41.0% 
(range 5–85%), both at the moment of questioning. Hearing loss was present in 38 women 
(63%), diabetes was present in 27 women (45%) of which 18 (66%) are dependent on 
insulin. Twenty-three (38%) had a MIDD phenotype. Myopathy was present in 27 women 
(45%) and mild ataxia was present in 26 women (26%), there were no women in the cohort 
with the classic MELAS phenotype. 
Table 12.1: Cohort patients’ characteristics
General patient characteristics 
Questionnaires send 85 
Participants (response rate) 60 (71%) 
Mean age (range) 47 (20–70) 
Mean NMDAS (range) 14.6 (0–46) 
Mean heteroplasmy UEC (range) 41.0% (5–85%) 
Signs and symptoms m.3243A>G mutation 
Hearing loss 38 (63%) 
Diabetes / insulin treatment 27 (45%) / 18 (66%) 
Myopathy 27 (45%) 
Mild ataxia 26 (43%) 
MIDD fenotype 27 (45%) 
MELAS fenotype 0 (0%) 
Pregnancy characteristics 
Women with past pregnancy 46 
Total pregnancies; per women 98
Mean pregnancies per women (range) 2 (1–7)
Mean gestational duration in weeks (range) 38+4 (27+5– 42) 
Premature deliveries (<37 wks) 23 (25.3%) 
Extreme premature deliveries (<32 wks) 5 (5.5%) 
Obstetric results 
Forty-six (75%) women had had a pregnancy. Mean heteroplasmy level in UEC of these 
women was 36% (range 5–85%) Altogether these women had 96 cumulative pregnancies 
with a mean of two pregnancies (range 1–7 pregnancies). Of these pregnancies two were 
twin pregnancies and one triplet pregnancy. The mean age at labor of the women was 
27±6 years (range: 18–41 years). Furthermore 15 of 46 women had in total 21 miscarriages. 
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Of the 96 pregnancies 18 were verified by letters of the midwife, gynecologist or general 
practitioner.
Pregnancy outcome
The mean duration of gestation of the women was 38 4/7 ±3 weeks (range, 27 5/7–42 
weeks). Twenty-three (25.3%, 95% CI: 16.37–34.23) had a premature delivery (AD ≤37 
weeks) and of those five (5.5%, 95% CI: 0.82–10.18) had an extreme premature delivery 
(gestation less than 32 weeks). In the general Dutch population preterm birth occurs 
in 8,1% of the pregnancies (95% CI=7.97-8.23) and extreme premature birth in 1.5% 
(95% CI: 1.44-1.56) (28). Woman who had a premature delivery had a significant higher 
heteroplasmy level in UEC (Figure 12.1). 
In the 23 women with a premature delivery, 12 deliveries (52%) were artificially 
induced, while 11 (48%) started spontaneous. In the five cases with extreme premature 
delivery 4 (80%) were artificially induced while only 1 delivery (20%) started spontaneous. 
All of the inductions happened for fetal indications. In the group of the prematures 18 
(78%) were admitted in the hospital after birth. In the group of the extremely prematures 
all children were admitted. 
Overall the children had a good start. APGAR scores were reported from 39 births, 
an average APGAR score of 8.4 was reported. Three children had an APGAR score below 
6 after 5 minutes. From 40 births there were no APGAR scores available but a good start 
was reported. Of the remaining births we were unable to get data regarding the start of 
the children.  
Figure 12.1: Heteroplasmy levels (urine epithelial cells; UEC) were significantly higher in the 
mothers of children born extremely premature compared to children born a term.
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Eleven of 84 children (13%) had a birth weight below p5. In girls, 3/40 (7.5%) had a 
birth weight below p5, in boys this number was 8/44(18%). 
In total 39% of the babies were admitted after birth. The most common reason 
for this was low birth weight and observation for hypoglycemia. At birth, one baby had 
hemiplegia of unknown origin, without additional congenital abnormalities. Four fetal 
deaths occurred. One of these was an intra-uterine death at an unknown gestation in a 
woman with preeclampsia. Another fetus showed no heartbeat at 31 weeks of gestation. 
The other two fetal deaths occurred during a triplet pregnancy. One fetus died at 12 weeks 
of gestation due to total detachment of the placenta, the other fetus died during delivery 
at 34 4/7 weeks. This woman also suffered from preeclampsia. 
In general in 32% of the pregnancies delivery was artificially induced. For the first 
pregnancy this was even 50%. Furthermore, 15 of 95 children (15%) were born through 
cesarean section. Another 9 (9%) needed assisted delivery through forceps- or ventouse 
birth. In all cases artificial labor was initiated because of fetal indications. Maternal 
indications were not mentioned.
Preeclampsia 
During their pregnancies 11 of the women (12%; 95% CI: 5.2%–18.8%) suffered from 
preeclampsia (Table 12.2). In eight of the women (20%; 95% CI 7.4%–32.6%) preeclampsia 
occurred in their first pregnancy, while only three (6.3%; 95% CI 0%–13.1%) were affected 
in subsequent pregnancies. Of the nullipara women in the cohort who experienced 
preeclampsia 87.5% (n=7) had a second pregnancy, none of these pregnancies was 
complicated by preeclampsia. Data concerning the time of onset of preeclampsia were 
available for 6 women, ranging from 27 to 38 weeks, with a median of 32.5 weeks (Table 
12.1). 
The mean gestational duration of pregnancies complicated by preeclampsia was 35 
6/7 ±4 weeks (range 27 6/7–42 weeks). 
No significant differences in heteroplasmy levels or NMDAS scores were found 
between women with, or without preeclampsia.
Of the women with a history of preeclampsia 45% (5/11) is suffering from hypertension 
at this moment. Three patients are treated with ace-inhibitors for microalbuminuria. Only 
3 of these 11 women have no symptoms of hypertension nor microalbuminuria. 
Gestational diabetes
In our study, in nine of 85 pregnancies (11%, 95% CI: 2.92%–15.02%) women suffered 
from gestational diabetes (Table 12.3). None of these women had diabetes before their 
pregnancy. Three women had two pregnancies that were complicated by gestational 
diabetes. In the pregnancies with gestational diabetes none of the women suffered from 
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preeclampsia. In 7 pregnancies insulin treatment was needed. In eight out of these nine 
cases (88%), children needed to be admitted in the hospital after birth. In six cases this was 
necessary to monitor glucose levels. In three pregnancies the child was born premature. 
All six women developed diabetes mellitus after the pregnancies, five require insulin 
therapy, one is treated with oral anti-diabetic medication. 
Ethics
In this cohort of 60 women, six women (10%) with a child wish, consciously turned away 
from pregnancy. In all cases this decision was made on a combination of reasons. Reported 
arguments for the decision not to get pregnant were heredity of the mutation and health 
reasons of the woman, both reported by all six women. Other reasons include the burden 
of the children to live with a mother that has a progressive disease and a resent to complex 
fertility procedures such as PGD. One of the women adopted two children.
Discussion
Obstetric complications in carriers of the m.3243A>G mutations include preeclampsia, 
gestational diabetes, prematurity and dysmaturity. No cohort studies regarding obstetric 
risks in women with the m.3243A>G mutation have been performed, however several case 
reports have been reported. It has to be noted that in this cohort of m.3243A>G carriers 
the women who participated in this survey on obstetric complications have a relatively 
mild phenotype; hearing loss (63%), diabetes (45%), MIDD phenotype (38%). Women in 
our cohort with the classic MELAS syndrome did not participate, as compared to previous 
cohort studies (26, 29). So, however obstetric complications do occur significantly more 
frequent in this cohort compared to healthy women, this even may be an underestimation 
of the obstetric complications in all carriers of the m.3243A>G mutation. Previous case 
reports show several complications or worsening of symptoms during pregnancy in 
women carrying the m.3243A>G mutation. These symptoms include gestational diabetes, 
worsening myopathy, preterm labor, preeclampsia and intra-uterine death. In our cohort 
of 60 women all of these have also been described, which shows the big spectrum of 
complications that can occur in women carrying the m.3243A>G mutation. This stresses 
the importance of a cohort study to identify obstetric complications as presented in this 
study, but also stresses the importance of in depth research to the pathophysiology of 
obstetric complications in mitochondrial disease. Most importantly this study demonstrates 
that women with mitochondrial disease should be very well monitored during pregnancy 
to early detect possible obstetric complications. 
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Preeclampsia and mitochondrial disease
With a prevalence of 12% (20% in nullipara and 6.3% in multipara), preeclampsia is more 
prevalent in carriers of the m.3243A>G mutation, compared to the general population, 
in which preeclampsia occurs in 3% to 7% in nullipara pregnancies and in 1% to 3% in 
multipara pregnancies (30). The presence of preeclampsia seems not to be related the level 
of heteroplasmy. Evidence indicating that preeclampsia is linked to mitochondrial dysfunction 
is growing. Already in 1989 Torbergsen et al. (31) noticed a high incidence of preeclampsia 
in a family with mitochondrial dysfunction. Defects of the mitochondria are especially 
notable in tissues which claim a lot of energy. During pregnancy, the placenta is such a 
high demanding tissue (32). It is reasonable that particularly in this high energy demanding 
period mitochondria are an important source of oxidative stress. Several studies have found 
differences in proteins in placental mitochondria of women suffering from preeclampsia. The 
release of cytochrome c from the mitochondria is significantly increased and is associated 
with active caspase 3 increase in a preeclamptic placenta (33). Furthermore the mitochondrial 
antioxidant protein peroxredoxin III (PRDX3) was shown to be up regulated in preeclampsia 
(34). Also, evidence for accumulated mitochondrial stress was provided, demonstrated by 
increased stress markers and decreased antioxidants at preeclamptic subjects (35). 
Recently, morphological data demonstrating degenerative and apoptotic changes in 
the mitochondria of preeclamptic placentae have been demonstrated. In these placentae 
22 up regulated and 4 down regulated proteins were found compared with normotensive 
placentae (36). 
All these studies together suggest preeclampsia in carriers of the m.3243A>G 
mutation is a fundamental disorder of placental mitochondria. Although this could be 
an explanation for the higher prevalence of preeclampsia in women whose mitochondria 
suffer already from a deficit, we have not been able to study this hypothesis within this 
retrospective cohort study. A prospective study will be needed to confirm this hypothesis. 
Diabetes 
Gestational diabetes is every form of hyperglycemia discovered during pregnancy, not 
dependent on if it is dissolving or sustaining after pregnancy. It is caused by increased 
insulin resistance mediated by placental hormones like cortisone and progesterone and 
to a lesser extent increased fat deposits in pregnancy (37). Increased insulin resistance is a 
physiological finding in the second trimester. However, women with gestational diabetes 
have an insulin resistance which they cannot compensate by increased β-cell production 
in the pancreas. 
In our study a relatively high amount of women (11%; 95% CI: 2.92–15.02%) suffered 
from gestational diabetes in comparison to an estimation of the Dutch prevalence (2%–5%) 
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(38). Diabetes mellitus is a common finding in patients with the m.3243A>G mutation (26). 
This has been attributed to insufficient insulin secretion by pancreatic β-cells, which strongly 
depends on intact mitochondrial metabolism (39). Another contributing factor is insulin 
resistance due to impairment of muscle mitochondrial fitness (40). The vulnerability to 
obtain diabetes could explain the relatively high prevalence of diabetes during pregnancy 
in our cohort of m.3243A>G carriers. 
Women with poor glycemic control during pregnancy are at risk of spontaneous 
abortion, fetal anomalies, macrosomia, fetal growth restriction, prematurity and maternal 
complications (41, 42). Especially since the prevalence of diabetes mellitus is higher in 
people who carry the m.3243A>G mutation, regular monitoring of glucose levels during 
pregnancy is recommended. 
Neonatal outcome
We found a significantly higher heteroplasmy level in women who gave birth to a premature 
child compared to term deliveries. The reason for artificial delivery was in most cases fetal 
stress, most probably caused by diminished placental perfusion. 
As heteroplasmy levels can differ between tissues within a patient, it could be 
possible that the placentae of the women with obstetric complications as prematurity and 
preeclampsia had a higher heteroplasmy level, compared to the heteroplasmy levels in 
UEC. This may be an explanation for the absence of a difference in heteroplasmy levels 
in UEC in women with and without preeclampsia or gestational diabetes. 
The NMDAS scores were obtained at questioning, even if the pregnancy was a long 
time ago, the most recent scores were used. The NMDAS score can change over time, 
so his could explain the lack of difference in these scores. In order to study the effects 
of the m.3243A>G mutation on cellular level in the placenta affecting placental growth 
and development, a prospective study should be performed, studying mitochondrial 
dysfunction in the placenta of a patients carrying the m.3243A>G mutation.
Ethics
Besides the reports of pregnancies and obstetric complications, an interesting and sig-
nificant secondary finding was that 10% (n=6) of our patients reported to have decided 
not to have biological children of their own. Mostly because of the risk of transferring 
the mutation, and thereby the risk to develop an associated disease (MELAS, MIDD, 
etc). But also because of their own reduced health. Pre implantation genetic (PGD) 
diagnosis has been reported in carriers of the m.3243A>G mutation (24). One reported 
PGD procedure has led to the birth of a healthy child (43), another paper reports a child 
with low level of heteroplasmy (44). Five of the women, in our study, that decided not 
to become pregnant were counseled by a PGD expert, they however were advised not 
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to start the procedure because of their own health or they refrained themselves for the 
procedure because of its invasiveness and lack of certainty of a successful outcome. 
We expect that the dilemmas surrounding child wish in carriers of the m.3243A>G mutation 
will be more common problem in the future. All the above mentioned women are young. 
The women that had pregnancies longer ago, were not aware they were harboring a 
potentially disease causing mutation of their mitochondrial DNA, and therefore never had 
to make, and never had the opportunity to make the decisions these younger women 
are facing. 
Limitations
This is a descriptive study and most of the data are self-reported. Although over 70% of 
the subscribed women answered the survey, it could be possible some women who had 
complications did not fill in the survey because of the emotional or psychological stress. 
It is also possible more women who have had complications returned the survey because 
they are more dedicated to the topic.
Conclusion
In this descriptive cohort study, we show a higher incidence of obstetric complications 
as preeclampsia, diabetes and problems concerning fetal outcome in Dutch patients 
carrying the m.3243A>G mutation. Physicians should be aware of the possibly higher 
risks during pregnancy in these patients. A good guidance is important to reassure that 
complications are detected and treated as early as possible. A large group of young 
women decides to have no biological children because of the mode of inheritance of 
the disease. New techniques will be needed to form an opportunity for these women to 
conceive a biological child. 
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Summary 
The aim of this thesis was to expand knowledge of the natural disease course of carriers 
of the m.3243A>G mutation. Extended knowledge of the natural disease course of 
mitochondrial disease is important for patient care, counselling, and is also a prerequisite 
for treatment development for mitochondrial disease in general and for patients with the 
m.3243A>G mutation in particular. 
Following an introductory chapter, this thesis is divided in three main parts; Part I 
general disease involvement, Part II genetics and Part III organ specific disease involvement, 
all emphasizing different aspects of the natural disease course of carriers of the m.3243A>G 
mutation. 
Chapter 1, the introduction, describes a typical case of a family carrying the 
m.3243A>G mutation, followed by an introduction on mitochondrial disease, the 
m.3243>G mutation and an overview of previously reported cohort studies of m.3243A>G 
patients. 
Part I focuses on the general disease involvement. General disease involvement and 
progression of disease was measured using the NMDAS score. This is a validated scoring 
method for patients with mitochondrial disease and provides information on overall disease 
involvement in a quantifiable manner. 
Chapter 2 describes a cohort of 82 carriers of the m.3243A>G mutation. None of 
the included children (n=11) had specific complaints. In adults (n=71), a median NMDAS 
score of 15 (IQR 10–24) was found. The most prevalent symptoms were hearing loss (68%), 
gastro-intestinal problems (59%), exercise intolerance (54%) and glucose intolerance 
(52%). Ten patients had neurological involvement. Heteroplasmy in buccal mucosa had 
the best correlation with the NMDAS in all adults (r=0.437, p<0.001), whereas UEC had 
the strongest correlation with the NMDAS in severely affected patients (r=0.593, p=0.002). 
Heteroplasmy declined significantly with increasing age in all three samples (leucocytes 
r=-0.705 (p<0.001), UEC r=-0.374 (p=0.001), and buccal mucosa r=-0.460 (p<0.001).
The study demonstrates a wide variety of signs and symptoms caused by the mutation, 
MIDD being far more prevalent than MELAS. It confirmed previous studies that of the 
three non-invasively available tissues for testing heteroplasmy UEC are the preferred 
sample to test.
Chapter 3 reports on the 6-year prospective follow-up of the extended cohort, 
including 151 carriers of the m.3243A>G mutation from 61 families. Hundred-twenty-four 
carriers (out of 151) were symptomatic. Four clinical groups were identified: 1) Classical 
MELAS syndrome (n=7), 2) MIDD syndrome (n=60), 3) ‘Other’ (n=57) and 4) Dormant 
Carriers (n=27). A yearly increase of NMDAS score of 0.47 point was measured in the 
total group. Heteroplasmy levels in both leukocytes and UEC were weakly correlated to 
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disease severity. No correlation between heteroplasmy levels and disease progression 
was found if corrected for the different clinical groups. Physical QoL declined with age. 
Most important influencers of QoL decline were: hearing loss, speech problems, exercise 
intolerance, gait instability, psychiatric problems and gastro-intestinal involvement. It was 
concluded that the m.3243A>G mutation causes a slowly progressive disease, with a 
yearly increase of NMDAS score of ~0.5 point. Clinical phenotype is the only influencer 
of disease progression.
Part II focuses on the genetic characteristics of the mutation. The unique mitochondrial 
inheritance of the m.3243A>G mutation was studied and the characteristics of UEC in 
specific were studied.
In Chapter 4, 56 mother-child relations and 82 inter-sibling relations in 34 families 
were studied. A significant correlation between mother and child heteroplasmy levels 
(r=0.679, p<0.001) was found. In mothers with a heteroplasmy level below 25%, 30% of 
their offspring was without detectable mutation, while in mothers with a heteroplasmy 
level of above 25%, 100% of the offspring carried the m.3243A>G mutation. Heteroplasmy 
levels between siblings also correlated (r=0.512, p<0.001), but had limited value because 
of outliers. These new data on inheritance of the m.3243A>G mutation might be of value 
in counseling patients and preventing transmission of the mutation.
Chapter 5 describes three families in which the mutation appeared to occur sporadi-
cally in the index case. The symptomatic carriers presented with a variety of symptoms 
frequently observed in patients harbouring the m.3243A>G mutation. A more severe 
phenotype is seen in the de novo families compared to recent cohort studies, which might 
be due to reporting bias. The observation that de novo m.3243A>G mutations exist is of 
relevance for both the diagnostic procedure and genetic counselling. 
Chapter 6 studies intra-patient variability of UEC heteroplasmy levels. Fifteen 
carriers of the m.3243A>G mutation, collected five urine samples in a 14 days window for 
determination of heteroplasmy levels. In the samples of six patients heteroplasmy levels 
were within a 5% margin. In the samples collected from five patients the margin was >20%. 
The interpretation of a correlation between heteroplasmy levels in urine and disease 
severity can therefore not be reliable. For this reason, heteroplasmy levels in UEC should 
not be used as a prognostic biomarker in these patients.
Part III of this thesis focuses on organ specific involvement of the disease. To obtain 
more knowledge about the phenotypic expressions of the m.3243A>G mutation we 
studied the influence of the disease on several different organ-systems. In comparison to 
general disease involvement studies, the studies regarding specific organ involvement 
achieve much more precision and detail in the pathophysiology of the affected organ. This 
knowledge can be used for a better understanding of the variety of phenotypic expressions 
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of the m.3243A>G mutation, as for the development of organ specific outcome measures 
to monitor disease progression and for future treatment development.
Chapter 7 reports about Quality of Life and fatigue in carriers of the m.3243A>G 
mutation. Seventy-two out of the 122 invited patients completed online standardized 
questionnaires on quality of life, functional impairment, fatigue and mental health as assessed 
by the RAND-SF36, the Sickness Impact Profile (SIP), the Checklist Individual Strength (CIS) 
and the Hospital Anxiety and Depression scale (HADS). Patients reported impaired quality of 
life. Sixty percent showed severe levels of fatigue, and 37% showed clinical relevant mental 
health problems, which was significantly more than healthy norms. These patient reported 
health outcomes were not related to levels of heteroplasmy (r<0.30) and weak (0.30<r<0.50) 
to moderately (0.50<r<0.70) related to clinical manifestations. Patient reported outcomes 
on quality of life, fatigue and mental health problems, are only partly reflected by clinical 
assessments. In order to better support patients, integration of patient reported outcomes, 
alongside symptoms of their disease, in clinical practice is warranted.
Chapter 8 reports on the fear of progression of disease in carriers of the m.3243A>G 
mutation. Carriers answered questionnaires including items on socio-demographics, fear 
of progression, depression, anxiety, and quality of life. Seventy-six (out of 125) carriers 
participated in this study. Results showed that 18% reported high fear of progression. 
Fear of progression was significantly related to all domains of quality of life. Furthermore, 
fear of progression was moderately correlated with feelings of depression and anxiety. A 
substantial part of m.3243A>G mutation carriers experience high levels of fear of progres-
sion which coincide with significantly lower quality of life. Only a small relationship with 
disease characteristics was found. The impact of receiving a diagnosis without therapeutic 
possibilities on fear is important to consider.
In Chapter 9 detailed ophthalmological assessment of 29 carriers of the m.3243A>G 
mutation is described. Twenty-five (86%) had a spectrum of retinal abnormalities, that could 
be classified into four stages. Six patients (21%) had stage 1 retinal dystrophy characterized 
by fine pigmentary abnormalities that were better visible on fundus autofluorescence and 
fluorescein angiography. Stage 2 disease (11 patients; 38%) was characterized by one 
or a few yellowish or mildly pigmented deposits in the early stage. In advanced stage 2 
disease the pigmentary changes encompassed the entire macula and often encircled the 
optic disc. Six patients (21%) had stage 3 retinal dystrophy in which profound chorioretinal 
atrophy was present outside the fovea. Marked loss of visual acuity occurred only in 
stage 4 retinal dystrophy (2 patients, 7%), when the fovea was also affected by profound 
chorioretinal atrophy. The stage of mitochondrial retinal dystrophy significantly correlated 
with age (r=-0.483, p=0.008) and with visual acuity (r=-0.614, p<0.001). There was no 
correlation between the stage of retinal dystrophy and heteroplasmy levels or overall 
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disease involvement. Because of the absence of correlation to overall disease involvement, 
ophthalmological symptoms may be misdiagnosed.
Chapter 10 describes gastrointestinal problems and dysphagia in 92 carriers of the 
m.3243A>G mutation. Gastrointestinal involvement, dysphagia and the risk for malnutri-
tion were scored using the Gastrointestinal Symptoms Questionnaire and The Malnutrition 
Universal Screening Tool. 
Height, weight and BMI of the patients were lower than the national average (p<0.05). 
Seventy-nine patients (86%) suffered from at least one gastrointestinal symptom, flatulence, 
hard stools or bloating. Both frequency and severity of symptoms were significantly 
increased compared with reference data of healthy Dutch adults. Forty-five percent of 
the patients reported (mostly mild) dysphagia. Solid foods caused more problems than 
liquids. A negative correlation between BMI and heteroplasmy levels in UEC was present.
Chapter 11 describes five non-MELAS phenotype carriers of the m.3243A>G mutation 
who received a kidney transplant, including follow-up data up to 13 years. Further more, all 
cases of kidney transplantation in m.3243A>G carriers described in literature are reviewed. 
Proteinuria with or without renal failure was the first clinical presentation of renal involvement 
in thirteen out of eighteen (72%) patients. FSGS (Focal Segmental Glomerulosclerosis) 
was found in nine out of thirteen (69%) biopsies. Sixteen out of eighteen (84%) patients 
developed hearing loss. All patients were diagnosed with diabetes mellitus of whom eight 
(44%) developed the disease after transplantation. All patients with reported follow-up 
data (13/18) had a stable kidney function from 6 months to thirteen years of follow-up 
after transplantation. It is feasible for non-MELAS phenotype carriers of the m.3243A>G 
mutation to be considered for a kidney transplantation in case of ESRD. These patients 
should not be excluded from transplant solely for their mitochondrial diagnosis. Proper 
recognition of the mitochondrial origin of the renal disease in these patients is important 
for adequate treatment selection and suitable supportive care.
Chapter 12 describes obstetric complications in carriers of the m.3243A>G mutation. 
Sixty female carriers responded to a questionnaire regarding their obstetric history. Ninety-
eight pregnancies in 46 women were reported. Twenty-three (25.3%) had a premature 
delivery and five of them (5.5%) had a gestation of ≤32 weeks. Eleven of the women (12%) 
suffered from preeclampsia. No difference in heteroplasmy level was found in the women 
with preeclampsia. Nine pregnancies (11%) were complicated by gestational diabetes. It 
is concluded that obstetric complications occur frequently in carriers of the m.3243A>G 
mutation. Proper guidance during pregnancies and early detection of possible obstetric 
complications are recommended. As techniques to prevent transmission of mitochondrial 
mutations are being explored at the moment it is important to realise that these patients 
have a higher risk of complications from the ensuing pregnancy.
Chapter 13
230
General discussion
This cohort of 151 adult carriers of the m.3243A>G mutation is to date the second largest 
cohort published. The aim of this thesis was to make a significant contribution to the 
knowledge on natural disease course in carriers of the m.3243A>G mutation. Several 
characteristics of the m.3243A>G mutation were already suggested by experienced 
clinicians, however, different chapters in this thesis provide scientific proof of these 
suggestions. 
The overall progression of disease in carriers of the m.3243A>G mutation is ~0.5 
NMDAS point per year in the total cohort; this result can be regarded as slowly progressive 
disease development. This knowledge is important in designing clinical trials. Heteroplasmy 
levels and NMDAS scores do not have a significant impact on this progression. Only clinical 
phenotype had a significant effect on disease progression. MELAS syndrome patients have 
an accelerated progression and dormant carriers have no progression at all. 
Patients with mitochondrial disease due to the m.3243A>G often suffer from multi 
organ disease. Knowledge and appropriate diagnostics of specific organ involvement 
is imminent to provide adequate (supportive) care. Only experienced health care 
professionals, both medical, nursing and paramedical, will be able to provide this adequate 
supportive care. Treatment of mitochondrial disease should therefore be centralized 
in expert centers for mitochondrial medicine with one of the medical specialists being 
the Head Mitochondrial Practioner. Some examples of this care are summarized here. 
Ophthalmological involvement can occur in all symptomatic carriers, regardless of their 
other symptoms (Chapter 9). Ophthalmologic screening by an ophthalmologist with 
adequate knowledge of mitochondrial disease is therefore indicated for all patients. 
Chapter 11 shows that although these patients have a severe multi organ disease, long term 
outcome after kidney transplantation is good. Therefore, carriership of the m.3243A>G 
mutation alone should not be considered an exclusion criterion for kidney transplantation. 
Cardiac involvement was studied extensively in this cohort, as a large proportion of the 
carriers has cardiac involvement (1). Cardiac involvement can be subtle, but warrants 
treatment to prevent progress, therefore knowledge of the clinical spectrum of m.3243A>G 
mutation carriers of the cardiologist is needed. The need of expert obstetric guidance 
of these patients is shown in Chapter 12. The increased risk for obstetric complications 
is serious for these women, who often already experience symptoms of mitochondrial 
disease. This is even more important in the face of emerging reproductive techniques 
including pre-implantation genetic diagnosis and mitochondrial donation. As a very large 
proportion has gastro-intestinal problems, including malnutrition and severe constipation 
(Chapter 10), expert dietician involvement is needed. Muscle complaints are among most 
frequently reported problems. Training of endurance, strength, mobility and gait need an 
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expert approach of physiotherapist, occupational therapist and rehabilitation physician. 
Specialist paramedic treatment and guidance is therefore also of great importance in the 
care of carriers of the m.3243A>G mutation. 
Pavlakis et al. used the acronym MELAS first in 1984. Later, the m.3243A>G muta-
tions was found to be the most prevalent genetic cause of this syndrome. Therefore the 
m.3243A>G mutation has been named the MELAS mutation ever since. However, many 
studies have showed the m.3243A>G mutation to cause a large number of other phenotypic 
expressions as well. MIDD syndrome being the most prevalent of these other phenotypes, 
but still only accounting for about 50% of the patients. This study demonstrates that it 
is not possible to assign the proper syndromic diagnosis based on genetic information 
only. Health care professionals treating patients with the m.3243A>G mutation should 
be very cautious to allocate a syndromic diagnosis as this might have major implications 
for the patient’s prospect of disease progression. It is therefore better to describe the 
phenotypic expressions when studying a carrier of the m.3243A>G mutation, and only 
diagnose a particular mitochondrial syndrome if all features are present. This is especially 
important for dormant carriers of the m.3243A>G mutation, as we have shown that they 
do not exhibit any symptoms of the mutation, and have no significant disease progression. 
There is much literature on the ethical aspects of genetic testing in minors, summarized 
by Borry et al. (2), and published as recommendations of the European Society of Human 
Genetics (3). They identify three different scenarios in which genetic testing in asymptomatic 
minors is considered. First, presymptomatic and predictive genetic testing for adult-
onset disorders. Second, presymptomatic and predictive genetic testing for preventable 
or treatable childhood-onset disorders. Third, presymptomatic and predictive genetic 
testing for unpreventable or untreatable childhood-onset disorders. These different groups 
have different ethical considerations towards genetic testing in pre- / asymptomatic 
children. It is however very difficult to classify the m.3243A>G mutation to one of these 
groups. As MELAS syndrome can frequently be classified in the third group and MIDD 
syndrome and ‘other’ m.3243A>G carriers are most probably sorted in the first group. 
It is not possible to allocate the group of dormant carriers in a specific group, leaving 
them with no available advice. There is however no test to predict the future phenotype 
before onset of symptoms, making it impossible to select the proper scenario. As there 
is only support to test children in group two and three, and there is very little evidence to 
support any benefit from testing children in the first group, there is no definitive answer 
to the ethical dilemma clinicians and geneticists face when counseling parents of (young) 
children towards testing of the m.3243A>G mutation. To my opinion, genetic testing in 
pre-symptomatic children at risk of carrying the m.3243A>G mutation should be done in 
extensive consultation with parents and with mayor restraint toward testing, as almost all 
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patients carrying the m.3243A>G have an untreatable adult onset disease to which genetic 
testing should be deferred to when the child reaches the age of maturity. Parents should 
however be very keen on identifying subtle symptoms as fatigue and muscle cramps as 
proper supportive care could impact quality of live in these children. 
To date, therapy for carriers of the m.3243A>G mutation is restricted to supportive 
care and optimal treatment of symptoms caused by the mutation. The research of this thesis 
provides information on which drug development trials can base their methodology. The 
KHENERGY study was the first RCT phase 2a trial in carriers of the m.3243A>G mutation 
with the innovative redox modulator KH176 (4). The results in this thesis provided the 
part of the foundation on which the KHENERGY trial design has been and future clinical 
trials will be build.
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Het doel van dit proefschrift was om de kennis van het natuurlijke ziekteverloop van dra-
gers van de m.3243A>G-mutatie uit te breiden. Uitgebreide kennis van het natuurlijke 
ziekteverloop van mitochondriële ziektes is belangrijk voor patiëntenzorg en is ook een ver-
eiste voor de ontwikkeling van de behandeling van mitochondriële aandoeningen in het 
algemeen en voor patiënten met de m.3243A>G-mutatie in het bijzonder.
Na een inleidend hoofdstuk, wordt dit proefschrift opgedeeld in drie delen; deel 
I algemene ziektebetrokkenheid, deel II genetica en deel III orgaanspecifieke ziektebe-
trokkenheid, alle met nadruk op de verschillende aspecten van het natuurlijke ziektever-
loop van dragers van de m.3243A>G-mutatie.
hoofdstuk 1, de introductie, beschrijft een typisch geval van een familie met de 
m.3243A>G-mutatie, gevolgd door een introductie op de mitochondriële ziekte en de 
m.3243A>G-mutatie. Hieronder staat een samenvatting van deze introductie. Daarna 
wordt een overzicht gegeven van alle cohortstudies met dragers van de m.3243A>G-
mutatie uit de literatuur. 
Mitochondriën zijn in onze cellen verantwoordelijk voor de productie van energie, 
ook wel adenosinetrifosfaat (ATP) genoemd, via oxidatieve fosforylering (OXPHOS). 
Mitochondriële disfunctie kan het gevolg zijn van mutaties in het nucleaire DNA (nDNA) 
of het mitochondriële DNA (mtDNA). De incidentie van aangeboren mitochondriële 
aandoeningen op basis van een OXPHOS defect is minstens 1 op 5000 tot 1 op 8500 
van alle levendgeborenen. De meeste patiënten met mitochondriële aandoeningen 
vertonen klachten van meerdere orgaansystemen. De organen die de meeste energie 
nodig hebben, zoals de hersenen, het netvlies, het hart, de nieren en de skeletspier, 
worden meestal en ernstig aangetast. De ziekte kan op iedere leeftijd beginnen en de 
klachten zijn bijna altijd progressief. Tot op heden is er geen genezing beschikbaar voor 
mitochondriële aandoeningen. 
Aangezien de m.3243A>G-mutatie een mitochondriële DNA-mutatie is, is het 
belangrijk de specifieke eigenschappen van mtDNA te begrijpen. Twee belangrijke 
kenmerken van mitochondriële mutaties zijn maternale overerving en heteroplasmie. 
Aangezien mitochondriën alleen aanwezig zijn in eicellen en niet in spermacellen, vindt 
overerving van het mitochondriële DNA alleen plaats via de moeder. Een kind met een 
mtDNA-mutatie zal daarom altijd deze mutatie van zijn moeder hebben geërfd. Menselijke 
cellen bevatten allemaal meerdere mitochondriën, elk mitochondrion bevat meerdere 
kopieën van mtDNA. Wanneer alle mtDNA kopieën zijn gemuteerd, is er sprake van een 
homoplastische mutatie. Wanneer echter niet alle mtDNA kopieën zijn gemuteerd, is er 
een variatie in mutatiebelasting en wordt de mutatie heteroplastisch genoemd. Hetero-
plasmiewaarden kunnen in één patiënt in de tijd variëren en tussen verschillende weefsels 
van één patiënt wisselen. Deze variatie in heteroplasmie tussen weefsels bemoeilijkt het 
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aantonen van een verband tussen de ernst van de ziekte in een niet-toegankelijk orgaan 
(bijvoorbeeld het hart, de hersenen of het oog) en de mate van heteroplasmie in bloed, 
urine of wangslijmvlies. 
Het acroniem MELAS werd voor het eerst gebruikt in 1984 om een groep patiënten te 
beschrijven met mitochondriële myopathie, encefalopathie, lactaatacidose en stroke-like 
episodes. In 1990 werd de A naar G mutatie op plaats 3243 van het mitochondriële DNA 
(m.3243A>G) gevonden als moleculaire basis voor deze ziekte. De m.3243A>G-mutatie in 
het MT-TL1-gen is de meest voorkomende oorzaak van het MELAS-syndroom, daarom is 
de mutatie ook bekend als de MELAS-mutatie. Later werden meer en meer fenotypische 
expressies van de m.3243A>G-mutatie gevonden, waaronder maternaal overgeërfde 
diabetes doofheid (MIDD), hypertrofische cardiomyopathie, maculaire dystrofie, focale 
segmentale glomeruloslerose (FSGS), myoclonische epilepsie met rafelige rode vezels 
(MERRF) en oligosymptomatische varianten van het acroniem MELAS. Epidemiologische 
studies tonen een prevalentie van m.3243A>G-mutatie van 7,59 / 100.000 in de popu-
latie van Noordoost-Engeland, 16,3 / 100.000 in de bevolking van Noord-Finland en tot 
236 / 100.000 in de bevolking van Australië. Deze studies gaven geen volledig inzicht 
in de fenotypische expressie van de m.3243A>G-mutatie in de onderzochte personen. 
De hoge prevalentie van mutaties in de meest recente studie wijst op een groot aantal 
niet-gediagnosticeerde dragers van de m.3243A>G-mutatie. 
Deel I richt zich op de algemene ziektebetrokkenheid. Algemene ziektebetrokken-
heid en de progressie van de ziekte werd gemeten met behulp van de NMDAS-score. Dit 
is een gevalideerde scoremethode voor patiënten met mitochondriële aandoeningen en 
geeft op kwantificeerbare wijze informatie over de totale ziektebetrokkenheid.
hoofdstuk 2  beschrijft  een cohort van  82  dragers van de  m.3243A>G-muta-
tie. Geen van de onderzochte kinderen (n=11) had specifieke klachten. Bij volwassenen 
(n=71) werd een mediane NMDAS-score van 15 (IQR 10–24) gevonden.  De meest 
voorkomende symptomen waren gehoorverlies  (68%), maagdarmproblemen  (59%), 
inspanningsintolerantie (54%) en glucose-intolerantie  (52%).  Tien patiënten hadden 
neurologische betrokkenheid. Heteroplasmie in wangslijmvlies had de beste correlatie 
met de NMDAS bij volwassenen (r=0,437, p<0,001), terwijl urine de sterkste correlatie 
had met de NMDAS bij ernstiger aangedane patiënten (r=0,593,  p=0,002).  Hetero-
plasmie daalde significant met toenemende leeftijd in alle drie de weefsels bloed 
(r=-0,705; p<0,001), urine (r=-0,374; p=0,001) en buccale mucosa (r=-0,460; p<0,001).  
De studie demonstreert een breed scala aan symptomen veroorzaakt door de mutatie, 
waarbij MIDD veel vaker voorkomt dan MELAS.  Het bevestigde eerdere studies dat 
van de drie niet-invasief beschikbare weefsels voor het testen van heteroplasmie urine 
de voorkeur verdient om te testen.
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 hoofdstuk 3 rapporteert over de prospectieve follow-up, van maximaal 6 jaar, van 
151 dragers van de m.3243A>G-mutatie uit 61 families. Honderdvierentwintig dragers 
(van de 151) waren symptomatisch. Vier klinische groepen werden geïdentificeerd: 1) 
Klassiek MELAS-syndroom (n=7), 2) MIDD-syndroom (n=60), 3) ‘Anders’ (n=57) en 4) 
Slapende dragers of Dormant carriers (n=27). Een jaarlijkse toename van de NMDAS-
score van 0,47 punt werd gemeten in de totale groep. Heteroplasmie in zowel bloed als 
urine waren zwak gecorreleerd aan de ernst van de ziekte. Er werd geen correlatie tussen 
heteroplasmie waarden en ziekteprogressie gevonden als werd gecorrigeerd voor de ver-
schillende klinische groepen. Lichamelijke kwaliteit van leven daalde met de leeftijd. De 
belangrijkste beïnvloeders van de achteruitgang in kwaliteit van leven waren: gehoorverlies, 
spraakproblemen, inspanningsintolerantie, loopinstabiliteit, psychiatrische problemen 
en maag-darmbetrokkenheid. Er werd geconcludeerd dat de m.3243A>G-mutatie een 
langzaam progressieve ziekte veroorzaakt, met een jaarlijkse toename van de NMDAS-
score van ~0,5 punt. Het klinische fenotype is de enige beïnvloeder van ziekteprogressie, 
waarbij MELAS-patiënten een ernstiger beloop hebben dan MIDD of patiënten in de 
overige groep. Dormant carriers hebben geen progressie van ziekteactiviteit. 
 Deel II richt zich op de genetische kenmerken van de mutatie. De unieke mitochon-
driële overerving van de m.3243A>G-mutatie werd bestudeerd en de kenmerken van 
urine werden in een aparte studie beschreven.
In hoofdstuk 4 werden 56 moeder-kindrelaties en 82 broer-zusrelaties in 34 families 
bestudeerd. Er werd een significante correlatie tussen moeder en kind heteroplasmieni-
veaus (r=0,679, p<0,001) gevonden. Bij moeders met een heteroplasmie van minder dan 
25% had 30% van hun kinderen geen detecteerbare mutatie, terwijl bij moeders met een 
heteroplasmie van meer dan 25%, alle kinderen drager zijn van de m.3243A>G-muta-
tie. Heteroplasmieniveaus tussen broers en zussen correleerden ook (r=0,512, p<0,001), 
maar dit had een beperkte klinische waarde vanwege uitbijters. Deze nieuwe gegevens 
over de overerving van de m.3243A>G-mutatie zouden van waarde kunnen zijn bij het 
adviseren van patiënten aangaande de overerving en het voorkomen van overdracht van 
de mutatie.
 hoofdstuk 5 beschrijft drie families waarin de mutatie spontaan leek te zijn ont-
staan in de indexpatiënt. Een ernstiger fenotype werd gezien in de de novo families in 
vergelijking met recente cohortstudies, dit is mogelijk te wijten aan rapportagebias. De 
waarneming dat de novo m.3243A>G-mutaties bestaan, is van belang voor zowel de diag-
nostische procedure en genetische counseling.
hoofdstuk 6 bestudeert de intra-patiëntvariabiliteit van heteroplasmiewaarden in 
urine. Vijftien dragers van de m.3243A>G-mutatie verzamelden vijf urinemonsters in een 
periode van veertien dagen voor de bepaling van heteroplasmie. In de monsters van zes 
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patiënten lagen de niveaus van heteroplasmie binnen een marge van 5%. In de monsters 
verzameld bij vijf patiënten was de marge >20%. De interpretatie van een correlatie tus-
sen heteroplasmie in de urine en ernst van de ziekte kan dus niet betrouwbaar zijn. Om 
deze reden zouden heteroplasmiewaarden in urine niet moeten worden gebruikt als een 
prognostische biomarker bij deze patiënten.
Deel III van dit proefschrift concentreert zich op orgaanspecifieke betrokkenheid van 
de ziekte. In vergelijking met de studies naar algemene ziektebetrokkenheid bereiken de 
studies met betrekking tot specifieke organen veel meer precisie en detail in de patho-
fysiologie van het betreffende orgaan. Deze kennis kan worden gebruikt voor een beter 
begrip van de verscheidenheid aan fenotypische expressies van de m.3243A>G-mutatie. 
 hoofdstuk 7 gaat over kwaliteit van leven en vermoeidheid bij dragers van de 
m.3243A>G-mutatie.  Tweeënzeventig van de 122 uitgenodigde patiënten voltooiden 
online gestandaardiseerde vragenlijsten over de kwaliteit van leven, functionele beperkin-
gen, vermoeidheid en geestelijke gezondheid. Patiënten rapporteerden een verminderde 
kwaliteit van leven. Zestig procent vertoonde ernstige vermoeidheidsklachten en 37% 
vertoonde klinisch relevante psychische problemen, wat aanzienlijk meer was in gezonde 
mensen.  Deze patiëntgerapporteerde gezondheidseffecten  waren niet gerelateerd 
aan heteroplasmieniveaus en matig gerelateerd aan de algemene ziektebetrokkenheid. 
Het is daarom belangrijk om bij dragers van de m.3243A>G-mutatie aandacht te hebben 
voor deze specifieke psychische klachten. 
hoofdstuk 8 rapporteert over de angst voor progressie van ziekte bij dragers van de 
m.3243A>G-mutatie. Zesenzeventig (van de 125) dragers namen deel aan deze studie, 
zij beantwoordden vragenlijsten over angst voor progressie, depressie, angst en kwaliteit 
van leven. Uit de resultaten bleek dat 18% hoge angst voor progressie ervaarde. Angst 
voor progressie was significant gerelateerd aan alle domeinen van kwaliteit van leven. De 
impact van het ontvangen van een diagnose zonder therapeutische mogelijkheden kan 
angst geven welke de kwaliteit van leven beïnvloed.
  In  hoofdstuk  9  wordt een gedetailleerde oogheelkundige beoordeling van 29 
dragers van de m.3243A>G-mutatie beschreven. Vijfentwintig patiënten (86%) hadden 
een spectrum van retinale afwijkingen, die in vier stadia konden worden ingedeeld. Zes 
patiënten (21%) hadden stadium 1 retinale dystrofie, gekenmerkt door fijne pigmentaf-
wijkingen die beter zichtbaar waren op fundus autofluorescentie en fluoresceïne angio-
grafie. Stadium 2 (11 patiënten, 38%) werd gekenmerkt door een of een paar geelachtige 
of licht gepigmenteerde afzettingen in het vroege stadium 2. Bij gevorderd stadium 2 
omvatte de pigmentaire veranderingen de gehele macula en omringde vaak de optische 
schijf. Zes patiënten (21%) hadden stadium 3 retinale dystrofie waarbij diepe chorioreti-
nale atrofie aanwezig was buiten de gele vlek. Duidelijk verlies van gezichtsscherpte trad 
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alleen op in stadium 4 retinale dystrofie (2 patiënten, 7%), toen de gele vlek ook werd 
aangetast door diepe chorioretinale atrofie. Het stadium van mitochondriële retinale dys-
trofie correleerde significant met de leeftijd (r=-0,438, p=0,008) en met gezichtsscherpte 
(r=-0,614, p <0.001). Er was geen correlatie tussen het stadium van retinale dystrofie en 
heteroplasmie of algehele betrokkenheid van de ziekte. Vanwege de afwezigheid van 
een correlatie met de algemene betrokkenheid van de ziekte, kunnen oogheelkundige 
symptomen gemist worden of verkeerd worden gediagnosticeerd.
 hoofdstuk 10 beschrijft gastro-intestinale problemen en slikproblemen in 92 dragers 
van de m.3243A>G-mutatie. Gastro-intestinale betrokkenheid, slikproblemen en het risico 
op ondervoeding werden gescoord met behulp van een vragenlijst. Negenenzeventig 
patiënten (86%) hadden minstens één gastro-intestinaal symptoom zoals winderigheid, 
harde ontlasting of een opgeblazen gevoel. Zowel de frequentie als de ernst van de 
symptomen waren aanzienlijk toegenomen in vergelijking met gezonde Nederlandse 
volwassenen. Vijfenveertig procent van de patiënten rapporteerde (meestal lichte) slik-
problemen. Vast voedsel veroorzaakte meer problemen dan vloeistoffen. 
hoofdstuk 11  beschrijft  vijf niet-MELAS-fenotypedragers van de m.3243A>G-
mutatie die een niertransplantatie hebben ondergaan, inclusief follow-upgegevens tot 
13 jaar. Daarnaast beschrijft het ook alle gevallen van niertransplantaties in m.3243A>G-
dragers beschreven in de literatuur. Proteïnurie met of zonder nierfalen was de eerste 
klinische presentatie van nierbetrokkenheid bij dertien van de achttien (72%) patiën-
ten. FSGS (Focal Segmental Glomerulosclerosis) werd gevonden in negen van de dertien 
(69%) biopsieën. Zestien van de achttien (84%) patiënten ontwikkelden gehoorverlies. Alle 
patiënten werden gediagnosticeerd met diabetes mellitus, van wie acht (44%) diabetes 
na transplantatie ontwikkelden. Alle patiënten met gerapporteerde follow-upgegevens 
(13/18) hadden een stabiele nierfunctie van 6 maanden tot 13 jaar follow-up na transplan-
tatie. Het is dus mogelijk voor niet-MELAS-fenotypedragers van de m.3243A>G-mutatie 
om in aanmerking te komen voor een niertransplantatie in geval van eindstadium nierfa-
len. Deze patiënten mogen niet worden uitgesloten van transplantatie uitsluitend vanwege 
hun mitochondriële aandoening. Een goede herkenning van de mitochondriële etiologie 
van de nierziekte bij deze patiënten is belangrijk voor een adequate behandelingskeuze 
en geschikte ondersteunende zorg.
 hoofdstuk 12 beschrijft obstetrische complicaties bij dragers van de m.3243A>G-
mutatie.  Zestig vrouwelijke dragers hebben gereageerd op een vragenlijst over hun 
obstetrische geschiedenis.  Achtennegentig zwangerschappen bij 46 vrouwen werden 
gemeld. Drieëntwintig (25,3%) hiervan waren prematuur en vijf van hen (5,5%) hadden 
zelfs een draagtijd van ≤32 weken. Elf van de vrouwen (12%) leden aan pre-eclampsie. Er 
was geen verschil  in heteroplasmie bij  vrouwen met of zonder pre-eclampsie. Negen 
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zwangerschappen (11%) werden gecompliceerd door zwangerschapsdiabetes. Obstetri-
sche complicaties komen frequent voor bij dragers van de m.3243A>G-mutatie. Goede 
begeleiding tijdens zwangerschappen en vroege detectie van mogelijke obstetrische 
complicaties is belangrijk. Omdat technieken om overdracht van mitochondriële mutaties 
te voorkomen op dit moment worden onderzocht, is het belangrijk om te beseffen dat deze 
patiënten een hoger risico hebben op complicaties in de daaropvolgende zwangerschap.
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Sinds begin 2010 heb ik de mogelijkheid gekregen van velen om mij te ontwikkelen in 
het domein van de medische wetenschap, met dit proefschrift als resultaat. Graag wil 
ik iedereen die daaraan heeft bijgedragen bedanken in deze best gelezen pagina’s van 
dit boekwerk. Enkele personen zal ik bij naam noemen, enkele personen zal ik vergeten, 
daarvoor alvast mijn excuses, maar de steun die ik van iedereen heb ontvangen heb ik 
enorm gewaardeerd.
Allereerst gaat mijn dank uit naar de families die in de afgelopen jaren naar Nijmegen 
zijn gekomen om deel te nemen aan het onderzoek. Het meest heb ik van jullie geleerd, 
in mijn ontwikkeling als wetenschapper, als dokter en als mens. Het is fantastisch dat 
er door jullie inzet wetenschappelijk onderzoek gedaan kan worden naar deze enorm 
intrigerende ziekte. 
Prof. dr. Jan Smeitink. Jan, als promotor heb jij mij de kans gegeven om dit onderzoek 
te gaan doen. In het begin heb je me heel veel over mitochondriën moeten uitleggen, 
maar de vrijheid die je me gaf om er mijn onderzoek van te maken was fantastisch. Jouw 
kennis van wetenschappelijk onderzoek is fenomenaal en het onderzoekscentrum dat je 
hebt opgebouwd is fantastisch, ik ben blij dat ik daar onderdeel van mocht zijn. 
Dr. Mirian Janssen. Mirian, hoe meer het onderzoek vorderde hoe belangrijker jouw rol 
als co-promotor en dagelijks begeleider werd. Je bent een absoluut rolmodel als dokter 
en mens. De manier waarop jij patiëntenzorg, wetenschap en onderwijs combineert en 
daarbij ook gewoon een superleuk mens bent kom je niet vaak tegen. 
Prof. dr. Ans van der Ploeg, Prof. dr. Han Brunner en Dr. Christiaan Saris, ik wil jullie 
bedanken dat jullie zitting wilden nemen in de manuscriptcommissie, en de tijd hebben 
genomen om dit proefschrift te beoordelen.
Zonder geld geen onderzoek. Daarom wil ik ZonMw, de stichting Energy4All en de 
stichting TimStar danken voor het vertrouwen dat zij hebben getoond in mijn onderzoek 
door dit financieel mogelijk te maken. 
Als je onderzoek doet kom je veel mensen tegen, al deze mensen spelen een cruciale rol 
in het volbrengen van een succesvol onderzoekstraject. Het gaat te ver om iedereen te 
noemen die ik in de voorbije (bijna) tien jaar ben tegengekomen om mij te helpen, maar 
sommigen wil ik wel apart noemen. Op het laboratorium kindergeneeskunde was ik niet 
vaak te vinden, het werk voor mijn onderzoek werd daar vooral gedaan door Roel en Inge, 
ik ben jullie daar enorm dankbaar voor. Het secretariaat van de kindergeneeskunde, waarbij 
Annette een aparte vermelding verdient, was een basis waar ik altijd op terug kon vallen 
voor adviezen of gewoon voor een praatje, daarvoor dank. Alle verpleegkundigen op de 
polikliniek interne geneeskunde (balie blauw), en de verpleegkundigen van de kinderpoli 
dank voor al de gezellige momenten en de ondersteuning bij het zien van alle patiënten. 
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Wetenschappelijk onderzoek doe je niet alleen, dat mag inmiddels duidelijk zijn. Zo ook 
het schrijven van artikelen, naast Jan en Mirian wil ik ook graag alle andere co-auteurs 
danken voor hun inbreng, met name Dr. Saskia Koene en Dr. Richard Rodenburg. Jullie 
hebben bijgedragen aan een groot deel van mijn artikelen. Saskia, door jouw kritische 
maar altijd constructieve inbreng heb ik veel geleerd van artikelen schrijven, jij bent een 
klinische wetenschaper van het hoogste niveau. Richard, van jou heb ik veel geleerd 
van de verschillende laboratoriumtechnieken en hoe deze te interpreteren, ik heb onze 
afspraken altijd erg gewaardeerd.  
Naast een opleiding tot wetenschappelijk onderzoeker heb ik ook mijn opleiding tot 
kinderarts (bijna) achter de rug. De ondersteuning die ik heb gekregen om deze twee 
opleidingen in elkaar te verweven is voor mij zeer waardevol geweest. Naast Jan heeft vooral 
Dr. Jos Draaisma dit mogelijk gemaakt. Jos, jij maakte het in 2010 mogelijk om als oudste-
co-assistent te starten in Nijmegen en vervolgens maakte je het in 2017 mogelijk om weer 
terug te gaan naar Rotterdam voor de voltooiing van mijn opleiding in nabijheid van mijn 
gezin. De manier waarop jij individueel opleiden tot een kunst hebt verheven kent geen 
navolging. Ik heb enorm veel van je geleerd, zowel op de werkvloer als in onze gesprekken, 
dit heeft mij voor altijd een betere dokter gemaakt. Daarnaast hebben alle collega-arts-
assistenten kindergeneeskunde mij altijd onderdeel van de groep laten zijn, ook in de jaren 
dat ik niet in de kliniek was, dank dat ik altijd welkom was in de assistentenkamer en op 
alle borrels en feesten. Lara, ik vind het heel leuk dat jij mijn paranimf wil zijn. Nadat we in 
2014 een succesvol lustrum voor het Amalia kinderziekenhuis hebben georganiseerd, zijn 
we naast collega’s ook goede vrienden geworden. Ik hoop dat we dat nog heel lang blijven.
De combinatie van onderzoek, een opleiding kindergeneeskunde en de nodige neventaken 
zorgt voor een hectisch professioneel bestaan. Een thuisbasis met familie en vrienden 
waar je op terug kan vallen in goede en in slechte tijden is dan enorm fijn. 
Ik ben enorm blij met een hele goede groep vrienden die er altijd staan als je ze nodig 
hebt. Als het gaat om diners, borrels en partijen, maar ook voor de nodige verhuishulp. 
Ik reken erop dat er nog vele diners gaan volgen. 
Ik kom uit een groot gezin waarin familie een belangrijke rol speelt voor iedereen. De 
steun die ik van jullie heb gehad in de afgelopen jaren heeft geleid tot dit mooie boek. 
Met de voltooiing van deze opleiding ben ik als oudste van het gezin de laatste die zijn 
‘school’ afmaakt. Frank, Fleur, Anne, Jori, Vicky en Tom wat is het fantastisch om jullie 
als broers en zussen te hebben. 
Ate en Conny, jullie hebben mij opgenomen in jullie gezin als een tweede kind. De steun 
die jullie bieden aan ons in het opvoeden van onze kinderen is onmisbaar. Ik ben heel blij 
dat jullie mijn schoonouders zijn. 
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Papa en mama, die fles port kan nu eindelijk open, toch? Vanaf jongs af aan ben ik door 
jullie gesteund, aangemoedigd en aangespoord om het maximale te bereiken. De liefde 
waarmee jullie dat hebben gedaan heeft geleid tot alle successen die ik tot nu toe heb 
mogen bereiken. Jullie rol in mij was en is van onmeetbare waarde. Papa, de dubbele 
pet die jij hebt als opleider en vader kan je vandaag helemaal waar maken, ik ben blij dat 
jij naast mij staat als paranimf. 
Thije en Siebe, wat is het heerlijk om na een dag typen thuis te komen en weer even 
helemaal down-to-earth te zijn. Jullie maken mijn dag!
Klaske, dit boek was er niet geweest zonder jou, mijn leven was niet geweest wat het is 
zonder jou. Jij bent alles voor mij. Klaske, ik hou van jou!
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van het Radboudumc te Nijmegen. Eind 2010 heeft hij zijn artsenbul (cum laude) gehaald. 
Het in Nijmegen gestarte onderzoek werd doorgezet tot dit promotieonderzoek. 
Na een ANIOS-stage in het Rijnstate Arnhem, is hij in 2013 gestart met de opleiding tot 
kinderarts in Nijmegen (opleider dr. J. Draaisma), waarbij dit werd afgewisseld met onder-
zoekstijd in een AGIKO-constructie. De opleiding tot kinderarts heeft hij gecombineerd 
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